Studies on Biologically active heterocyclic analogous by Joshi, Niravkumar K.
    Saurashtra University 
     Re – Accredited Grade ‘B’ by NAAC 
     (CGPA 2.93) 
 
 
 
 
Joshi, Niravkumar K., 2012, "Studies on Biologically active heterocyclic 
analogous", thesis PhD, Saurashtra University 
  
http://etheses.saurashtrauniversity.edu/1027 
  
Copyright and moral rights for this thesis are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge. 
 
This thesis cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the Author. 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the Author 
 
When referring to this work, full bibliographic details including the author, title, 
awarding institution and date of the thesis must be given. 
 
 
 
 
 
 
 
 
Saurashtra University Theses Service 
http://etheses.saurashtrauniversity.edu 
repository@sauuni.ernet.in 
 
© The Author
STUDIES ON BIOLOGICALLY ACTIVE
HETEROCYCLIC ANALOGOUS
A THESIS
SUBMITTED TO THE
SAURASHTRA UNIVERSITY
FOR THE DEGREE OF
Doctor of Philosophy
IN
THE FACULTY OF SCIENCE (CHEMISTRY)
BY
Niravkumar K. Joshi
UNDER THE GUIDANCE OF
Dr. J. M. Parmar
DEPARTMENT OF CHEMISTRY
MAHARAJA SHREE MAHENDRASINHJI SCIENCE COLLEGE
MORBI- 363 642, GUJARAT (INDIA)
2012
The Sarvodaya Education Society’s
Maharaja Shree Mahendrasinhji Science College
Nazar Baugh, Bhadiyad Road
Morbi-363 642.
Dr. J. M. Parmar
M.Sc., Ph.D.
Associate Proffesor,
Maharaja Shree
Mahendrasinhji Science College,
Morbi - 363 642
Phone(O): - 02822-240601
Statement under o. Ph. D. 7 of Saurashtra University
The work included in the thesis is my own work under the supervision of Dr. J.
M. Parmar and leads to some contribution in chemistry subsidized by a number of
references.
Date : - -2012 (Niravkumar K. Joshi)
Place: Morbi
This is to certify that the present work submitted for the Ph.D. Degree of
Saurashtra University by Niravkumar K. Joshi (Reg.No.: 4155, Date:28/02/2009) is his
own work and leads to advancement in the knowledge of chemistry. The thesis has been
prepared under my supervision.
Date : - -2012 Dr. J. M. Parmar
Place: Morbi Maharaja Shree
Mahendrasinhji Science College,
Morbi – 363 642.
Dedicated 
To 
My Family
ACKNOWLEDGEMENT
It is a matter of immense pleasure and proud priviledge for me to
express my deep sense of gratitude to all those personality who have been
helping me in diversified ways. It is a moment of gratification and pride to
look back with a sense of contentment at the long traveled path, to be able
to recapture some of the fine moments, to be think of the infinite number of
people, some who were with me from the beginning, some who joined me at
different stages during this journey, whose kindness, love and blessings has
brought me to this day. I wish to thank each of them from the bottom of my
heart.
Who have given us everything that we possess in this life? The life
itself is their gift to us, therefore first and foremost I would like to bow my
head with utter respect to my parents, my late grandfather & grandmother.
My expression fails to express my feelings in acknowledging the incredible
debt that I owe to my beloved mother late Smt. Karunaben and most
esteemed father Shri Kishorbhai. It is only possible becouse of their
blessings, encouragement, constant support and inspiration that I have been
able to streer through the stresses and strains of this study. I would like to
special thanks to my younger brother Vatsal for his unwavering love,
inspiration and moral support throught my work. I am also thankful to all my
parental and maternal relatives for their constant help and moral support. I
bow my head humbly before Lord Shiva, Ganeshji and Saraswati Maa for
making me much capable that I could adopt and finish this huge task.
I would like to express my sincere gratitude to my supervisor Dr. J.
M. Parmar for accepting me as his research student and who made this
research a success. It is with Dr. Parmar’s enthusiasm and integral view on
research combined with his willingness to provide quality chemistry and not
less that kept me going and I wish to say thank you sir. I consider myself
privileged to work under his generous guidance, because I got the newer
creative dimensions and positive attitude in my thinking and analyzing
capacity, which helped me to make things simple but programmatic. Besides
being a wonderful Supervisor, He is as close as family and a very good friend
and I am deeply honored to have wonderful person like him in my life. I wish
to say thank you so much again for all the help you offered over the years
both in and out of my academic life. It is with no doubt that without your
help I would not be where I am now.
I also owe to, from the deepest corner of heart, deepest sense of
gratitude and indebtedness to Dr. P. K. Patel and Dr. Y. T. Naliapara for their
selfless help whenever I needed, as I have been constantly benefited with
their scientific research approach, and the motivation as well as their highly
punctual affectionate. I would like to express my feelings of gratitude to Dr.
P. H. Parsania, Dr. H. S. Joshi, Dr. Anamik Shah, Dr. Jignesh Pandya and Dr.
M. V. Parsania, for their constant inspiration with keen interest and ever
vigilant guidance without which this task could not have been achieved.
Words are inadequate to thank my most beloved friends and seniors
Dr. Dinesh Kundariya and Dr. Renish Ghetiya who were always with me since
the time of graduation up to Ph. D., helping me in all situations. His constant
support, care and moral boost always kept me encouraged in all the difficult
situations. I will never forget their all kind concern, help, best wishes and
that they have done for me.
I would like to express my deep sense of gratitude and lots of love
towards my dearest friends Dr. Bhavesh Dodiya, Ashish patel, Dr. Vipul
Audicya, Sudhir Saradva, Pankaj Godhaviya, Sagar Gami, Dr. Dhairya Bhavsar,
Dr. Anil Patel, Nirav Shah and Bharat Baria for their most willing co-
operation in search references, spectroscopic analysis, comprehensive
exchange of ideas and selfless help whenever I needed during the course of
my research work. I will never forget the company I had from my colleagues
Jitu, Naresh, Vaghasiya, Manoj, Dhaval, MD, Panera, Danger, Butani, Kavar,
Pradeep, Shiva, Arvind, Sodha, Raju, Denish, Mahesh and Ankola.
I would like to reserve a special thank for my dear friends and seniors
like Dr. Mehul, Dr. Piyush, Dr. Chirag Bhuva, Dr. Amit, Gaurang pandya, Dr.
Harshad, Gaurav, Yogesh and all my M. Sc. friends who helped me with their
constant support. I am also thankful to all research students of Department
of Chemistry for their direct or indirect help.
I am very thankful to my colleagues Sanjay, Dhaval, Hardik and
Chintan for their most willing co-operation during the course of my research
work. I wish to Special thanks to Dr. Dhaval Vashi, Dr. U. P. Singh, Dr. Nikul
Patel, Dr. Yogesh Rupala, Dr. Niraj Kumar, Yogesh Ahir, Bipin, Nirav, Prakruti,
Vaishali, Rupala, Ravat, Krunal, Jignesh, Mahesh and Sharad for their
unforgotable help. I am also thankful to Dr. B. M. Sharma, Dr. A. M. Virparia,
Dr. V. A. Modhwadia, Dr. D. R. Bhadja, Dr. B. M. Bheshdadiya and
Sanghanibhai, Bhailalbhai and Amarbhai for their kind concern and moral
support.
I gratefully acknowledge the most willing help and co-operation shown
by CDRI Lucknow for spectral studies and MICROCARE LABORATORIES-
SURAT for analysis of biological activity.
Finally, I express my grateful acknowledgment to Department of
Chemistry, M. M. Science College, Morbi, for providing me the excellent
laboratory facilities. I would also like to thank teaching and non-teaching
staff members of M. M. Science College, Morbi, for their kind help for
accomplishing this work.
Nirav K. Joshi
CONTENTS
SYNOPSIS........................................................................................................................................1
STUDIES ON BIOLOGICALLY ACTIVE HETEROCYCLIC ANALOGOUS
Intoduction.......................................................................................................................................10
CHAPTER-1 : STUDIES ON TETRAHYDROPYRIMIDINES BY COVENTIONAL
METHOD AND MICROWAVE ASSISTED METHOD
Introduction.....................................................................................................................................14
Therapeutic Importance..................................................................................................................24
Comparision of Conventional Biginelli Method and Microwave Assisted Method........................29
Section-I
Synthesis of 4-aryl-6-isopropyl-N-(5-methyl-1,3-thiazol-2-yl)-2-oxo-1,2,3,4-tetrahydropyrim-
idine-5-carboxamide using conventional method & microwave assisted method and
biological screening
Reaction Scheme......................................................................................................................…....31
Spectrul Studies...............................................................................................................................32
Experimental....................................................................................................................................36
Data of In Vitro Evaluation of Antimicrobial Screening…....................………………………….40
Section-II
Synthesis of 4-aryl-6-isopropyl-N-(5-methyl-1,3-thiazol-2-yl)-2-thioxo-1,2,3,4-tetrahydropyr-
imidine-5-carboxamide using  conventional method & microwave assisted method and
biological screening
Reaction Scheme......................................................................................................................…....42
Spectrul Studies...............................................................................................................................43
Experimental....................................................................................................................................47
Data of In Vitro Evaluation of Antimicrobial Screening.................................................................50
References........................................................................................................................................52
CHAPTER-2 : STUDIES ON PIPERAZNE AND CHROMENE DERIVATIVES
Part-1
Studies on piperazine derivatives
Introduction.....................................................................................................................................58
Therapeutic Importance..................................................................................................................60
Section-I
Synthesis and characterization of 2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetohydrazide
Reaction Scheme..............................................................................................................................68
Spectrul Studies...............................................................................................................................69
Experimental……………………………………………………………............................………72
References........................................................................................................................................73
Part-2
Studies on chromene derivatives
Introduction.....................................................................................................................................79
Therapeutic Importance..................................................................................................................84
Section-I
Synthesis and characterization of 6-fluoro-3,4-dihydro-2H-chromene-2-carbohydrazide
Reaction Scheme..............................................................................................................................89
Spectrul Studies...............................................................................................................................90
Experimental……………………………………………………………............................………93
References........................................................................................................................................94
CHAPTER-3 : STUDIES ON SCHIFF DERIVATIVES
Introduction.....................................................................................................................................97
Therapeutic Importance..................................................................................................................99
Section-I
Synthesis and biological screening of N'-arylmethylidene-2-(4-(2,3-dichlorophenyl)piperazin
-1-yl)acetohydrazide
Reaction Scheme............................................................................................................................104
Spectrul Studies.............................................................................................................................105
Experimental..................................................................................................................................109
Data of In Vitro Evaluation of Antimicrobial Screening…...........................................................111
Section-II
Synthesis and biological screening of N'-(1-arylethylidene)-2-(4-(2,3-dichlorophenyl)
piperazin-1-yl)acetohydrazide
Reaction Scheme......................................................................................................................…..113
Spectrul Studies.............................................................................................................................114
Experimental..................................................................................................................................118
Data of In Vitro Evaluation of Antimicrobial Screening...............................................................120
Section-III
Synthesis and biological screening of N'-arylmethylidene-6-fluoro-3,4-dihydro-2H-
chromene-2-carbohydrazide
Reaction Scheme............................................................................................................................122
Spectrul Studies.............................................................................................................................123
Experimental..................................................................................................................................127
Data of In Vitro Evaluation of Antimicrobial Screening…...........................................................129
Section-IV
synthesis and biological screening of N'-(1-arylethylidene)-6-fluoro-3,4-dihydro-2H-
chromene-2-carbohydrzide
Reaction Scheme......................................................................................................................…..131
Spectrul Studies.............................................................................................................................132
Experimental..................................................................................................................................136
Data of In Vitro Evaluation of Antimicrobial Screening...............................................................138
References......................................................................................................................................140
CHAPTER-4 : STUDIES ON THIAZOLIDINONE DERIVATIVES
Introduction...................................................................................................................................146
Therapeutic Importance................................................................................................................149
Section-I
Synthesis and biological screening of N-(2-aryl-4-oxothiazolidin-3-yl)-2-(4-(2,3-dichloro-
phenyl)piperazin-1-yl)acetamide
Reaction Scheme............................................................................................................................152
Spectrul Studies.............................................................................................................................153
Experimental..................................................................................................................................157
Data of In Vitro Evaluation of Antimicrobial Screening…...........................................................160
Section-II
Synthesis and biological screening of N-(2-aryl-5-methyl-4-oxothiazolidin-3-yl)-2-(4-(2,3-
dichlorophenyl)piperazin-1-yl)acetamide
Reaction Scheme......................................................................................................................…..162
Spectrul Studies.............................................................................................................................163
Experimental..................................................................................................................................167
Data of In Vitro Evaluation of Antimicrobial Screening...............................................................170
References......................................................................................................................................172
CHAPTER-5 : STUDIES ON OXADIAZOLE DERIVATIVES
Introduction...................................................................................................................................177
Therapeutic Importance................................................................................................................179
Section-I
Synthesis and biological screening of 5-aryl-2-((4-(2,3-dichlorophenyl)piperazin-1-
yl)methyl)-1,3,4-oxadiazole
Reaction Scheme............................................................................................................................184
Spectrul Studies.............................................................................................................................185
Experimental..................................................................................................................................189
Data of In Vitro Evaluation of Antimicrobial Screening…...........................................................191
Section-II
Synthesis and biological screening of 5-aryl-2-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)-
1,3,4-oxadiazole
Reaction Scheme......................................................................................................................…..193
Spectrul Studies.............................................................................................................................194
Experimental..................................................................................................................................198
Data of In Vitro Evaluation of Antimicrobial Screening...............................................................200
References......................................................................................................................................202
CHAPTER-6 : STUDIES ON TRIAZOLE DERIVATIVES
Introduction...................................................................................................................................206
Therapeutic Importance................................................................................................................209
Section-I
Synthesis and biological screening of 4-((arylmethylidine)amino)-5-((4-(2,3-
dichlorophenyl)piperazin-1-yl)methyl)-4H-1,2,4-triazole-3-thiol
Reaction Scheme............................................................................................................................214
Spectrul Studies.............................................................................................................................215
Experimental..................................................................................................................................219
Data of In Vitro Evaluation of Antimicrobial Screening…...........................................................222
References......................................................................................................................................224
CHAPTER-7 : STUDIES ON ARYL AMIDE DERIVATIVES
Introduction...................................................................................................................................228
Therapeutic Importance................................................................................................................230
Section-I
Synthesis and biological screening of N'-(arylcarbonyl)-6-fluoro-3,4-dihydro-2H-chromene-
2-carbohydrazide
Reaction Scheme............................................................................................................................234
Spectrul Studies.............................................................................................................................235
Experimental..................................................................................................................................239
Data of In Vitro Evaluation of Antimicrobial Screening…...........................................................242
References......................................................................................................................................244
LIST OF PUBLICATION...........................................................................................................249
Synopsis
Studies on Biologically Active... 1
Synopsis...
STUDIES ON BIOLOGICALLY ACTIVE HETEROCYCLIC
ANALOGOUS
The work to be presented in the thesis entitled “STUDIES ON
BIOLOGICALLY ACTIVE HETEROCYCLIC ANALOGOUS” is divided into
seven chapters.
CHAPTER 1 STUDIES ON TETRAHYDROPYRIMIDINES BY
CONVENTIONAL METHOD AND MICROWAVE
ASSISTED METHOD
Pyrimidine nucleus possesses remarkable pharmaceutical importance and
biological activities, some of their derivatives occur as natural products, like nucleic acids
and vitamin B. Several pyrimidine derivatives have displayed diverse pharmacological
activities like antitumor, calcium channel blocker etc. Pyrimidine moiety has attained
great interest of medicinal chemists because of its broad activity spectrum. A large
number of tetrahydropyrimidine derivatives can be synthesized by applying structural
modification of the building blocks of Biginelli reaction. Such structural modifications
have lead to interesting exhibition of biological activity. Our aim has to synthesize several
modified tetrahydropyrimidines by conventional methods as well as microwave assisted
synthesis.
In the present chapter, efforts have been made for the synthesis of 4-aryl-6-
isopropyl-N-(5-methyl-1,3-thiazol-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxa-
mide (type-I) and 4-aryl-6-isopropyl-N-(5-methyl-1,3-thiazol-2-yl)-2-thioxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (type-II) derivatives. 4-methyl-N-(5-methyl-1,3-
thiazol-2-yl)-3-oxopentanamide, urea / thiourea and various aromatic aldehydes have
been used to the multicomponent cyclocondensation reaction. These reactions were
conventionally carried out in ethanol in the presence of the catalytic amount of con. HCl
for 12-24 hours at reflux temperature. Intermediate 4-methyl-N-(5-methyl-1,3-thiazol-2-
yl)-3-oxopentanamide was prepared by condensatation of methyl-4-methyl-3-
oxopentanoate with 5-methylthiazole-2-amine .
In continuation of work, the same molecules (type-I) and (type-II) when
synthesized through green chemistry approach by using etidronic acid as a catalyst
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through microwave irradiation technique, resulted in formation of all newly synthesized
compounds with higher yields and reaction hours are also reduced to a great extent in
compare to conventional method. Synthesized compounds are well characterized by
elemental analysis, mass, IR and 1H NMR spectroscopy.
Section-I: Synthesis and biological screening of 4-aryl-6-isopropyl-N-(5-methyl-1,3-
thiazol-2-yl)-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
Section-II: Synthesis and biological screening of 4-aryl-6-isopropyl-N-(5-methyl-1,3-
thiazol-2-yl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide
CHAPTER 2 STUDIES ON PIPERAZINE & CHROMENE
DERIVATIVES
Part-1 STUDIES ON PIPERAZINE DERIVATIVES
Piperazines and their analogs are amongst the most important backbones in recent
drug discovery. Moreover, piperazine derivatives are core fragments in number of API
and piperazine scaffold occurs regularly in variety of complex natural products.
Piperazine derivatives containing a wide spectrum of biological activities viz.
antidepressant, antifungal, anti-inflammatory, antibacterial, antimalarial, anticonvulsant,
antipyretic, antitumor, anthelmintics, analgesic, antitubercular, anticancer, antidiabetic
etc. This observation stimulated our interest in construction, characterisation and
biological evaluation of some piperazine derivatives.
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Section-I: Synthesis and characterization of 2-(4-(2,3-dichlorophenyl) piperazin-1-
yl)acetohydrazide
Acetohydrazide derivative of (Type-III) has been synthesized by the condensation
of ethyl 2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetate with hydrazine hydrate in
absolute ethanol. Intermediate ethyl 2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetate was
prepared by condensation of 1-(2,3-dichlorophenyl)piperazine  with ethylbromoacetate.
Part-2 STUDIES ON CHROMENE DERIVATIVES
Chromene derivatives are well-known heterocyclic compounds among the organic
and medicinal chemists. The synthesis of these heterocycles has received considerable
attention in recent years. The derivatives of Chromene scaffold have occupied an unique
place in the field of medicinal chemistry due to wide range of biological activities like
antifungal, antihypertensive, anti-coagulant, antibacterial etc. All these facts were driving
force to develop some novel Chromene derivatives with wide structural variation. In
continuation to the same research topic, we report here some 2-substituted-3,4-dihydro-
2H-Chromene derivatives.
Section-I: Synthesis and characterization of 6-fluoro-3,4-dihydro-2H-chromene-2-
carbohydrazide
Carbohydrazide derivative of (Type-IV) has been synthesized by the condensation
of methyl 6-fluoro-3,4-dihydro-2H-chromene-2-carboxylate with hydrazine hydrate in
absolute ethanol. Intermediate methyl 6-fluoro-3,4-dihydro-2H-chromene-2-carboxylate
was prepared by esterification of 6-fluoro-3,4-dihydro-2H-chromene-2-carboxylic acid in
methanolic HCl.
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CHAPTER 3 STUDIES ON SCHIFF BASE DERIVATIVES
Schiff base derivatives represent one of the important classes of biological active
agent which has been deeply studied during searching of new potential agent. These have
been reported to be active as antimicrobial, anti-inflammatory, antitubercular, anticancer,
anthelmintics etc.
Schiff bases are also known as Azomethines and they are well known intermediate
for the preparation of azetidinone, thiazolidinone and many other scaffold derivatives.
These are the compounds contain characteristic -C=N group, which is significantly
efficient for cyclization.
In view of these observations, we have synthesized some new Schiff base
derivatives, which have been described as under.
Section-I: Synthesis and biological screening of N'-arylmethylidene-2-(4-(2,3-
dichlorophenyl)piperazin-1-yl)acetohydrazide
Schiff base derivatives of (Type-V) have been synthesized by the condensation of
2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetohydrazide with various aromatic aldehydes
in the presence of catalytic amount of glacial acetic acid in absolute ethanol.
Section-II: Synthesis and biological screening of N'-(1-arylethylidene)-2-(4-(2,3-
dichlorophenyl)piperazin-1-yl)acetohydrazide
Schiff base derivatives of (Type-VI) have been synthesized by the condensation of
2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetohydrazide with various aromatic
acetophenones in the presence of catalytic amount of glacial acetic acid in absolute
ethanol at reflux temperature.
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Section-III: Synthesis and biological screening of N'-arylmethylidene-6-fluoro-3,4-
dihydro-2H-chromene-2-carbohydrazide
Schiff base of (Type-VII) have been synthesized by the condensation of 6-fluoro-
3,4-dihydro-2H-chromene-2-carbohydrazide with various aromatic aldehydes in the
presence of catalytic amount of glacial acetic acid in absolute ethanol.
Section-IV: Synthesis and biological screening of N'-(1-arylethylidene)-6-fluoro-3,4-
dihydro-2H-chromene-2-carbohydrzide
Schiff base of (Type-VIII) have been synthesized by the condensation of 6-fluoro-
3,4-dihydro-2H-chromene-2-carbohydrazide with various aromatic acetophenones in the
presence of catalytic amount of glacial acetic acid in absolute ethanol at reflux
temperature.
CHAPTER 4 STUDIES ON THIAZOLIDINONE DERIVATIVES
4-Thiazolidinones play a vital role due to their wide range of biological activities
and industrial importance. 4-Thiazolidinones are always being an attraction point for
researchers because of their efficiency exhibit by various pharmacological usages.
Thiazolidinone is one of the most intensively investigated class of aromatic five
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membered heterocycles. The derivatives of 4-thiazolidinone nucleus have occupied a
unique place in the field of medicinal chemistry due to wide range of biological activities
like antibacterial, antitubercular, anticancer, anticonvulsant and antifungal.
To approach this goal, synthesis of some new thiazolidinone derivatives have been
undertaken, which have been described as under.
Section-I: Synthesis and biological screening of N-(2-aryl-4-oxothiazolidin-3-yl)-2-(4-
(2,3-dichlorophenyl)piperazin-1-yl)acetamide
The 4-Thiazolidinone derivatives of (Type-IX) have been synthesized by the
cyclocondensation reaction of Schiff base of Type (V) and thioglycolic acid.
Section-II: Synthesis and biological screening of N-(2-aryl-5-methyl-4-
oxothiazolidin-3-yl)-2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetamide
The 4-Thiazolidinone derivatives of (Type-X) have been synthesized by the
cyclocondensation reaction of Schiff base of Type (V) with thiolactic acid.
CHAPTER 5 STUDIES ON OXADIAZOLE DERIVATIVES
1,3,4- Oxadiazole derivatives constitute an important family of heterocyclic
compounds. Since many of them display a remarkable biological activity and find wide
usage. Particularly, the 2-aryl-5-substituted-1,3,4-oxadiazole have been reported to show
broad spectrum of pharmacological activity like analgesic, anti-inflammatory, anesthetic,
hypnotic, antibacterial, hypoglycemic and antifungal. These valid observations promoted
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us to synthesize 1,3,4- oxadiazole derivatives with better therapeutic value, Which have
been described as under.
Section-I: Synthesis and biological screening of 5-aryl-2-((4-(2,3-
dichlorophenyl)piperazin-1-yl)methyl)-1,3,4-oxadiazole
Oxadiazole derivatives of (type-XI) have been synthesized by the cyclo
condensation of 2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetohydrazide with different
aromatic acids in POCl3.
Section-II: Synthesis and biological screening of 5-aryl-2-(6-fluoro-3,4-dihydro-2H-
chromen-2-yl)-1,3,4-oxadiazole
Oxadiazole derivatives of (type-XII) have been synthesized by the cyclo
condensation of 6-fluoro-3,4-dihydro-2H-chromene-2-carbohydrazide with different
aromatic acids in POCl3.
CHAPTER 6 STUDIES ON TRIAZOLE DERIVATIVES
Triazole derivatives are the important class of heterocyclic compounds, found in
many potent biologically active molecules. Particularly 1,2,4-triazoles represents rapid
developing field in modern heterocyclic chemistry. From literature it is predictable that,
1,2,4-triazole scaffold represents important pharmacophores, and play a vital role as
medicinal agents. 1,2,4-Triazoles exhibit a wide range of biological activities such as
antifungal, antibacterial, antitubercular, anticancer, analgesic and anti-inflammatory.
In view of obtaining better therapeutic agents, we have synthesized some new
1,2,4-triazole derivatives, which have been described as under.
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Section-I: Synthesis and biological screening of 4-((arylmethylidine)amino)-5-((4-
(2,3-dichlorophenyl)piperazin-1-yl)methyl)-4H-1,2,4-triazole-3-thiol
1,2,4-Triazole derivatives of (Type-XIII) have been synthesized by the
condensation of 4-amino-5-((4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-4H-1,2,4-
triazole-3-thiol with various aromatic aldehydes in the presence of catalytic amount of
hydrochloric acid in absolute ethanol. Intermediate 4-amino-5-((4-(2,3-
dichlorophenyl)piperazin-1-yl)methy)-4H-1,2,4-triazole-3-thiol has been prepared from
2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetohydrazide in two step.
CHAPTER 7 STUDIES ON ARYLAMIDE DERIVATIVES
Arylamide derivatives showed different biological activity such as antihista
manic, anti-inflammatory, anticonvulsant, antitubercular, antipyretic, analgesic, antiseptic
etc. To getting better therapeutic agent and to evaluate its pharmacological profile, some
new aryl amide derivatives have been synthesized, which have been described as under.
Section-I: Synthesis and biological screening of N'-(arylcarbonyl)-6-fluoro-3,4-
dihydro-2H-chromene-2-carbohydrazide
Aryl amides of (type-XIV) have been synthesized by the condensation of 6-
fluoro-3,4-dihydro-2H-chromene-2-carbohydrazide with various aromatic acids in the
presence of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), 1-
hydroxybenzotriazole (HOBt) and triethylamine in dichloromethane.
All the synthesized compounds have been screened for antibacterial and
antifungal activity. The biological activities of the synthesized compounds have been
compared with standard drugs.
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The constitution of all the synthesized compounds has been characterized by using
elemental analysis, 1H-NMR & IR spectroscopy and further supported by mass
spectroscopy. Purity of all the compounds has been checked on thin layer
chromatography.
Introduction
STUDIES ON BIOLOGICALLY
ACTIVE HETEROCYCLIC
ANALOGOUS
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INTRODUCTION
The chemistry of the heterocyclic compounds is as logical as that of aliphatic or
aromatic compounds. This study is of great interest both from the theoretical as well as
practical point of view. A heterocyclic compound is one which possesses a cyclic
structure with at least one different kinds of atom other than carbon in the ring system.
The most common type, contains largely nitrogen, oxygen and sulphur heteroatoms, but
many other elements, including even phosphorous, boron, silicon, arsenic can also serve.
The heterocyclic compounds containing the less common atoms have been subject to
much investigation in recent years.
The variety of heterocyclic compounds is enormous, their chemistry is complex
and synthesizing them requires great skill. Among large number of heterocycles found in
nature nitrogen heterocycles are most abundant than those containing oxygen or sulphur
owing to their wide distribution in nucleic acid instance and involvement in almost every
physiological process of plants and animals.
Heterocyclic systems are encountered in many groups of organic compounds
possessing great applicability in industry as well as in our life in various ways i. e. most
of the sugars and their derivatives, including vitamin C, for instance, exist largely in the
form of five membered (Furanoside str.) or six membered (Pyranoside str.) ring
containing one oxygen atom. Most members of the vitamin B group possess heterocyclic
rings containing nitrogen; one example is vitamin B6 (Pyridoxine), which is a derivative
of the pyridine essential in amino acid metabolism. Many other examples of the
importance of heterocyclic compounds in biological systems can be given.
Natural products containing heterocyclic compounds such as alkaloids and
glycosides have been used since old age, as medicinal agents. Adlumine alkaloid isolated
from Adlumina, codenine isolated from opium (0.7 to 2.5 %), one of the first alkaloids
isolated in pure form from seeds of strychnos nuxvomica these all are the examples of
naturally occurring heterocyclic compounds. Many antibiotics including penicillin,
cephalosporin, norfloxacin, streptomycin etc. also contain heterocyclic ring systems.
Majority of the large number of drugs being introduced in pharmacopeias in recent years
are heterocyclic compounds.
Important drugs, such as metformin, pioglitazone, sulphathiazole,
ibuprofen, zolpidem, fluconazole, atorvastatin, reserpine, ranitidine, omeprazole, certain
of the antihistamines, barbiturates etc. are heterocyclic compounds. Many veterinary
products like pyrantel and morantel are the drug of choice as broad spectrum
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anthelmintics. The herbicides atrazine and simazine are well known example of
heterocyclic agrochemicals. Plant pigments such as indigo, heamin and anthocyanine,
chlorophyll has contributed much colour chemistry and many other heterocyclic
colouring matters are in use since prehistoric times.
Heterocyclic compounds are obtainable by the following methods.
(a) Isolation from natural sources, i.e. alkaloids, amino acids, indigo dyes etc.
(b) Degradation of natural products i.e. acridine, furfural, indol, pyridine, quinoline,
thiophene etc.
(c) Synthesis: Synthesis methods for obtaining heterocyclic compounds may be
divided into ring closer reactions, addition reaction and replacement reaction.
Cyclisation is usually accomplished by elimination of some small molecules such
as water or ammonia from chain of suitable length.
Heterocyclic compounds have a great applicability as drugs because,
(i) They have a specific chemical reactivity.
(ii) They play a vital role in the metabolism of all the living cells.
The current interest in the creation of large, searchable libraries of organic
compounds has captured an imagination of organic chemists and the drug discovery
community. Efforts in numerous laboratories focused on the introduction of chemical
diversity have been recently reviewed and pharmacologically interesting compounds have
been identified for libraries of widely different compositions.
Research in the field of pharmaceutical has its most important task in the
development of new and better drugs and their successful introduction into clinical
practice. Central to this efforts, the search for pharmaceutical substances and preparation
which are new and better than previous. In addition to these objectives, we may search for
newer entities which exhibit some clear advantages over a drug already known. Such
advantages may be qualitatively or quantitatively improvement in activity, a partial or
total absence of undesirable side effects, lower toxicity, improved stability or decreased in
cost.
In medicinal chemistry the study of relationships between the chemical structure
of a particular compound or group of compounds and their effects on biological activity,
which is known as SAR (structural activity relationship) study and the mechanism by
which the substance influences the biological system, which is known as its mode of
action both play a very important role in drug discovery.
Studies on Biologically Active...
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Pharmacological activity of substance is associated with molecular structure, so
medicinal chemist is focused on the choice of functional groups, main scaffold and side
chain for the design of new drugs. They find or encounter a situation where a structure
has adequate pharmacological activity but has an inadequate pharmacokinetic profile (i.e.,
absorption, distribution, metabolism and excretion). This is because pharmacology and
pharmacokinetic departments in the pharmaceutical industry often do not collaborate at
the early stage of drug development. It is only later, when the new compound is tested in
animals or in humans, that pharmacokinetic disadvantages become obvious.
Drug action is believed to be due to the drug with enzymes, receptors and other
molecules found in the biological system. The binding of a drug to the active or other
sites of an enzyme usually has the effect of preventing the normal operation of that
enzyme. Binding of the drug to the enzyme and number of occupied binding sites play
important role in inhibiting the action of the enzyme.
The degree of drug activity is directly related to the concentration of the drug in
the aqueous medium in contact with the active or receptor site. The factors affecting this
concentration in a biological system can be classified in to two phases.
(I) The pharmacokinetic phase
It is concerned with the study of the parameters that control the journey of the
drug from its point of administration to its point of action. It includes the absorption,
distribution, metabolism and elimination of a drug.
(II) The pharmacodynamic phase
It deals with the result of the interaction of drug and body cell at the receptor site,
that is, what the drug does to the body. This includes physiological and biochemical
effects of drugs and their mechanism of action at macromolecular/sub cellular organ
systems.
Heterocyclic chemistry and medicinal chemistry share a venerable common
history. Many of the founders of heterocyclic systems had an intense interest in both the
natural as well as synthetic molecules. There are two main divisions of medicinal
chemistry. The first chemotherapy, concerns the treatment of infections, parasite or
malignant disease by chemical agents, usually substances that show selective toxicity
toward the pathogen. The other division relates to bodily dysfunctions and the agents
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employed are mainly compounds that effect the functioning of enzymes, the transmission
of impulses or the action of hormones on receptors.
The current interest in the creation of large, searchable libraries of organic
compounds has captured an imagination of organic chemist and the drug discovery
community. Efforts in numerous laboratories focused on the introduction of chemical
diversity have been recently reviewed and pharmacologically interesting compounds have
been identified from libraries of widely different composition.
AIMS AND OBJECTIVES
Taking in view of the applicability of heterocyclic compounds, we have
undertaken the preparation of heterocycles bearing tetrahydropyrimidine, piperazine and
chromene nucleus. The placements of a wide variety of substituents of these nuclei have
been designed in order to evaluate the synthesized products for their pharmacological
profile against several strains of bacteria and fungi.
During the course of our research work, looking to the application of heterocyclic
compounds, several entities have been designed, synthesized and characterized using
spectral studies. The details are as under.
 To generate several derivatives of oxo/thiotetrahydropyrimidines by conventional
method and by microwave irradiation method in the presence of catalyst by using
MCR (Multi Component Reaction) concepts.
 To generate several derivatives like Schiff base, Thiazolidinone, Oxadiazole,
Triazole, aryl amide nucleus.
 To characterize these products for structure elucidation using various
spectroscopic techniques like IR, PMR and Mass spectral studies.
 To evaluate these products for antimicrobial activity by screening against different
strains of bacteria and fungi.
Chapter-1
STUDIES ON
TETRAHYDROPYRIMIDINES BY
CONVENTIONAL METHOD &
MICROWAVE ASSISTED METHOD
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INTRODUCTION
Pyrimidine is a well known heterocyclic compound, which has been subjected to a
large variety of structural modification in order to synthesize derivatives with different
biological properties. Pyrimidine derivatives have been reported to possess a broad
spectrum of pharmacological properties.
Pyrimidine is the most important member of all the diazines as this ring system
occurs widely in living organisms. Purines, uric acid, barbituric acid and some anti-
malarial and anti-bacterial agents also contain the pyrimidine ring. The chemistry of
pyrimidine has been widely studied. Pyrimidine was first isolated by Gabriel and Colman
in 1899. Despite the importance of dihydroazines (particularly those containing the 1,4-
dihydropyrimidine and dihydropyridine moiety1) for clarifying a wide range of
theoretical, medicinal and biological problems, the chemistry of this group of compounds
is still extremely spotty.2-6
From the theoretical point of view, it is essential to predict the structure, binding
properties, chemical reactivity, etc. of dihydro compounds from the number and
positioning of nitrogen atoms in the ring, as well as from the disposition of double bonds.
Such quantum mechanical calculations also enable an evaluation of the degree of
aromatic character in potential “homoaromatic” and “antiaromatic” isomers. Availability
of novel model compounds for verifying these predictions would open up new horizons in
theoretical heterocyclic chemistry, particularly in clarifying the structures leading to
spontaneous isomerization of a derivative or in verifying its redox properties.
From the biochemical point of view, dihydroazines are of intense interest because
of presence of this group at the active site of the hydrogen transferring coenzyme
(nicotinamide adenine dinucleotied hdrogenase-NADH or reduced nicotinamide adenine
dinucleotide). This nucleotide, a central participant in metabolic processes in living
organisms, participates in the reduction of various unsaturated functionalities.
In drug development, dihydroazines show great promise, particularly since the 4-
aryldihydropyridines exhibit powerful vasodilation activity via modifying the calcium ion
membrane channel.7-10 Additionally, dihydropyridines have been found to actively
transport medication across biological membranes.11
Until recently, most of the information available on dihydroazines centered around
dihydropyridines, with very little data extending to the related dihydropyrimidines.
This lacuna has motivated our deep involvement in developing dihydropyrimidine
chemistry, particularly dihydropyrimidines without any substituents on the ring
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nitrogen.12 These molecules have long been considered unstable for oxidation,
polymerization or disproportionation reactions.13
Figure below present the five possible isomeric structures of dihydropyrimidines,
exhibiting different dispositions of the double bonds.
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However, these structures are not easy to synthesize and, as a result, most of the
known dihydropyrimidines have either 1,2- or the tautomeric 1,4- and 1,6- geometry. On
the basis of data available in the literature14,15, the dihydropyrimidines can be
conveniently divided into two groups, within each of which interconversion between
isomers is possible under thermal conditions, namely, the 1,4-, 1,6-, and 4,5- isomers, and
the 1,2- and 2,5- isomers. It is worthwhile to note that, while thermal interconversion
between the two groups is not observed, photochemical rearrangement of 1,4- (or 1,6-)
dihydropyrimidines to 1,2-isomers has been reported16,17.
It should be stressed that dihydroazines take part in various isomerization
processes, usually characterized by reversible or irreversible migrations within the ring,
the study of which is still in its infancy. Hydrogen migration, for example, is classified
either as rearrangement or tautomerism depending on its kinetic and thermodynamic
parameters, the former term is reserved for irreversible processes, while the latter is used
to describe fast reversible exchanges18. A study of isomerization in dihydropyrimidines
provides an excellent opportunity for clarifying the factors regulating these processes.
After successfully developing versatile synthetic techniques for obtaining a
variety of 1,4- and 1,6-dihydropyrimidines19-21, as well as the observation of amidinic
tautomerism between the two22,23, A. L. Weis et al.14 examining the possibility of
preparative synthesis of similarly 1,2-dihydro derivatives and studying their properties.
Particularly important goals of this study were the possible observation of the formally
allowed hydrogen shift23, of homoaromaticity24,25 or of imine-enamine tautomerism26 in
these compounds, behaviors of which have been seen in other systems.
Recently few reports on the formation of 1,2-dihydropyrimidines exist in the
literature, and in those cases where a product could be isolated and characterized, the
material was either an N-substituted derivative or else it contained geminal disubstitution
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at position 2, situations that prevent the molecule from oxidizing to the corresponding
pyrimidine.
Pyrimidine ring carrying various substituents may be built up from two or three
small fragments by the principle synthesis or by a variety of other synthesis, which are
complimentary rather than alternative to it. A second type of synthesis is the
isomerisation or break down of another heterocycles such as hydration of purine but such
roots are frequently used.
SYNTHETIC ASPECT
Biginelli Reaction
In 1893, Italian chemist Pietro Biginelli27 reported an acid catalyzed
cyclocondensation reaction of ethyl acetoacetate, benzaldehyde, and urea. The reaction
was carried out by simply heating a mixture of the three components dissolved in ethanol
with a catalytic amount of HCl at reflux temperature. The product of this novel one-pot,
three-component synthesis that precipitated on cooling of the reaction mixture was
identified correctly by Biginelli as 3,4-dihydropyrimidin-2(1H)-one.
Me O
O
EtO2C
O H
+
NH2
NH2 O
N
NMe O
O
EtO2C H
H
H+
EtOH
Alternative synthetic routes for better yield, shorter reaction time to synthesize new
analogs
Various modifications have been applied to Biginelli reaction to get better yield and to
synthesize biologically active analogs. Different catalysts have been reported to increase
the yield of the reaction. Microwave synthesis strategies have also applied to shorten the
reaction time. Solid phase synthesis and combinatorial chemistry has made possible to
generate library of DHPM analogs. The various modifications are discussed in the
following section.
Catalysts
Min Yang and coworkers28 have synthesized the different DHPMs by using different
inorganic salts as a catalyst. They found that the yields of the one-pot Biginelli reaction
can be increased from 20-50 % to 81-99 %, while the reaction time shorted for 18-24 hr
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to 20-30 min. This report discloses a new and simple modification of the Biginelli type
reaction by using Yb(OTf)3 and YbCl3 as a catalyst under solvent free conditions. One
additional important feature of this protocol is the catalyst can be easily recovered and
reused.
R
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O
NH2
NH2
O
R1
R2
O
NH
N
H
RO
R1
R2 O+
Yb(OTf)3
100  °C
Indium(III) chloride was emerged as a powerful lewis catalyst imparting high
region and chemo selectivity in various chemical transformations. B. C. Ranu and
coworkers29 reported indium(III) chloride (InCl3) as an efficient catalyst for synthesis of
3,4-dihydropyrimidn-2(1H)-ones. A variety of substituted aromatic, aliphatic and
heterocyclic aldehydes have been subjected to this condensation very efficiently.
Thiourea has been used with similar success to provide the corresponding
dihydropyrimidin-2(1H)-thiones.
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Where X = O or S
R
O
Majid M. Heravi et al. have reported a simple, efficient and cost-effective method
for the synthesis of 3,4-dihydropyrimidin-2(1H)-ones/thiones by one pot three-component
cyclocondensation reaction of a 1,3-dicarbonyl compound, an aldehyde and urea or
thiourea using 12-tungstophosphoric acid30 and 12-molybdophosphoric acid31 as a
recyclable catalyst.
NH2
NH2 X
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O
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N
H
R1 H
R2COO
X
Where X = O or S
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O
+
12 - tungstophosphoric acid/
12 - molybdophosphoric acid
AcOH/reflux
A novel covalently anchored sulfonic acid onto the surface of silica was prepared
and investigated for the Biginelli reaction by Satya Paul and co-workers32. The catalyst is
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highly stable, completely heterogeneous and recyclable for several times. The workup
procedure is very simple and products were obtained in good to excellent yields.
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Where X = O or S
Catalyst 1
Stirring, 80°C, 7 - 12 h
An efficient three-component synthesis of 3,4-dihydropyrimidinones using
trichloroisocyanuric acid (TCCA) as mild, homogeneous and neutral catalyst for Biginelli
reaction in ethanol or DMF under reflux condition33.
Very recently, many researchers34-40 have investigated an efficient Biginelli
reaction under solvent-free conditions for one-pot synthesis of 3,4-dihydropyrimidin-2-
ones/thiones using various catalyst.
Solid phase synthesis
The generation of combinatorial libraries of heterocyclic compounds by solid
phase synthesis is of great interest for accelerating lead discovery and lead optimization
in pharmaceutical research41,42. Multi-component reactions (MCRs) leading to
heterocycles are particularly useful for the creation of diverse chemical libraries, since the
combination of n (where n ≥ 3) building blocks in a single operation leads to high
combinatorial efficiancy41-43. Therefore, solid phase modifications of MCRs are rapidly
become the cornerstone of combinatorial synthesis of small-molecule libraries41-47.
The first solid-phase modification of the Biginelli condensation was reported by
Wipf and Cunningham48 in 1995. In this sequence, -aminobutyric acid derived urea was
attached to Wang resin using standard procedures. The resulting polymer-bound urea was
condensed with excess β-ketoester and aromatic aldehydes in THF at 55 °C in the
presence of a catalytic amount of HCl to afford the corresponding immobilized DHPMs.
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Subsequent cleavage of product from the resin by 50 % trifluoroacetic acid (TFA)
provided DHPMs in high yields and excellent purity.
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2. TFA, CH2Cl2
Weiwei Li and Yulin Lam49 described the synthesis of 3,4-dihydropyrimidin-2-
(1H)ones/thiones using sodium benzenesulfinate as a traceless linker. The key steps
involved in the solid-phase synthetic procedure include sulfinate acidification,
condensation of urea or thiourea with aldehydes and sulfinic acid and traceless product
release by a one-pot cyclization-dehydration process. Since a variety of reagents can be
used, the overall strategy appears to be applicable to library generation.
SO2H
R1
O
NH2 X
NH2+
DMF
SO2
NH
R1
NH2
X
R3
O O
R2
1. KOH, EtOH
2. TsOH
1. Pyrrolidine, THF
2. TsOH
R2
O
O
OH
N
H
NH
X
R2
O
R3
R1
N
H
NH
X
R2
R1
O
OH
Recently, Gross et al.50 developed a protocol based on immobilized α-ketoamides
to increase the diversity of DHPM. The resulting synthetic protocol proved to be suitable
for the preparation of a small library using different building blocks. They found that the
expected DHPM derivatives were formed in high purity and yield, if aromatic aldehyde
and α-ketoamide building blocks were used. The usage of an aliphatic aldehyde leads to
an isomeric DHPM mixture. Purities and yields were not affected if thiourea was used
instead of urea.
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Liquid phase synthesis
In the solid phase synthesis there are some disadvantages of this methodology
compared to standard solution-phase synthesis, such as difficulties to monitor reaction
progress, the large excess of reagents typically used in solid-phase supported synthesis,
low loading capacity and limited solubility during the reaction progress and the
heterogeneous reaction condition with solid phase51. Recently, organic synthesis of small
molecular compounds on soluble polymers, i.e. liquid phase chemistry has increasingly
become attractive field52. It couples the advantages of homogeneous solution chemistry
with those of solid phase chemistry.
Moreover owing to the homogeneity of liquid-phase reactions, the reaction
conditions can be readily shifted from solution-phase systems without large changes and
the amount of excessive reagents is less than that in solid-phase reactions. In the recent
years, Task Specific room temperature Ionic Liquids (TSILs) has emerged as a powerful
alternative to conventional molecular organic solvents or catalysts. Liu Zuliang et al.53
reported cheap and reusable TSILs for the synthesis of 3,4-dihydropyrimidin-2(1H)-ones
via one-pot three component Biginelli reaction.
Ionic liquid-phase bound acetoacetate react with thiourea and various aldehydes
with a cheap catalyst to afford ionic liquid-phase supported 3,4-dihydropyrimidin-2(1H)-
thiones by Jean Pierre Bazureau and co-workers54. 3,4-dihydropyrimidinones was
synthesized in one-pot of aldehydes, β-dicarbonyl compounds and urea, catalyzing by
non-toxic ionic liquid 1-n-butyl-3-methylimidazolium saccharinate (BMImSac)55 at room
temperature.
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Microwave assisted synthesis
In general, the standard procedure for the Biginelli condensation involves one pot
condensation of the three building blocks in a solvent such as ethanol using a strongly
acidic catalyst that is hydrochloric acid56. One major drawback of this procedure, apart
from the long reaction times involving reflux temperatures, are the moderate yields
frequently observed when using more complex building blocks. Microwave irradiation
(MWI) has become an recognized tool in organic synthesis, because the rate
enhancement, higher yields and often, improved selectivity with respect to conventional
reaction conditions57. The publication by Anshu Dandia et al.58 described microwave-
enhanced solution-phase Biginelli reactions employing ethyl acetoacetate, thiourea and a
wide variety of aromatic aldehydes as building blocks. Upon irradiation of the individual
reaction mixtures (ethanol, catalytic HCl) in an open glass beaker inside the cavity of a
domestic microwave oven the reaction times were reduced from 2-24 hours of
conventional heating 80 °C, reflux to 3-11 minutes under microwave activation (ca. 200 –
300 W). At the same time the yields of DHPMs obtained were markedly improved
compared to those reported earlier using conventional conditions.
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In recent years, solvent free reactions using either organic or inorganic solid
supports have received increasing attention59. There are several advantages to performing
synthesis in dry media: (i) short reaction times, (ii) increased safety, (iii) economic
advantages due to the absence of solvent. In addition, solvent free MWI processes are
also clean and efficient. Activated fly ash, an industrial waste (pollutant) is an efficient
and novel catalyst for some selected organic reactions in solvent free conditions under
microwave irradiation60. M. Gopalakrishnan and co-workers have reported Biginelli
reaction under microwave irradiation in solvent-free conditions using activated fly ash as
a catalyst.
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Ultrasound assisted synthesis
Ultrasound as a green synthetic approach has gradually been used in organic
synthesis over the last three decades. Compared with the traditional methods, it is more
convenient, easier to be controlled, and consumes less power. With the use of ultrasound
irradiation, a large number of organic reactions can be carried out in milder conditions
with shorter reaction time and higher product yields61. Ultrasound irradiated and
amidosulfonic acid (NH2SO3H) catalyzed synthesis of 3,4-dihydropyrimidi-2-(1H)ones
have reported by Ji-Taai Li and co-workers62 using aldehydes, β-ketoester and urea.
Chenjiang Liu et al.63 have synthesized a novel series of 4-substituted pyrazolyl-
3,4-dihydropyrimidin-2(1H)-thiones under ultrasound irradiation using magnesium
perchlorate [Mg(ClO4)2] as catalyst, by the condensation of 5-chloro/phenoxyl-3-methyl-
1-phenyl-4-formylpyrazole, 1,3-dicarbonyl compound and urea or thiourea in moderate
yields. The catalyst exhibited remarkable reactivity and can be recycled.
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Sonication of aromatic aldehydes, urea and ethyl acetoacetate in presence of
solvent (ethanol) or solvent-less dry media (bentonite clay) by supporting-zirconium
chloride (ZrCl4) as catalyst at 35 kHz gives 6-methyl-4-substitutedphenyl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxylic acid ethyl esters proficiently in high yields reported by
Harish Kumar et al64.
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REACTION MECHANISM
In 1893 Biginelli65 reported the first synthesis of dihydropyrimidines by a simple
one-pot condensation reaction of ethyl acetoacetate, benzaldehyde and urea.
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H+
EtOH
(1)
(2)
(3) (4)
Despite the importance and current interest in dihydropyrimidines of the Biginelli
type, the mechanism of the classical three-component Biginelli condensation has not been
elucidated with certainty66. Since the 1930s several mechanistic pathways have been
proposed for the Biginelli reaction. In 1933, Folkers and Johnson67 reported that one of
three intermediates was likely to be present in this reaction.
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Fourty years after the initial praposal, In 1973 Sweet and Fissekis68 proposed
more detailed pathway involving carbenium ion spices, The mechanism was then
reexamined 25 years later in 1997 by Kappe, C. O. Kappe69 used 1H and 13C-NMR
spectroscopy to support the argument that the key intermediate in the Biginelli reaction
was iminium species (9). In the event, benzaldehyde (2) reacted with urea (3) to form an
intermediate “hemiaminal” (8) which subsequently dehydrated to deliver N-acyl
imminium spices (9). Iminium cation (9) then reacted with ethyl acetoacetate (1) to give
uride (11), which underwent facile cyclodehydration to give (4). Kappe also noted that in
the absence of (1), bisureide (10) was afforded as a consequence of nucleophilic attack of
(9) by urea (3). This discovery confirmed the conclusion of Folkers and Johnson67 in
1933. As far as the proposal from 25 years earlier by Sweet and Fisselus, Kappe saw no
evidence by 1H and 13C-NMR spectroscopy that a carbenium ion was a required species
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in the Biginelli reaction. The reaction mechanism can therefore be classified as α-
amidoalkylation, or more specifically as α-uridoalkylation70.
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THERAPEUTIC IMPORTANCE
4-Aryl-1,4-dihydropyridines (DHPs) of the nifedipine type e.g. nifedipine are the
most studied class of organic calcium channel modulators. More than 30 years after the
introduction of nifedipine (12), many DHP analogs have now been synthesized and
numerous second-generation commercial products have appeared on the market e.g.
nitrendipine, nicardipine and amlodipine71. The aza-analogs such as dihydropyrimidines
(13) which show a very similar pharmacological profile to classical dihydropyridine
calcium channel modulators72-76. Over the past several lead-compounds were developed
e.g. (13) SQ 32926 and (14) SQ 3257473,75 that are superior in potency and duration of
antihypertensive activity to classical dihydropyridine drugs and compare favorable with
second-generation analogs such as amlodipine and nicardipine73.
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(12) (13) SQ 32926 (14) SQ 32574
Calcium ion plays a vital role in a large number of cellular processes, including
excitation-contraction and stimulus-secretion77,78. The regulation of the intracellular
concentration of this ion makes possible the control of such Ca2+ dependent processes.
One means of accomplishing this is by the use of agents known as calcium channel
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antagonists, which inhibit the movement of calcium through certain membrane channel79-
81.
K. S. Atwal82 prepared the 2-heterosubstituted-4-aryl-l,4-dihydro-6-methyl-5
pyrimidinecarboxylic acid esters (15), which lack the potential C3 symmetry of
dihydropyridine calcium channel blockers, were prepared and evaluated for biological
activity. Biological assays using potassium-depolarized rabbit artery and radioligand
binding techniques showed that some of these compounds are potent mimics of
dihydropyridine calcium channel blockers. The combination of a branched ester e.g.
isopropyl, sec-butyl and thioalkyl group e.g. –SMe group was found to be optimal for
biological activity. Dihydropyrimidines (15) were found to be 30 fold less active than
dihydropyridines. The solid-state structure of dihydropyrimidine analogue (16) shows that
these compounds can adopt a molecular conformation which is similar to the reported
conformation of dihydropyridine calcium channel blockers.
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K. Atwal et al.83 synthesized the 3-substituted 1,4-dihydropyrimidine (17) and
documented that vasorelaxant activity was critically dependent on the size of the C5 ester
group, isopropyl ester being the best, a variety of substituents (carbamate, acyl, sulfonyl,
alkyl) were tolerated at third position. The dihydropyrimidines (17) are significantly more
potent than corresponding 2-heteroalkyl-l,4-dihydropyrimidines. Dihydropyridine
enantiomer usually show 10-15 fold difference in activity, while the enantiomers of
dihydropyrimidine (18) show more than a 1000 fold difference in activity. These results
strengthen the requirement of an enamino ester for binding to the dihydropyridine
receptor and indicate a nonspecific role for the substituent present on the third position.
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N
H
N
X
COOR1R2
N
H
N
S
NH2 O
O
N+O-
O
R3
(17) (18)
George C. Rovnyak et al.84 examined a series of novel dihydropyrimidine calcium
channel blockers that contain a basic group attached to either C5 or N3 of the heterocyclic
ring. One of these compounds was identified as a lead, and the individual enantiomers
(19a) (R) and (19b) (S) were synthesized. Dihydropyrimidine (19a) is equipotent to
nifedipine and amlodipine in vitro. In the spontaneously hypertensive rat,
dihydropyrimidine (19a) is more potent and longer acting than nifedipine and compares
most favorably with the long-acting dihydropyridine derivative amlodipine.
Dihydropyrimidine (19a) has the potential advantage of being a single enantiomer.
N
N
H
O
Oi-Pr
S
CO2 N
F
CF3
(19a) (R), (19b) (S)
Selma Sarac and co-workers85,86 have synthesized 4-arlyl-3,4-dihydropyrimidin-
2(1H)-one/thione derivatives. The calcium channel blocker activities of all compounds
performed on isolated rat ileum. Product (20), 2-nitrophenyl derivative and (21), 2-
bromophenyl derivative have potent antispasmodic activity on BaCl2 stimulated rat ileum.
NH
N
H
S
O
O
NO2
NH
N
H
Br
O
O
(20) (21)
N. Dhanapalan and co-workers87 have synthesized dihydropyrimidinones and
describe compound (22) have a high binding affinity (Ki = 0.2nM) for α1a receptor and
greater than 1500 fold selectivity over α1b and α1d adreno receptors. Modification of the
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linker in (22) gave compounds (23) and (24)88 viz µ-opioid receptor. Both these
compounds showed good α1a binding affinity (Ki = 0.2nM) and selectivity (>800-fold
over α1b and α1d), also showed good selectivity over several other recombinant human G-
protein coupled receptors. They have also identified that compound (25)89 was a lead
compound with a binding and functional profile comparable to that of (22). (25) have
negligible affinity for the µ-opioid receptor.
N
N
H
O
NH2
O
NH
O
N
COOMe
Ph
F
F
N
N
H
O
NH2
O
NH
O
N
CN
Ph
F
F
(22) (23)
N
N
H
H2NOC
Et O
NH
O
N
Ph
F
F
N
N
H
H2NOC
Et O
NH
O
N
F
F
CONH2
(24) (25)
The synthesis and differential antiproliferative activity of monastrol (26a),
oxomonastrol (26b) and eight oxygenated derivatives (28a,b)-(31a,b) on seven human
cancer cell lines are described by Dennis Russowsky90. For all evaluated cell lines,
monastrol (26a) was shown to be more active than its oxo-analogue, except for HT-29
cell line, suggesting the importance of the sulfur atom for the antiproliferative activity.
Monastrol (26a) and the thio derivatives (28a), (29a) and (31a) displayed relevant
antiproliferative properties with 3,4-methylenedioxy derivative (31a) being approximately
more than 30 times more potent than monastrol (26a) against colon cancer (HT-29) cell
line.
NH
N
H
X
OH
O
EtO NH
N
H
X
O
EtO NH
N
H
X
O
EtO
O
(26a) X = S Monastrol (27a) X = S (28a) X = S
(26b) X = O Oxo-monastrol (27b) X = O (28b) X = O
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NH
N
H
X
O
EtO
O
NH
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X
O
EtO
O
O
NH
N
H
X
O
EtO
O
O
O
(29a) X = S (30a) X = S (31a) X = S
(29b) X = O (30b) X = O (31b) X = O
Y. Mizutani and co-workers91,92 identify that dihydropyrimidine dehydrogenase
(DPD) is the rate-limiting enzyme in the pathway of uracil and thymine metabolism. DPD
is also the principle enzyme involved in the degradation of 5-fluorouracil and anticancer
chemotherapeutic agent that is used clinically to treatment of bladder cancer and renal
cell carcinoma.
CATALYTIC STUDY OF ETIDRONIC ACID THROUGH MICROWAVE
IRRADIATION TECHNIQUE
More than 100 year ago the first 1,4-DHPMs were synthesized by Pietro
Biginelli93. The classical method involves a simple one-pot condensation reaction of
ethylacetoacetate, aryl aldehyde and urea/thiourea under strong acidic condition94. The
major limitations of biginelli reaction are lower yield and longer reaction time. Moreover,
product separation and work up also cause problem and needed special techniques. Thus,
main disadvantages in biginelli reaction are lower yield, longer reaction time and tidious
work up.
Due to these disadvantages of biginelli method, there are several efficient
methods developed for the synthesis of 1,4-DHPMs, which comprise the use of Silica
triflate95, Iodotrimethylsilane in acetonitrile96, Strontium(II)nitrate97, PEG-400098,
chloroacetic acid99, InBr3100, microwave101,102, KSF montmorillonite103 etc as catalysts.
However, the use of high temperatures, expensive metal precursors and longer reaction
times are limits of these methods.
CURRENT WORK
To avoid these unconvenency, the development of an efficient and versatile
method has been made for the synthesis of 1,4-DHPMs, The work of such heterocycle is
an interesting research area and there is a scope for further improvement towards
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conventional reaction conditions and to improve the reaction yield and decrease the
reaction time.
In extension of our work, the tetrahydropyrimidine derivatives have been
synthesized through green chemistry approach by utilizing Etidronic acid through
microwave irradiation technique.
PO
OH
OH
P
OH
O
OHCH3
OH
(44)
Etidronic acid [(1-hydroxyethylidene)bisphosphonic acid]
Etidronic acid [(1-hydroxyethylidene)bisphosphonic acid] is a phosphonic acid
and is also known as a bisphosphonate having a molecular formula C2H8O7P2. The two
PO3 (phosphonate) groups are covalently linked to a single carbon atom.104 By using this
method we found increased yield about 20-25% more than conventional method.
COMPARISION OF CONVENTIONAL BIGINELLI METHOD AND
MICROWAVE ASSISTED METHOD
The microwave assisted organic synthesis (MAOS) are attracting the interest of
organic chemists and other researchers due to their significant potential for converting
reactant into respective product in short reaction time with quantitative yields. Several
procedures have been reported in the literature for the synthesis of DHPMs under
microwave irradiations with different conditions and differnt catalyst.
In this chapter we have synthesised tetrahydropyrimidine derivatives of type-I and
type-II by conventional beginelli method and also by microwave assisted method, the
results obtained from the both method are noted. Comparition of the catalyst used,
reaction time and yield in both methods are given below in tabular form.
Parameter Conventional biginellimethod
Microwave assisted
method
Catalyst Con. HCl Etidroni acid
Reaction time 10 to 20 hours 6 to 18 minutes
Yield 40 to 60 % 60 to 90 %
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Thus, by using microwave assisted impruved method, it get optimum yields and
also reaction hours are reduced to a great extent (from hours to minutes) in comparison
with conventional biginelli method as mentioned in literature.
WORK DONE FROM OUR LABORATORY
Synthesis anticancer, antitubercular and antimicrobial activity of some new
pyrimidine derivatives have been reported by K. S. Nimavat105, some new thiopyrimidine
and oxopyrimidine heterocycles bearing 4-(methylsulfonyl)phenyl nucleus as potent
antitubercular and antimicrobial agents was developed and reported by D. J. Paghdar106.
M. R. Patel107 have reported synthesis and evaluation of pharmacological activity of some
new aminopyrimidine and thiopyrimidine derivatives.
J. D. Akbari and coworkers reported synthesis of some new 1,2,3,4-
tetrahydropyrimidine-2-ones and their thiazolo[3,2-a]pyrimidine derivatives as a potential
biological agents108, synthesis of some new pyrazolo[3,4-d]pyrimidines and thiazolo[4,5-
d]pyrimidines and evaluation of their antimicrobial activities109, green chemistry
approach to synthesis of some new trifluoromethyl containing tetrahydropyrimidines
under solvent free conditions110, synthesis and antimicrobial activities of some new
pyrazolo[3,4-d]pyrimidines and thiazolo[4,5-d]pyrimidines111.
SECTION-I: SYNTHESIS OF 4-ARYL-6-ISOPROPYL-N-(5-METHYL-1,3-
THIAZOL-2-YL)-2-OXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDES USING CONVENTIONAL METHOD &
MICRO-WAVE ASSISTED METHOD AND BIOLOGICAL
SCREENING.
SECTION-II:SYNTHESIS OF 4-ARYL-6-ISOPROPYL-N-(5-METHYL-1,3-
THIAZOL-2-YL)-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-
5-CARBOXAMIDES USING CONVENTIONAL METHOD &
MICROWAVE ASSISTED METHOD AND BIOLOGICAL
SCREENING.
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SECTION-I
SYNTHESIS OF 4-ARYL-6-ISOPROPYL-N-(5-METHYL-1,3-THIAZOL-2-YL)-2-
OXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE USING CONVE-
NTIONAL METHOD & MICROWAVE ASSISTED METHOD AND
BIOLOGICAL SCREENING.
Much interest has been focused around tetrahydropyrimidine derivatives because
of their wide variety of pharmacological properties and industrial applications. In view of
these reports, we have synthesized 4-aryl-6-isopropyl-N-(5-methyl-1,3-thiazol-2-yl)-2-
oxo-1,2,3,4-tetrahydropyrimidine-5-carboxamide of Type-(I) by the cyclocondensation
reaction  of 4-methyl-N-(5-methylthiazol-2-yl)-3-oxopentanamide, aromatic aldehyde and
urea in ethanol.
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
REACTION SCHEME
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IR SPECTRUM OF 6-ISOPROPYL-N-(5-METHYL-1,3-THIAZOL-2-YL)-2-OXO-4-
PHENYL-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE
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Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2941
2883
1450
1344
2975-2920
2880-2860
1470-1435
1395-1370
112
”
”
”
Aromatic
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
3113
1535
1163
775
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Carbonyl C=O 1693 1700-1650 ”
Amide -NH str. 3414 3400-3200 ”
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1H-NMR SPECTRUM OF 6-ISOPROPYL- N-(5-METHYL-1,3-THIAZOL-2-YL)-2-OXO-
4-PHENYL-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE
Internal Standard: TMS; Solvent: DMSO-D6 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
4
5
6
7
8
9
1.06-1.08
1.15-1.18
2.26
5.49
7.07
7.20-7.62
7.62
8.62
11.73
3H
3H
3H
1H
1H
5H
1H
1H
1H
doublet
doublet
singlet
doublet
doublet
multiplet
singlet
singlet
singlet
-CH(CH3)2
-CH(CH3)2
-CH3
Ha
-CO-NH-
Ar-H
Hb
-CO-NH-
-CO-NH-
6.9
6.9
-
2.7
0.9
-
-
-
-
NH
NHNH
ON
S
O
a
b
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EXPANDED 1H-NMR SPECTRUM
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MASS SPECTRUM OF 6-ISOPROPYL-N-(5-METHYL-1,3-THIAZOL-2-YL)-2-OXO-4-
PHENYL-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE
MASS SPECTRUM OF 4-(3-CHLOROPHENYL)-6-ISOPROPYL-N-(5-METHYL-1,3-
THIAZOL-2-YL)-2-OXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE
NH
NHNH
ON
S
O
Mol. Wt. = 356.4
m/z = 357.3 (M+1)
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EXPERIMENTAL
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. Ethyl acetate:hexane (3:7)
was used as a mobile phase.
[A] PREPARATION OF 4-METHYL-N-(5-METHYL-1,3-THIAZOL-2-YL)-3-
OXOPENTANAMIDE.
A suspension of methylisobutryl acetate (2.88 gm, 0.02 mol) and 5-methyl-1,3-
thiazole-2-yl (1.14 gm, 0.01 mol) in toluene (20 ml) containing catalytic amount of NaOH
solution (0.05 ml, 40 %) was reflux on oil bath for 12 hr. The progress of reaction was
monitored by TLC, after completion of the reaction solvent was removed under reduced
pressure to give residue, the residue was crystallized from mixture of hexane and ethyl
acetate.Yield 51 %.
[B] PREPARATION OF 6-ISOPROPYL-N-(5-METHYL-1,3-THIAZOL-2-YL)-
2-OXO-4-PHENYL-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDE
(1) Conventional method
The warm mixture of 4-methyl-N-(5-methyl-1,3-thiazole-2-yl)-3-oxopentanamide
(2.26 gm, 0.01 mole), benzaldehyde (1.06 gm, 0.01 mol), urea (0.9 gm, 0.015 mol) and
ethanol (15 ml), in the presence of catalytic of concentrated HCl (2-3 drops) was stirred at
reflux temperature for 12 hr. The progress of reaction was monitored by TLC, after
completion of the reaction, the reaction mixture was allowed to stand at room temperature
for several hours so precipitation was obtained. The product was filtered, washed with
chilled methanol and isolated product was recrystallized from ethanol. Yield 62 %.
(2) Microwave assisted method
A well stirred mixture of 4-methyl-N-(5-methyl-1,3-thiazole-2-yl)-3-oxopentan
amide (2.26 gm, 0.01 mole), benzaldehyde (1.06 gm, 0.01 mol), urea (0.9 gm, 0.015 mol)
and ethanol (15 ml) in the presence of etidronic acid (100 mg/0.01 mol) was irradiated
under microwave oven for 8 min at 300W. The progress of reaction was monitored by
TLC. After completion of reaction, the reaction mixture was allowed to stand at room
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temperature for several hours so precipitation was obtained. The product was filtered,
washed with chilled methanol and isolated product was recrystallized from ethanol. Yield
89 %.
Similarly, other 6-isopropyl-N-(5-methyl-1,3-thiazol-2-yl)-4-aryl-2-oxo-1,2,3,4-
tetrahydropyrimidine-5-carboxamide (1a-j) were prepared. The physical constants are
recorded in Table-1a, page no. 39.
[C] BIOLOGICAL SCREENING OF 4-ARYL-6-ISOPROPYL-N-(5-METHYL-
1,3-THIAZOL-2-YL)-2-OXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDE
 DETERMINATION OF MINIMAL INHIBITION CONCENTRATIONS BY
BROTH DILUTION METHOD
All the synthesized compounds (1a-j) were tested for their antibacterial and
antifungal activity (MIC) in vitro by broth dilution method113-115 with two Gram-positive
bacteria Staphylococcus aureus MTCC-96 and Streptococcus pyogenes MTCC 442, two
Gram-negative bacteria Escherichia coli MTCC 443 and Pseudomonas aeruginosa
MTCC 1688 and three fungal strains Candida albicans MTCC 227, Aspergillus Niger
MTCC 282 and Aspergillus clavatus MTCC 1323 taking gentamycin, ampicillin,
chloramphenicol, ciprofloxacin, norfloxacin, nystatin and greseofulvin as standard drugs.
The standard strains were procured from the Microbial Type Culture Collection (MTCC),
Institute of Microbial Technology, Chandigarh, India.
The minimal inhibitory concentration (MIC) values for all synthesized compounds
(1a-j), defined as the lowest concentration of the compound preventing the visible
growth, were determined by using micro dilution broth method according to NCCLS
standards113.
Minimal Inhibition Concentration [MIC]
The main advantage of the Broth Dilution Method for MIC determination lies in
the fact that it can readily be converted to determine the MIC as well.
1. Serial dilutions were prepared in primary and secondary screening.
2. The control tube containing no antibiotic is immediately subcultured (before
inoculation) by spreading a loopful evenly over a quarter of plate of medium
suitable for the growth of the test organism and put for incubation at 37 0C
overnight.
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3. The MIC of the control organism is read to check the accuracy of the drug
concentrations.
4. The lowest concentration inhibiting growth of the organism is recorded as the
MIC.
5. The amount of growth from the control tube before incubation (which represents
the original inoculums) is compared.
Methods used for primary and secondary screening
Each sample was diluted obtaining 2000 μg mL-1 concentration, as a stock
solution. Inoculum size for test strain was adjusted to 108 cfu (colony forming unit) per
milliliter by comparing the turbidity.
Primary screen: In primary screening 1000 μg mL-1, 500 μg mL-1 and 250 μg mL-1
concentrations of the synthesized compounds were taken. The active samples found in
this primary screening were further tested in a second set of dilution against all
microorganisms.
Secondary screen: The samples found active in primary screening were similarly diluted
to obtain 200 μg mL-1, 100 μg mL-1, 62.5 μg mL-1, 50 μg mL-1, 25 μg mL-1, 12.5 μg mL-1
and 6.250 μg mL-1 concentrations.
Reading Result: The highest dilution showing at least 99 % inhibition zone is taken as
MIC. The result of this is much affected by the size of the inoculums. The test mixture
should contain 108 organism/mL.
The results obtained from antimicrobial testing are recorded in Table-1b, page no.
40.
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TABLE-1a: PHYSICAL CONSTANTS OF 4-ARYL-6-ISOPROPYL-N-(5-
METHYL-1,3-THIAZOL-2-YL)-2-OXO-1,2,3,4-TETRAHYDROPYRI-
MIDINE-5-CARBOXAMIDE
NH
NH O
O
NHS
N
R
Sr.
No. R
Molecular
Formula/
Molecular
Weight
MP
oC
Classical
method
Microwave
Method
% Composition
Calcd./Found
Yield
%
Time
(hr.)
Yield
%
Time
(min.) C H N
1a H C18H20N4O2S356.44
219-
221 62 12 89 8
60.65
60.34
5.66
5.59
15.72
15.55
1b 4-OMe C19H22N4O3S386.47
229-
331 54 11 76 6
59.05
58.76
5.74
5.65
14.50
14.38
1c 4-F C18H19FN4O2S374.43
207-
209 59 14 78 10
57.74
57.37
5.11
5.08
14.96
14.81
1d 3-Cl C18H19ClN4O2S390.89
204-
206 51 16 81 14
55.31
55.14
4.90
4.78
14.33
14.11
1e 2,3-diCl
C18H18Cl2N4O2S
425.33
231-
232 53 12 69 8
50.83
50.54
4.27
4.16
13.17
13.05
1f 4-N(Me)2
C20H25N5O2S
399.51
191-
194 56 11 71 8
60.13
59.95
6.31
6.19
17.53
17.36
1g 2,5-diOMe
C20H24N4O4S
416.49
245-
247 47 14 67 12
56.68
56.31
5.81
5.74
13.45
13.29
1h 4-NO2 C18H19N5O4S401.44
211-
214 60 13 87 10
53.85
53.62
4.77
4.65
17.45
17.32
1i 3-NO2 C18H19N5O4S401.44
223-
225 45 12 83 8
53.85
53.62
4.77
4.62
17.45
17.26
1j 4-OH C18H20N4O3S372.44
246-
247 54 15 77 12
58.05
57.81
5.41
5.39
15.04
14.88
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TABLE-1b:BIOLOGICAL SCREENING OF 4-ARYL-6-ISOPROPYL-N-(5-
METHYL-1,3-THIAZOL-2-YL)-2-OXO-1,2,3,4-TETRAHYDROPYRI-
MIDINE-5-CARBOXAMIDE
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 1a 250 250 250 250 1000 250 250
2 1b 500 250 62.5 250 100 100 250
3 1c 200 100 500 500 500 1000 1000
4 1d 250 500 100 200 250 500 1000
5 1e 500 250 500 500 200 500 500
6 1f 250 500 250 250 250 >1000 >1000
7 1g 250 500 200 100 250 500 500
8 1h 200 500 200 250 500 1000 1000
9 1i 250 500 250 250 250 1000 1000
10 1j 500 250 250 500 500 >1000 >1000
MINIMAL INHIBITION CONCENTRATION
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
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ANTIBACTERIAL ACTIVITY:
From screening results, substituted Pyrimidines 1c (R= 4-F) & 1h (R= 4-NO2)
against S.aureus and 1b (R= 4-OMe) against E-coli possess excellent activity as compare
to ampicillin. While 1c (R= 4-F) against S.pyogenus, 1d (R= 3-Cl) against E-coli and 1g
(R= 2,5-di OMe) against P.aeruginosa, possess good activity as compare with ampicillin.
The remaining compounds possess moderate to poor activity against all four bacterial
species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data shows that substituted Pyrimidine 1b (R= 4-OMe) show
highly promising activity against C.albicans & A.niger compare with greseofulvin. While
1e (R = 2,3-di Cl) against C.albicans, 1a (R = -H) against A.niger and 1a (R = -H) & 1b
(R= 4-OMe) against A.clavatus, possess good activity compare to standard drug. The
remaining compounds exhibite moderate to poor activity.
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SECTION-II
SYNTHESIS OF 4-ARYL-6-ISOPROPYL-N-(5-METHYL-1,3-THIAZOL-2-YL)-2-
THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE USING
CONVENTIONAL METHOD & MICROWAVE ASSISTED METHOD AND
BIOLOGICAL SCREENING.
Compounds containing pyrimidine moiety are widely distributed in nature. Many
of these derivatives are reported to possess different biological activities. In view of these
reports, we have synthesized 4-aryl-6-isopropyl-N-(5-methyl-1,3-thiazol-2-yl)-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide of Type-(II) by the cyclocondensation
reaction  of 4-methyl-N-(5-methylthiazol-2-yl)-3-oxopentanamide, aromatic aldehyde and
thiourea in ethanol.
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
REACTION SCHEME
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IR SPECTRUM OF 6-ISOPROPYL-4-(4-METHOXYPHENYL)-N-(5-METHYL-1,3-
THIAZOL-2-YL)-2-THIOXO-1,2,3,4-TETRAHYDRO-PYRIMIDINE-5-CARBOXAMIDE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2968
2914
1483
1357
2975-2920
2880-2860
1470-1435
1395-1370
112
”
”
”
Aromatic
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
3105
1570
1105
831
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Carbonyl C=O 1676 1700-1650 ”
Amide -NH str. 3433 3400-3200 ”
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1H-NMR SPECTRUM OF 4-(4-FLUOROPHENYL)-6-ISOPROPYL-N-(5-METHYL-1,3-
THIAZOL-2-YL)-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE
Internal Standard: TMS; Solvent: DMSO-D6 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
5
6
7
8
9
10
1.08-1.10
1.19-1.22
2.26
3.35
5.49-5.50
7.10-7.11
7.14-7.28
9.52+9.53
9.70
3H
3H
3H
1H
1H
1H
5H
1H
1H
doublet
doublet
singlet
multiplet
doublet
doublet
multiplet
doublet
singlet
-CH(CH3)2
-CH(CH3)2
-CH3
-CH(CH3)2
Chiral-Hb
-CO-NH-
Ar-H+Hc
-CO-NH-
-CO-NH-
-
-
-
-
3.3
1.2
-
1.8
-
NH
NHNH
ON
S
S
F
c
b
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EXPANDED 1H-NMR SPECTRUM
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MASS SPECTRUM OF 6-ISOPROPYL-4-(4-METHOXYPHENYL)--N-(5-METHYL-1,3-
THIAZOL-2-YL)-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE
MASS SPECTRUM OF 4-(4-FLUOROPHENYL)-6-ISOPROPYL-N-(5-METHYL-1,3-
THIAZOL-2-YL)-2-THIOXO-1,2,3,4-TETRAHYDROPYRIMIDINE-5-CARBOXAMIDE
NH
NHNH
ON
S
S
Mol. Wt. = 402.5
m/z = 403.2(M+1)
OMe
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EXPERIMENTAL
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. Ethyl acetate:hexane (3:7)
was used as a mobile phase.
[A] PREPARATION OF 4-METHYL-N-(5-METHYL-1,3-THIAZOL-2-YL)-3-
OXOPENTANAMIDE.
See Chapter-1, Section-I, Experimental [A], Page no. 36.
[B] PREPARATION OF 6-ISOPROPYL-4-(4-METHOXYPHENYL)-N-(5-
METHYL-1,3-THIAZOL-2-YL)-2-THIOXO-1,2,3,4-TETRAHYDROPYRI-
MIDINE-5-CARBOXAMIDE
(1) Conventional method
The warm mixture of 4-methyl-N-(5-methyl-1,3-thiazole-2-yl)-3-oxopentanamide
(2.26 gm, 0.01 mole), 4-methoxy benzaldehyde (1.36 gm, 0.01 mol) and thiourea (1.14
gm, 0.015 mol) in ethanol (15 ml), containing 3-4 drops of concentrated HCl was stirred
under reflux for 13 hr. The progress of reaction was monitored by TLC, after completion
of the reaction, the reaction mixture was allowed to stand at room temperature for several
hours so precipitation was obtained. The product was filtered, washed with chilled
methanol and isolated product was recrystallized from ethanol. Yield 52 %.
(2) Microwave assisted method
A well stirred mixture of 4-methyl-N-(5-methyl-1,3-thiazole-2-yl)-3-
oxopentanamide (2.26 gm, 0.01 mole), 4-methoxy benzaldehyde (1.36 gm, 0.01 mol) and
thiourea (1.14 gm, 0.015 mol) in ethanol (15 ml) in the presence of etidronic acid (100
mg/0.01 mol) was irradiated under microwave oven for 10 min at 300W. The progress of
reaction was monitored by TLC, after completion of reaction, the reaction mixture was
allowed to stand at room temperature for several hours so precipitation was obtained. The
product was filtered, washed with chilled methanol and isolated product was
recrystallized from ethanol. Yield 78 %.
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Similarly, other 4-aryl-6-isopropyl-N-(5-methyl-1,3-thiazol-2-yl)-2-thioxo-
1,2,3,4-tetrahydropyrimidine-5-carboxamide (2a-j) were prepared. The physical constants
are recorded in Table-2a, page no.49.
[C] BIOLOGICAL SCREENING OF 4-ARYL-6-ISOPROPYL-N-(5-METHYL-
1,3-THIAZOL-2-YL)-2-THIOXO-1,2,3,4- TETRAHYDROPYRIMIDINE-5-
CARBOXAMIDE.
Antimicrobial testing was carried out as described in Chapter-1, Section-I,
Experimental [C], page no. 37. The results obtained from antimicrobial testing are
recorded in Table-2b, page no. 50.
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TABLE-2a: PHYSICAL CONSTANTS OF 4-ARYL-6-ISOPROPYL-N-(5-
METHYL-1,3-THIAZOL-2-YL)-2-THIOXO-1,2,3,4-TETRAHYDRO-
PYRIMIDINE-5-CARBOXAMIDE
NH
NH S
O
NHS
N
R
Sr.
No. R M.F. / M.W.
MP
oC
Classical
method
Microwave
Method
% Composition
Calcd./Found
Yield
%
Time
(hr.)
Yield
%
Time
(min.) C H N
2a 4-OMe C19H22N4O2S2402.53
239-
242 60 13 81 10
56.59
56.33
5.51
5.34
13.92
13.67
2b H C18H20N4OS2372.51
227-
229 56 15 85 8
58.04
57.81
5.41
5.31
15.04
14.88
2c 4-F C18H19FN4OS2390.50
217-
218 55 14 76 7
55.36
55.09
4.90
4.86
14.35
14.23
2d 3-Cl C18H19ClN4OS2406.95
198-
201 41 17 77 9
53.12
53.08
4.71
4.59
13.77
13.51
2e 2,3-diCl
C18H18Cl2N4OS
441.40
224-
226 49 16 63 16
48.98
48.71
4.11
4.04
12.69
12.47
2f 4-N(Me)2
C20H25N5OS2
415.58
208-
210 55 12 68 8
57.80
57.55
6.06
5.94
16.85
16.69
2g 2,5-diOMe
C20H24N4O3S2
432.56
229-
231 43 20 64 18
55.53
55.26
5.59
5.47
12.95
12.81
2h 4-NO2 C18H19N5O3S2417.51
222-
225 54 13 82 14
51.78
51.42
4.59
4.41
16.77
16.52
2i 3-NO2 C18H19N5O3S2417.51
231-
234 48 15 79 17
51.78
51.58
4.59
4.45
16.77
16.60
2j 4-OH C18H20N4O2S2388.51
252-
253 51 19 74 13
55.65
55.28
5.19
5.07
14.42
14.16
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TABLE-2b: BIOLOGICAL SCREENING OF 4-ARYL-6-ISOPROPYL-N-(5-
METHYL-1,3-THIAZOL-2-YL)-2-THIOXO-1,2,3,4-TETRAHYDRO-
PYRIMIDINE-5-CARBOXAMIDE
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 2a 200 200 200 250 500 250 250
2 2b 500 500 200 250 500 500 1000
3 2c 250 250 100 100 250 500 500
4 2d 250 250 200 62.5 1000 500 500
5 2e 500 100 62.5 250 500 1000 1000
6 2f 500 500 250 500 500 1000 >1000
7 2g 200 200 500 500 500 1000 1000
8 2h 500 500 250 250 1000 >1000 >1000
9 2i 500 500 250 250 500 1000 1000
10 2j 500 500 200 250 500 >1000 >1000
MINIMAL INHIBITION CONCENTRATION
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
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ANTIBACTERIAL ACTIVITY:
From screening results, substituted Pyrimidines 2a (R= 4-OMe) & 2g (R= 2,5-di
OMe) against S.aureus, 2e (R= 2,3-di Cl) against E-coli and 2d (R= 3-Cl) against
P.aeruginosa possess very good activity compare to ampicillin. While 2c (R= 4-F) & 2d
(R= 3-Cl) against S.aureus, 2e (R= 2,3-di Cl) against S.pyogenus and 2c (R= 4-F) against
E-coli & P.aeruginosa, possess moderate activity as compare with ampicillin. The
remaining compounds possess moderate to poor activity against all four bacterial species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data shows that substituted Pyrimidine 2c (R= 4-F) exhibite
promissing activity against C.albicans while 2a (R= 4-OMe) exhibite moderate activity
against A.niger & A.clavatus compare to Greseofulvin. The remaining compounds
exhibite moderate to poor activity.
Studies on Biologically Active... 52
Chapter-1 Studies on Tetrahydropyrimidines...
REFERENCES
1. A. L. Weis; Adv. Het. Chem, 38, 1-103 (1985).
2. S. Yasui, K. Nakamura; A. Ohno; J. Org. Chem., 49(5), 878-882 (1984).
3. N. Baba, M. Amano, J. Oda, Y. Inouye; J. Am. Chem. Soc., 106(5), 1481-1486
(1984).
4. U. Eisner, J. Kuthan; Chem. Rev., 72(1), 1-42 (1972).
5. J. Kuthan, A. Kurfurst; Ind. Eng. Chem. Prod. Res. Dev., 21(2), 191-261 (1982).
6. D. M. Stout, A. I. Meyers; Chem. Rev., 82(2), 223-43 (1982).
7. F. Bossert, W. Vater; Naturwissenshaften, 58(11), 578 (1971).
8. W. Vater, G. Kroneberg, F. Hoffmeister, H. Kaller, K. Meng, A. Oberdorf, W.
Puls, K. Schlossmann, K. Stoepel; Arzneim. Forsch., 22(1), 1-14 (1972).
9. B. Loev, M. M. Goodman, K. M. Snader, R. M. Tedeschi, E. Macko; J. Med.
Chem., 17(9), 956-965 (1974).
10. F. Bossert, H. Meyer, E. Wehinger; Angew. Chem., 93(9), 755-763 (1981).
11. N. Bodor, E. B. Roche; Design of Biopharmaceutical Properties Through
Prodrugs and Analog, (Ed. American Pharmaceutical Association: Washington,
DC), 98 (1977).
12. A. L. Weis, C. V. Henk; Heterocycles, 24(5), 1433-1455 (1986).
13. D. J. Brown, A. Weissberger; The Chemistry of Heterocyclic Compounds, The
Pyrimidine Suppl. 1 (Ed., Wiley: New York), 16, 1127 (1970).
14. A. L. Weis, F. Frolow, R. Vishkautsan; J. Org. Chem., 51(24), 4623-4626 (1986).
15. A. L. Weis, R. Vishkautsan; Heterocycles 23(5), 1077-1080 (1985).
16. R. E. van der Stoel, H. C. van der Plas; J. Chem. Soc., Perkin Trans., 1, 1288
(1979).
17. R. E. van der Stoel, H. C. van der Plas; J. Chem. Soc., Perkin Trans., 1, 2393
(1979).
18. V. I. Minkin, L. P. Olekhnovich, Y. A. Zhdanov; Acc. Chem. Res., 14(7), 210-217
(1981).
19. A. L. Weis; Synthesis, 5, 528-530 (1985).
20. A. L. Weis, F. J. Frolow; J. Chem. Soc., Perkin Trans., 1, 83-90 (1986).
21. A. L. Weis, R. Vishkautsan; Israel J. Chem., 27(1), 105-110 (1986).
22. A. L. Weis; Tet. Lett.; 23(4), 449-452 (1982).
23. A. L. Weis, Z. Luz, Z. Porat; J. Am. Chem. Soc., 106(26), 8021-8024 (1984).
Studies on Biologically Active... 53
Chapter-1 Studies on Tetrahydropyrimidines...
24. L. A. Paquette; Angew. Chem., 90(2), 114-125 (1978).
25. R. Breslow; Acc. Chem. Res. 6(12), 393-398 (1973).
26. J. Armand, K. Chekir, J. Pinson; Can. J. Chem., 52(23), 3971-3980 (1974).
27. P. Biginelli; Gazz. Chim. Ital,; 23, 360-416 (1893).
28. Y. Ma, C. Qian, L.Wang, M. Yang; J. Org. Chem., 65(12), 3864-3868 (2000).
29. B. C. Ranu, A. Hajra, U. Jana; J. Org. Chem., 65(19), 6270-6272 (2000).
30. M. M. Heravi, F. Derikvand, F. F. Bamoharram; J. Mol. Catal. A: Chem., 242(1-
2), 173-175 (2005).
31. M. M. Heravi, K. Bakhtiari, F. F. Bamoharram; Catal. Comm., 7(6), 373-376
(2006).
32. R. Gupta, S. Paul, R. Gupta; J. Mol. Catal. A: Chem., 266(1-2), 50-54 (2007).
33. M. A. Bigdeli, S. Jafari, G. H. Mahdavinia, H. Hazarkhani; Catal. Comm., 8(11),
1641-1644 (2007).
34. Y. Yu, Di Liu, C. Liu, G. Luo; Bioorg. Med. Chem. Lett., 17(12), 3508–3510
(2007).
35. W. Y. Chen, Su D. Qin, J. R. Jin; Catal.Comm., 8(2), 123–126 (2007).
36. A. Kumar, R. A. Maurya; J. Mol. Catal. A: Chem., 272(1-2), 53–56 (2007).
37. X. Wang, Z. Quan, Z. Zhang; Tetrahedron, 63(34), 8227-8233 (2007).
38. N. Ahmed, J. E. van Lier; Tet. Lett., 48(31), 5407-5409 (2007).
39. N. S. Nandurkar, M. J. Bhanushali, M. D. Bhor, B. M. Bhanage; J. Mol. Catal. A:
Chem., 271(1-2), 14-17 (2007).
40. F. Shirini, K. Marjani, H. T. Nahzomi; ARKIVOC, (i) 51-57 (2007).
41. A. Nefzi, J. M. Ostresh, R. A. Houghton; Chem. Rev., 97(2), 449-472 (1997).
42. J. W. Corbett; Org. Prep. Proced. Int., 30(5), 489-550 (1998).
43. I. Ugi; J. Prakt. Chem., 339(6), 499-516 (1997).
44. A. Domling; Combi. Chem. High Throughput Scr., 1(1), 1-22 (1998).
45. L. F. Tietze, M. E. Lieb; Curr. Opin. Chem. Biol., 2(3), 363-371 (1998).
46. S. L. Dax, J. J. McNally, M. A. Youngman; Curr. Med. Chem., 6(3), 255-270
(1999).
47. C. O. Kappe; Tetrahedron, 49(32), 6937-6963 (1993).
48. P. Wipf, A. Cunningham; Tet. Lett., 36(43), 7819-7822 (1995).
49. W. Li, Y. Lam; J. Comb. Chem., 7(5), 721-725 (2005).
50. G. A. Gross, H. Wurziger, A. Schober; J. Comb. Chem., 8(2), 153-155 (2006).
51. P. H. Toy, K. D. Janda; Acc. Chem. Res., 33(8), 546-554 (2000).
Studies on Biologically Active... 54
Chapter-1 Studies on Tetrahydropyrimidines...
52. (a) D. J. Gravert, K. D. Janda; Chem. Rev., 97(2), 489-509 (1997). (b) P.
Wentworth, K. D. Janda; Chem. Comm., 19, 1917-1924 (1999).
53. D. Fang, J. Luo, X. Zhou, Z. Ye, Z. Liu; J. Mol. Catal. A: Chem., 274(1-2), 208-
211 (2007).
54. C. L. Jean, J. V. E. Jean, T. Loic, P. B. Jean; ARKIVOC, iii 13-28 (2007).
55. Li Ming, G. Wei-Si, W. Li-Rong, Li Ya-Feng, Y. Hua-Zheng; J. Mol. Catal. A:
Chem.,258(1-2), 133-138 (2006).
56. G. A. Gross, H. Wurziger, A. Schober; J. Comb. Chem., 8(2), 153-155 (2006).
57. (a) S. Caddick; Tetrahedron, 51(38), 10403-10432 (1995). (b) S. Deshayes, M.
Liagre, A. Loupy, J. Luche, A.Petit; Tetrahedron, 55(36), 10851-10870 (1999).
(c) P. Lidstrom, J. Tierney, B. Wathey, J. Westman; Tetrahedron, 57(45), 9225-
9283 (2001). (d) A. Kirschning, H. Monenschein, R. Wittenberg; Angew. Chem.
Int. Ed., 40(4), 650-679 (2001). (e) R. S. Varma; Pure Appl. Chem., 73(1), 193-
198 (2001). (f) A. Loupy; Microwaves in Organic Synthesis (Wiley-VCH:
Weinheim), 499 (2002).
58. A. Dandia, M. Saha, H. Taneja; J. Fluorine Chem., 90(1), 17-21 (1998).
59. P. Diddams, M. Butters; Solid Supports and Catalysts in Organic Synthesis, K.
Smith; (Ed.; Ellis Harwood and PTR Prentice Hall: New York and London), 03-
39 (1992).
60. M. Gopalakrishnan, P. Sureshkumar, V. Kanagarajan, J. Thanusu, R. Govindaraju;
ARIKVOC, xiii 130-141 (2006).
61. (a) H. A. Stefani, C. M. P. Pereira, R. B. Almeida, R. C. Braga, K. P. Guzen, R.
Cella; Tet. Lett., 46(40), 6833-6837 (2005). (b) Z. L. Shen, S. J. Ji, S.Y. Wang , X.
F. Zeng; Tetrahedron, 61(44), 10552-10558 (2005) .
62. Ji-Tai Li, Jun-Fen Han, Jin-Hui Yang, Tong-Shuang Li; Ultrasonics Sonochem.
10(3), 119-122 (2003).
63. X. Zhang, Y. Li, C. Liu, J. Wang; J. Mol. Catal. A: Chem., 253(1-2), 207-211
(2006).
64. H. Kumar, A. Parmar; Ultrasonics Sonochem., 15(2), 129-132 (2007).
65. P. Biginelli; Gazz. Chim. Ital., 23, 360-416 (1893).
66. C. O. Kappe; Tetrahedron, 49(32), 6937-6963 (1993).
67. K. Folkers, T. B. Johnson; J. Am. Chem. Soc., 55, 3784-3791 (1933).
68. F. Sweet, J. D. Fissekis; J. Am. Chem. Soc., 95(26), 8741-8749 (1973).
69. C. O. Kappe; J. Org. Chem., 62(21), 7201-7204 (1997).
Studies on Biologically Active... 55
Chapter-1 Studies on Tetrahydropyrimidines...
70. H. Petersen; Synthesis, 5, 243-292 (1973).
71. F. Bossert, W. Vater; Med. Res. Rev., 9(3), 291-324 (1989).
72. H. Cho, M. Ueda, K. Shima, A. Mizuno, M. Hayashimatsu, Y. Ohnaka, Y.
Takeuchi, M. Hamaguchi, K. Aisaka, T. Hidaka, M. Kawai, M. Takeda, T.
Ishihara, K. Funahashi, F. Sarah, M. Morita, T. J. Noguchi; J. Meal. Chem., 32,
2399-2406 (1989).
73. K. S. Atwal, B. N. Swanson, S. E. Unger, D. M. Floyd, S. Moreland, A. Hedberg,
B. C. O’Reilly; J. Med. Chem., 34(2), 806-811 (1991).
74. G. J. Grover, S. Dzwonczyk, D. M. McMullen, D. E. Normadinam, P. G. Sleph, S.
Moreland; J. Cardiovasc. Pharmacol., 26(2), 289-294 (1995); M. Negwer,
Organic-Chemical Drugs and their Synonyms (Akademie Verlag: Berlin), 2558
(1994).
75. G. C. Rovnyak, S. D. Kimball, B. Beyer, G. Cucinotta, J. D. DiMarco, J.
Gougoutas, A. Hedberg, M. Malley, J. P. McCarthy; J. Med. Chem., 38(1), 119-
129 (1995); For a discussion, see: D. J. Triggle, S. Padmanabhan; Chemtracts:
Org. Chem., 8(3), 191-196 (1995).
76. B. Jauk, T. Pernat, C. O. Kappe ; Molecules, 5(3), 227-239 (2000).
77. R. H. Kretsinger; Adv. Cyclic Nucleotide Res., 11, 1-26 (1979).
78. J. W. Putney Jr; Pharmacol. Rev., 30(2), 209-245 (1978).
79. L. B. Rosenberger, D. J. Triggle; Calcium Drug Action; G. B. Weiss, Ed.; Plenum
Press: New York (1978).
80. D. J. Triggle; New Perspect. Calcium Antagonists; G. B. Weiss, Ed.; Am. Physiol.
Soc.: Bethesda, MD (1981).
81. A. Fleckenstein; Annu. Rev. Pharmacol. Toxicol., 17, 149-166 (1977).
82. K. S. Atwal, G. C. Rovnyak, J. Schwartz, S. Moreland, A. Hedberg, J. Z.
Gougoutas, M. F. Malley, D. M. Floyd; J. Med. Chem., 33(5), 1510-1515 (1990).
83. K. S. Atwal, G. C. Rovnyak, D. S. Kimball, M. F. David, M. Suzanne, N. S.
Brian, Z. G. Jack, S. Joseph, M. S. Kaye, F. M. Mary; J. Med. Chem., 33(9), 2629
(1990).
84. G. C. Rovnyak, K. S. Atwal, A. Hedberg, S. D. Kimball, S. Moreland, J. Z.
Gougoutas, B. C. O’Reilly, J. Schwartz, M. F. Malleys; J. Med. Chem., 35(17),
3254-3263 (1992).
85. I. S. Zorkun, S. Sarac, S. Celebi, K. Erol; Bioorg. Med. Chem., 14(24), 8582–8589
(2006).
Studies on Biologically Active... 56
Chapter-1 Studies on Tetrahydropyrimidines...
86. M. Yarim, S. Sarac, M. Ertan, O. Batu, K. Erol ; IL Farmaco, 54(6), 359–363
(1999).
87. N. Dhanapalan, S. W. Miao, B. Lagu, G. Chiu, J. Fang, T. G. Muralidhar, J.
Zhang, S. Tyagrajan, M. R. Marzabadi, F. Zhang, W. C. Wong, W. Sun, D. Tian,
J. M. Wetzel, K. P. Vyas; J. Med. Chem., 42(23), 4764-4777 (1999).
88. T. G. Muralidhar, N. Dhanapalan, M. R. Marzabadi, B. Lagu, W. C. Wong, G.
Chiu, S. Tyagrajan, S. W. Miao, F. Zhang, W. Sun, D. Tian, Q. Sen, J. M. Wetzel,
C. Gluchovski; J. Med. Chem., 42(23), 4778-4793 (1999).
89. B. Lagu, D. Tian, N. Dhanapalan, W. C. Wong, S W. Miao, F. Zhang, W. Sun, G.
Chiu, F. James, C. Gluchovski; J. Med. Chem., 42(23), 4794-4803 (1999).
90. D. Russowsky, R. F. S. Canto, S. A. A. Sanches, M. G. M. D’Oca, A. de Fatima,
R. A. Pilli, L. K. Kohn, M. A. Antonio, J. E. de Carvalho; Bioorg. Chem., 34(4),
173–182 (2006).
91. Y. Mizutani, H. Wada, M. Fukushima, O. Yoshida, O. Ukimura, A. Kawauchi, T.
Miki; Euro. J. Cancer, 37(5), 569–575 (2001).
92. Y. Mizutani, H. Wada, O. Yoshida, M. Fukushima, H. Nakanishi, M. Nakao, T.
Miki; Euro. J. Cancer, 39(4), 541–547 (2003).
93. P. Biginelli; Gazz. Chim. Ital., 23, 360-416 (1893).
94. C. O. Kappe; Tetrahedron, 49(32), 6937-6963 (1993).
95. F. Shirini, K. Marjani, H. T. Nahzomi; ARKIVOC, i, 51-57 (2007).
96. G. Sabitha, G. S. Reddy, K. Kumar, Ch. S. Reddy, J. S. Yadav; Synlett, 6, 858-860
(2003).
97. C. Liu, J. Wang, Y. Li; J. Mol. Catal. A: Chem;, 258(1-2), 367-370 (2006).
98. M. Xia, Y. Wang; Synthesis, 2, 262-266 (2003).
99. Y. Yu, L. Di, C. Liu, G. Luo; Bioorg. Med. Chem. Lett., 17, 3508-3510 (2007).
100. Nan-Yan Fu, Yao-Fang Yuan, Z. Cao, Shan-Wei Wang, Ji-Tao Wang, C. Peppe;
Tetrahedron, 58(24), 4801-4807 (2002).
101. L. Pisani, H. Prokopcova, J. M. Kremsner, C. O. Kappe; J. Comb. Chem., 9(3),
415-421 (2007).
102. H. Khabazzadeh, S. Kazem, H. Sheibani; Bioorg. Med. Chem. Lett., 18(1), 278-
280 (2008).
103. F. Bigi, S. Carloni, B. Frullanti, R. Muggi, G. Sartori; Tet. Lett. 40(17), 3465-3468
(1999).
Studies on Biologically Active... 57
Chapter-1 Studies on Tetrahydropyrimidines...
104. L. A. Dixon; Encyclopedia of Reagents for Organic Synthesis (L. Paquette, Ed.;
Wiley: Chichester), 6, 4166-4169 (1995).
105. K. S. Nimavat, K. H. Popat, S. L. Vasoya, H. S. Joshi; Ind. J. Het. Chem., 12(3),
217-220 (2003).
106. D. J. Paghdar, J. D. Akbari, S. D. Tala, M. F. Dhaduk, H. S. Joshi; Ind. J. Het.
Chem., 17(2), 113-116 (2007).
107. M. R. Patel, J. D. Akbari, D. H. Purohit, H. S. Joshi; J. Ind. Chem. Soc., 84(11),
1169-1173 (2007).
108. J. D. Akbari, S. D. Tala, P. K. Kachhadia, A. H. Bapodra, M. F. Dhaduk, K. B.
Mehta, S. J. Pathak, H. S. Joshi; Phosphorous, Sulfur and Silicon and  the Related
Elements, 183(8), 1911-1922, (2008).
109. J. D. Akbari, S. D. Tala, M. F. Dhaduk, H. S. Joshi; Phosphorous, Sulfur and
Silicon and the Related Elements, 183(6), 1471-1477 (2008).
110. R. C. Khunt, J. D. Akbari, A. T. Manvar, S. D. Tala, M. F. Dhaduk, H. S. Joshi,
Anamik Shah; ARKIVOC, xi, 277-284 (2008).
111. J. D. Akbari, K. B. Mehta, S. J. Pathak, H. S. Joshi; Ind. J. Chem. 47B, 477-480
(2008).
112. (a) V. M. Parikh; Absorption spectroscopy of organic molecules (Addition-
Wesley Pub. Co. London), 243-258 (1978). (b) B. D. Mishtry; A. Hand book of
spectroscopic data (1st ed. ABD Press Jaipur), 11-36 (2000).
113. National Committee for Clinical and Laboratory Standards, Method for Dilution
Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically Approved
Standard (fourth ed. NCCLS, Villanova, Italy), Document M 100-S7, S100-S157
(1997).
114. D.H. Isenberg; Essential Procedure for Clinical Microbiology (American Society
for Microbiology, Washington), (1998).
115. J. R.Zgoda, J. R. Porter; Pharm. Biol., 39, 221-225 (2001).
Chapter-2, Part-1
STUDIES ON PIPERAZINE
DERIVATIVES
Studies on Biologically Active...
Chapter-2, Part-1 Studies on Piperazine...
58
INTRODUCTION
Piperazine was used early in the 20th century for the treatment of gout. Giround
discovered the anthelmintic activity of piperazine, synthesized by Cloez in 1853,
fortuitously in 1942; the same effect was observed by Biosmare in 1948 and conformed
by Bayared in 1949. Structural modification of this molecule in the search for effective
filaricidal resulted in diethyl carbamazine synthesized by Kishner et al in 1946 and
studied pharmacologically by Hewitt et al in 1947. Clinical studies have shown that the
drug is highly effective against both ascaris lumbricoides and enterobius (oxyuris)
vermicularis.
CHEMISTRY
Piperazine is a six member saturated cyclic secondary diamine with the nitrogen
in the 1, 4 - position. It can also be called as Hexahydropirazine, 1,4-Diazacyclohexane,
1,4-Diethylenediamine, Diethyleneimine or Antiren, its molecular formula is C4H10N2, its
molecular weight is 86.14 and structural formula shown as under (1).
N
H
N
H
(1)
PHYSICAL PROPERTIES
Piperazine is available in the form of hygroscopic colourless crystals or white
flakes, with pungent odour, it is soluble in water and ethanol, but insoluble in ether. An
aqueous solution reacts strongly alkaline, the pka being 9.8, M.P. 106 °C, B.P. 146 °C
and density is 1.1 gm/ml. It is commonly available industrially as the hexahydrate (M.F.-
C4H10N2. 6H2O, M.P. 44°C, B.P. 125-130°C) which contains about 44 % of base and in
addition, Two common salts in the form of which piperazine is usually prepared for
pharmaceutical or veterinary purposes are the citrate (M.F.-3C4H10N2.2C6H8O7, M.P.
182-187 °C) and the adipate (M.F.-C4H10N2.C6H10O4, M.P. 256-257 °C).
PHARMACOLOGICAL EFFECT
Piperazine was first introduced as an anthelmintic. A large number of piperazine
derivatives have anthelmintic action. Their mode of action is generally by paralysing
parasites, which allows the host body to easily remove or expel the invading organism.
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This action is mediated by its agonist effects upon the inhibitory GABA (γ-aminobutyric
acid) receptor.
Orally administrated piperazine is almost devoid of pharmacological activity.
Intravenous administration results in a transient fall in blood pressure. Lethal doses cause
convulsions and respiratory depression.
In addition to anthelmintic activity, piperazine derivatives possess various
pharmacological activities such as antihistamines, antipsychotics, antianginals, anti-
depressants, antihypertensives, anesthetics, analgesics, anticonvulsants, antispasmodics
and urologicals.
Piperazine and its derivatives are also used in the manufacturing of rubbers, anti-
oxidants, corrosion inhibitors, additives, cosmetics, dyeing agents, plastics, resins,
pesticides, polymers, synthetic fibers and analytical reagents.
SYNTHETIC ASPECT
piperazine itself can be synthesized by reacting alcoholic ammonia with 1,2-
dichloroethane, by the action of sodium and ethylene glycol on ethylene diamine
hydrochloride, or by reduction of pyrazine with sodium in ethanol. However Industrially
piperazine is synthesized by different method, some of them are described as below.
(A) Preparation of piperazine at atmospheric pressure;
N-(2-aminoethyl)ethane-1,2-diamine was heated with Raney nickel under various
experimental conditions. In all cases ammonia was evolved and piperazine formed
according to the reaction. A temperature at about 150 0C or somewhat higher was found
to be most suitable for the reaction.
N
N
H
H
NH3+N
NH2 NH2
H
Ni
(B) Autoclave method for the preparation of piperazine;
The autoclave was charged with 150 gm of 2-((2-aminoethyl)amino)ethanol in
200 ml of dioxane 15 gm of catalyst was added, and reaction was carried out for 3 hours
at a temperature in the range of 200-300 0C. The reaction mixture was filtered to remove
catalyst and distilled; dioxane-water azeotrope distilled at 87 0C, then dioxane at 100-103
0C, and finally piperazine at 140-150 0C. Raney nickel appeared the catalyst at choice;
copper chromium oxide, activated alumina, silica gel, cupric oxide and iron, were
intermediate in effectiveness1-9.
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THERAPEUTIC IMPORTANCE
Rastogi et al10 prepared N-(2-substituted-ethyl)-N-aryl piperazine (2)
as potential antihookworm agents.
O
N N
R1
R
(2)
A variety of analogues of 1-[4-methoxy-3,5-dimethyl benzyl]-4-[3-(ethyl amino)-
2-pyridyl]piperazine hydrochloride (3) was synthesized & evaluated for their anti HIV
activity by N. Serradji et al11.
N
N
N
H3CO
NH
.HCl
(3)
H. J. Shaue et al12 synthesized a series of triazolopyridine derivatives, in order to
explore effects of modifications of the alkyl piperazine moiety of triazolone on binding
affinity for 5HT2A & 1 receptor. Hydrochlorides of compound (4) have been tested for
their antispasmodic and antihistaminic properties and found to possess good activities
comparable to standard compounds now used in medicinal practice13.
Cl
N
S
N N
Cl
Cl
(4)
R. B. Petigara et al14 synthesized various N1-N4-substituted piperazine derivatives
(5) and reported their CNS depressant activity.
O
N
N R
MeO
OMe
MeO (  )n
Where n= 0,1,2,3
R=methyl, cyclohexyl, phenyl or benzyl
(5)
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S. K. Saxena et al15 synthesized piperazine derivatives (6) and B. M. Khadilkar et
al16 synthesised (7) showed best CNS depressant, anti-inflammatory and diuretic ativities.
R. C. Tripathi et al17 have been synthesized piperazine derivatives and evaluated its
hypotensive and CNS depressant activities.
O
ClNH2
N
N
OMe
(6)
N
O
Cl
O
N N
MeO
R
(7)
A. Ejima and S. Ohsuki18 suggested that pyrazole derivatives (8) and (9)
containing substituted piperazine nucleus possess good antitumor activity.
N
N
N
N
N
N Cl
(8)
N
N
N N
N Cl
Cl
O
F
(9)
The effect of piperazine derivative (10) on blood pressure of cat was studied by B.
M. Khadilkar & S. D. Samant 19 for intracerebroventricular administration at the dose of
50-µg/kg weights. The fall in B.P. was so rapid that cat died within 15 minutes.
NO
O
OH N N
R.HCl
(10)
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S. K. Agrawal et al20 prepared some novel piperazine derivatives (11), some of
these compounds show potent CNS depressant, hypotensive & -adrenoceptor blocking
activities.
O
N NHOOC
(11)
Korgaonkar et al21 have prepared ethyl-8-[4-(3-chloro)-1-piperazinyl methyl]-7-
hydroxycoumarin-4-acetate (12) as most effective antiinflammatory agents. Analgesic
and antiinflammatory activities of piperazines reported by several researcher.22-27
N
NO
OEtOOC
Cl
(12)
Preparation of (13) and terir activity against plasmodium berghei were described
by Herrin and his co-workers.28 Some nitrogen containing heterocycles found to posses
high antimalarial activity, which was described by F. S. Mikhalitsym et al.29
O
NO
Br/Cl
N N O
OCH3
(13)
L. C. Meurer and his coworkers30 synthesized some alkyl & halo substituted
piperazine derivatives and studied their hypoglycemic activity. In these derivatives some
compounds showed potent hypoglycemic activity. Varieties of hypoglycemic agents
containing piperazine moiety were also assessed by several investigators.31,32
Some piperazine derivatives are showed a useful activities like as brain
protectant33, diagnosis of schizophrenia34, neurokinine35,36, serration antagonist
receptors37-39, heart muscle receptor40, and cholesterol reducing agents41, HIV-I
inhibitors42,43, dopamine transporter44-46, sorbitol dehydrogenase inhibitor47-49,
spermicidal agent50. Besides the anathematic application of piperazine51-53, anesthetic54,
antiparkinson55, anticonvulsant56-58, antidepressant agents59, antipshycotic60-61,
antiallergic62-64, antiulcer65, insecticide66, antiparasitics67, normolipemic hypoglycemic &
hypotriglyceridemic activity.68
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M. Kurokawa et. al.69 reported selective activity of 5-((4-(4-(Fluorophenyl)-1-
piperazinyl)-butyryl)amino)-5H-dibenzo[a,d]cyclohepene) (14) for cardiac tissue over
vascular tissue, thereby conferring antianginal activity without an effect on blood
pressure.
NH
O N N
F
(14)
G. R. Brown70 synthesized 1-(Arylsulfonyl)-4-{[1-(4-pyridyl)piperazine-1-yl]
carbonyl}piperazines and analogs (15) and reported as oxido-sqelene cyclase inhibitors.
2-Piperazine-1-acetic acid derivatives are used as platelet aggregation inhibitors and
antithrombotics71, piperazinyl ethyl indazoles derivatived as calmodulin inhibitors72 and
piperazine carboxylic ester derivatives as tryptase inhibitors.73
N N N
O
N
N
SO
O
Br
(15)
S. Paris et. al.74 synthesized pyrrolo[3,2,1-i,j]quinoline (16) and documented as
potential therapeutic application in asthma.
N
R1
R
N N
N
(16)
2-(((3-methyl-4-((3-(4-(pyrimidin-2-yl)piperazin-1-yl)propyl)thio)pyridin-2-
yl)methyl)thio)-1H-benzo[d]imidazole (17) was recommended for the control of
helicobacter pybri bacteria by G. Hanauer and his co-workers.75
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N
N
N
N S
N
S N
NH
(17)
S. Seshadri et. al.76 prepared dimeric products (18) and (19) of dithioacetals with
piperazine showed moderate to significant activity. These compounds also show better
activity against gram negative bacteria as compared to gram positive bacteria.
N
N
SCH3
N
SCH3
N
SO2
SO2
CH3COHN
NHCOCH3
(18)
N
N
SCH3
N
SCH3
N
SO2
SO2
NH2
NH2
(19)
S. J. Brickner et. al.77 prepared potent synthetic oxazolidin-2-one derivative (20)
which is currently in clinical development for the gram positive bacterial infections
caused by strains of Staphylococci, Streptococci & Enterococci. The in vitro and in vivo
activities of above compound, against representative strains are similar to these of
vancomycin. These compounds demonstrate potent in vitro activity against
mycobacterium tuberculosis.
NH O
ON
F
N
N
O
OH
H
O
(20)
Some quinazolinone derivatives containing piperazines (21) found to posses
strong antibacterial activity.78-84 Substituted piperazinyl-phenyl-oxazolidione derivatives
used as antibacterial agents, which showed MIC of 0.5 µg/ml against S. auresas by G. D.
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Cung et. al.85
N
O
COOH
R1
N
NR
(21)
7-((4-Substitutedphenylpierazine-1-yl)-alkoxyl)-4-methylchromene-2-ones (22) as
potential antipsychotic agents, synthesized and evaluated by S. H. Bhosale and his co-
workers.86
OO O(CH2)n N N
R1 R2
R3
(22)
N1-(2-Substituted-4-nitrophenyl)-N4-(2,3-disubstitutedpropyl)-piperazines (23) as
useful antifungal agent prepared and characterized by G. L. Talesara et. al.87
N NO2N
X R R
(23)
Preparation and biological evaluation of (5-methyl-1H-indol-2-yl)-4-methyl-
piperazine-1-yl)-methanone (24) as potent human histamine H4 antagonists by J. D.
Venable and his co-workers.88
N
H
N
O
N
(24)
N-(4-(4-(2,3-Dichlorophenyl)-piperazine-1-yl)trans-but-2-enyl)-4-(3-pyridyl)-2-
yl-benzamide (25) as selective probes with high affinity for the dopamine D3 receptor has
been prepared by P. Grundt et. al.89
N
NH
O
N N
Cl Cl
(25)
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N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methyl
pyrimidin-4-yl)amino)thiazole-5-carboxamide (26), a dual Src/Abl kinase inhibitors with
potent antitumor activity in preclinical assays has been synthesized and discovered by L.
J. Lombardo et al.90
NH
Cl O S
N
NH
N N
N
N OH
(26)
Several investigators synthesized varieties of new compounds with piperazine
moiety and found their antimicrobial activities such as antifungal and antibacterial.91-101
Lomerizine(1-(2''',3''',4'''-trimethoxybenzyl)-4-[(4',4"-diflurodiphenyl)-Methyl)-
piperazine) (27) is a calcium channel blocker with antimigraine properties.102-106
F
F
NN
H3CO
H3CO OCH3
(27)
Flunarizine (brand name sibelium) {1-cinnamyl-4-[(4',4"-diflurodiphenyl)-
methyl]-piperazine}(28) was discovered at Janssen Pharmaceutical in 1967. Flunarizine is
a drug classified as a calcium channel blocker. Flunarizine is a selective calcium entry
blocker with calmodulin binding properties and histamine H1 blocking activity by W. K.
Amery.107 It is effective in the prophylaxis of migraine, occlusive peripheral vascular
disease, vertigo of central and peripheral origin, and as an adjuvant in the therapy of
epilepsy. It may help to reduce the severity and duration of attacks of paralysis associated
with the more serious form of alternating hemiplegia. Potent visodilater improve cerebral
blood flow reduce duration and incidences of migraine attack by J. M. Van Nueten.108
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F
F
NN
(28)
Thus the important role displayed by piperazine and its derivatives for various
therapeutic and biological activities prompted us to synthesize some Schiff base,
Thiazolidinone, Oxadiazole and Triazole derivatives bearing piperazine moiety in order
to achive compounds having better biological activities.
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SECTION-I
SYNTHESIS AND CHARACTERIZATION OF 2-(4-(2,3-DICHLOROPHENYL)
PIPERAZIN-1-YL)ACETOHYDRAZIDE
REACTION SCHEME
N
NH
Cl
Cl
Acetone, 15 hrs
N
N
Cl
Cl
O
O
Ethanol, Ref lux
6 hrs
N
N
Cl
Cl
HN
O
NH2
BrCH2COOEt, K2CO3 NH2NH2.H2O
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IR SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRA-
ZIDE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2956
2889
1450
1369
2975-2920
2880-2860
1470-1435
1395-1370
109
”
”
”
Aromatic
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
3064
1450
1112
819
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Carbonyl
Ether
Halide
C=O
C-O-C
C-Cl
1668
1236
779
1650-1700
1200-1275
650-850
”
”
”
Amide
Amine
-NH str.
-NH str.
3207
3292 3200-3400 ”
N
N
Cl
Cl
HN
O
NH2
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1H-NMR SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-
YL)ACETOHYDRAZIDE
Internal Standard: TMS; Solvent: CDCl3; Instrument: BRUKER Spectrometer (300
MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
4
5
6
7
2.71-2.74
3.06
3.17
3.89-3.90
6.93-6.96
7.12-7.19
8.17
4H
4H
2H
2H
1H
2H
1H
triplet
broad singlet
singlet
doublet
double doublet
multiplet
broad singlet
-CH2 (d,d’)
-CH2 (e,e’)
-CH2 (c)
-NH2 (a)
Ar-H (f)
Ar-H (g,h)
-CO-NH (b)
-
-
-
3.3
3.0 & 6.3
-
-
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EXPANDED 1H-NMR SPECTRUM
MASS SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-
YL)ACETOHYDRAZIDE
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EXPERIMENTAL
SYNTHESIS AND CHARACTERIZATION OF 2-(4-(2,3-DICHLOROPHENYL)
PIPERAZIN-1-YL)ACETOHYDRAZIDE
[A] PREPARATION OF ETHYL 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-
1-YL)ACETATE
To the stirred solution of 1-(2,3-dichlorophenyl)piperazine (23.1 gm, 0.1 mol) and
potassium carbonate (20.7 gm , 0.15 mol) in 100 ml acetone was added ethyl bromo
acetate (18.37 gm, 0.11 mol) drop wise at 10oC then stirred the reaction at room
temperature for 14 hr. The progress of reaction was monitored by TLC using mobile
phase ethyl acetate / hexane (6/4), after completion of the reaction solvent was removed
to give residue, the residue was added to chilled water (500 ml) and stirred for overnight.
The separated solid was filtered, washed with water, dried and finally crystallized from
ethanol to give 24 gm cream solid. Yield: 76 %.
[B] PREPARATION OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-
YL)ACETOHYDRAZIDE
A mixture of 2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetate (3.16 gm, 0.01 mol)
and hydrazine hydrate 99 % (1 gm, 0.02 mol) in 10 ml ethanol was stirred and refluxed
for 8 hr. The progress of reaction was monitored by TLC using mobile phase ethyl acetate
/ hexane (8/2), after completion of the reaction the reaction mixture was kept in deep-
freezer for overnight. The precipitated product was filtered off, washed with hexane (10
ml) and crystallized from isopropyl alcohol (IPA) to give 2.44 gm white solid. Yield: 81
%.
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INTRODUCTION
Chromene is a polycyclic organic heterocycle in which benzene ring fused with a
heterocyclic pyran ring. It is also called as benzopyran. There are two isomers of
benzopyran that vary by the orientation of the fusion of the two rings compared to the
oxygen, 1-benzopyran (chromene) and 2-benzopyran (isochromene) the number denotes
where the oxygen atom is located by standard naphthalene like nomenclature. Its
molecular formula is C9H8O, its molecular weight is 132.16.
The radical form of chromene is paramagnetic. The unpaired electron is
delocalized over the whole chromene molecule, rendering it less reactive than one would
expect otherwise, a similar example is the cyclopentadienyl radical. Commonly,
chromene is encountered in the reduced state, where it is partially saturated with one
hydrogen, introducing a tetrahedral methylene group in the pyran ring. Thus there are
many different structural isomers are possible due to multiple possible positions of the
oxygen atom and the tetrahedral carbon:
Structural isomer of chromene
O O
2H-chromene 4H-chromene
(2H-1-benzopyran)  (4H-1-benzopyran)
Structural isomer of isochromene
O O
1H-isochromene 3H-isochromene
(1H-2-benzopyran)  (3H-2-benzopyran)
Saturated chromene is called as chroman or 3,4-dihydro-2H-chromene. Chroman
is an aromatic bicyclic heterocycle. Its molecular formula is C9H10O, its molecular weight
is 134.18 and chemical structure shown as under (1).
O
1
2
3
456
7 8
(1)
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Chroman was first prepared in 1905; little interest was shown in the compound
until studies on the tocopherols (Vitamin-E) began to indicate that they were derivatives
of chroman. The monoalkyl chromans can be divided into two groups-one in which the
alkyl substituted attached to the benzene ring and the second in which attached to the
heterocyclic ring. The former can be obtained from appropriate derivatives of benzene
similar to those used for the preparation of chroman. Chroman is stable to acids and
oxidizing agents. It is soluble in common organic solvents1.
Many chroman derivatives are very useful in the synthesis of drug. 6-
Fluorochroman-2-carboxylic acid (2) is key intermediate in the synthesis of “Nebivolol”.
Nebivolol (3) is an antihypertensive drug. Nebivolol has been studied in over 3000
patients with hypertension. The use of nebivolol is contraindicated in patients with
cardiogenic shock, uncontrolled heart failure, sick sinus syndrome, second and third
degree heart block, asthma etc. 6-Fluorochroman-2-carboxylic acid (2) is a solid at room
temperature and it is also known as nebivolol acid
O
F
O
OH
(2) 6-fluorochroman-2-carboxylic acid
(Nebivolol acid)
O N O
F
OH OH
F
H
(3) Nebivolol
2,2'-azanediylbis(1-(6-fluorochroman-2-yl)ethanol)
Vitamin E (tocopherol) refers to a family of eight molecules having a chromanol
ring (chroman ring with an alcoholic hydroxyl group) and a 12-carbon aliphatic side
chain containing two methyl groups in the middle and two more methyl groups at the end.
Tocotrienols (found in high concentrations in palm oil) are many times more potent as
anti-oxidants than are tocopherols (4), but they are poorly assimilated by digestion, are
poorly distributed to tissues in blood and are rapidly metabolized and eliminated from the
body but tocotrienols are well-absorbed by the skin and thus are well suited for use as a
Vitamin E cream.
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O
OH
(4) α -tocopherol
SYNTHETIC ASPECT
1. K. J. Hodgetts2 has developed a new method for 2-substituted chroman by
intermolecular Mitsunobu reaction of a chiral halopropanol with 2-bromophenol.
+
Br
OH Ph
OH Cl
O Ph
THF
BuLi
2. C. Lherbet et al .3 have synthesized isochroman in the one pot-reaction by using
different benzaldehydes and phenylethanethiol or phenyl ethanol in presence of
bismuth triflate as a catalyst.
XH Ar-CHO, Bi(OTf)3
Toluene
X
Ar
X= O,S
3. C. S. López et al. 4 have developed a mild and convenient one-pot photochemical
synthesis of chroman-4-one derivatives.
hv
O
O O
O
4. H. Hamamoto et al.5 synthesized chroman by direct aromatic carbon–oxygen
bond-formation reaction involving aromatic cation radical intermediates using the
hypervalent iodine (III) reagent, phenyl iodine (III) bis(trifluoroacetate) (PIFA).
CatalystOHMeO
MeO O
MeO
MeO
5. S. Emami et al.6 have synthesized 3-azolyl chroman derivatives as
conformationally constrained analogs.
TriethylorthoformateN
O
OH
N
N
O
O
N N
N
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6. M. Venkati et al.7 have synthesized chroman derivative from substituted o-
hydroxy propiophenone and substituted benzaldehyde in 60% KOH.
+
60 % KOH
O
OHH3CO
O
O
H3CO
CHO
7. R. R. Karimi et al.8 have developed simple and clean route for synthesis of 2-
amino-3-cyano-2H-chromene derivatives.
+ +
Selectfluor 10 mol %
OH
CN
CN
O NH2
CN
R
RCHO
7. S. R. Sarda et al.9 have synthesized 2,4-diphenyl-4H-chromen-5-one  from α, β-
unsaturated carbonyl compounds and 1,3-cyclohexanedione under  microwave
irradiation in the presence ZnCl2/montmorillonite K-10.
+ K-10/ZnCl2
O O
O
O
O
MW
8. D. P. Kardile et al.10 have synthesized 7-hydroxy-4-methylcoumarin from
Pechmann condensation of resorcinol with ethylacetoacetate in presence of
concentrated sulphuric.
Conc. H2SO4+
OHOH OOH O
O
H5C2O O
9. R. Suthunuru et al.11 have developed highly effective, facile, one-pot
regioselective synthesis of a series of 7-hydroxy-4-phenyl-chroman-2-ones.
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+
R = H, Me, Cl
OHOH
R
OOH
R
O
OH
OH
O
OH
TFA, NaOAc
10. H. Lee et al.12 have synthesized 6-hydroxy-7-methoxy-4-chromanone using
aluminum chloride as catalyst.
+
OH
OH
MeO O
O
O
OHMeO
OH
O
O
O
AlCl3
CH2Cl2
11. Q. Wang et al.13 have synthesized 6-hydroxy chroman from condensation of 2-
methyl-3-butene-2-ol and substituted phenol in the presence of formic acid.
+
OH
OH
O
OH
OH
HCOOH
12. X. Meng et al.14 have synthesized highly functionalized chroman derivatives,
reaction was catalyzed by triphenylphosphine.
+ PPh3 (30 MOl %) R = Et, MeOH
NP(S)Ph2
COOR
O
NHP(S)Ph2
COORCH2Cl2
13. D. Lu et al.15 have synthesized 2-hydroxy-3-alkyl-4-nitromethyl-chroman
derivative by the michael type reaction between aliphatic aldehydes and (E)-2-(2-
nitrovinyl)phenols.
+ L,L-prolylprolinols
R = Me, Et, Bn etc
O OH
R
NO2
OH
NO2 CHO
R
N
O
N
H OH
14. Rajesha et al.16 synthesized ethyl 3-oxo-3H-benzo[f]chromene-2-carboxylate in
the presence of piperidine in dioxane from 2-hydroxynaphthalene-1-carboxlate
O O
COOEtOH
O
+ EtOOCEtOOC
Piperidine/Ethanol
30 min, Reflux
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15. C. Selenski et al.17 have synthesized chroman derivatives as like natural molecule
of (+)-mimosifoliol.
BOCO
HO
O R
OR
16. J. Barluenga et al.18 have synthesized chroman derivatives by the reaction of
different ally phenyl ethers with Ipy2BF4.
Ipy2BF4
O
Ph
IO
Ph
17. M. M. Biddle et al.19 have synthesized flavanones and chromanone using
bifunctional thiourea catalysts promote an asymmetric oxo-conjugate addition to a
β-ketoester alkylidene.
Chiral thiourea catalyst
O R
O
COO(t-Bu)
O ROH
THERAPEUTIC IMPORTANCE
Croman is the important heterocyclic compound. The number of bioactive
compounds containing croman ring system is so vast that the complete range of their
biological activities can be hardly classified20-22, however
1. Antifungal23 9. Antiallergic34
2. Antibacterial24,25 10. Anti-inflammatory35
3. Antioxidant 26 11. Antitumor36
4. Anti HIV27 12. Antitubercular37
5. Antiarrythmic28 13. Antidiabetic38
6. antiepileptic agents29-31 14. Hepatoprotective agents39
7. antihypertensive32 15. Antiulcer activity40
8. Antiviral33
M.C.Patel et al.41 have synthesized some novel chroman derivative (5) and studied
their antibacterial and antifungal activities, using the E. coli, P. aeruginosa, S. aureus, S.
Pyogenus and C. albicans.
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O
O O
NH
N
(5)
G. Hua et al.42 have synthesized chroman based derivative (6) as a potent and
highly selective kappa opioid receptor agonists.
O
O
N N
OH
(6)
B. S. Priya et al.43 have synthesized 6-fluoro-chroman-2-carboxamides (7). These
molecules were evaluated for their invitro efficacy as antimicrobials by disc diffusion and
microdilution method against pathogenic strains such as Bacillus substilis, Escherichia
coli, Pseudomonas fluorescens, Xanthomonas campestris pvs, X. oryzae, Aspergillus
niger, A. flavus, Fusarium oxysporum, Trichoderma species, F. monaliforme, and
Penicillum species.
O O
NH
F
CF3
Cl
(7)
P.V.Kumar et al.44 have synthesized 3-indolizin-3-yl-chromen-2-one (8) as a
antitubercular, antiviral and anticancer activities.
O O
NN
OCH3
(8)
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Z. Nazarian et al.45 have synthesized a chalconoids derivative containing a 6-
chloro-2H-chromen-3-yl (9) and showed cytotoxicity assessment against mouse
peritoneal macrophage cells.
O
Cl
O
(9)
S. Gowrisankar et al.46 have synthesized 4-substituted 3-exo-methylenechroman
derivatives (10) and evaluated as a antimicrobial agents.
O
EtOOC
(10)
J. G. Kanga et al.47 have isolated 2-hydroxymethyl-chroman-4-one (11) which
exhibited good activities against phytopathogen such as Pythium ultimum, Phytophthora
capsici and Sclerotinia sclerotiorum.
O OH
O
(11)
K.Hatzade et al.48 have synthesized 7-hydroxy-3-pyrazolyl-chroman-4-ones
derivaive (12) and evaluated for their in vitro antimicrobial and antioxidant activity.
O
O
N
H
N
Cl
Cl OH
(12)
M. Koufaki et al.49 have synthesized 6-hydoxy-5-substituted chroman derivatives
(13) and evaluated their activity against oxidative Stress Induced Cellular Damage.
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O
OH
NH
O
OH
OH
(13)
T. Shankar et al.50 have synthesized 3-arylidene-7-methoxy-4-cromanones (14)
and evaluated their anti-inflamatory activity.
O
O
MeO
Ar
(14)
K. A. Reddy et al.51 have synthesized chroman derivatives having 2,4-
thiazolidinone moiety (15) and evaluated for hypolipidemic activities.
O N
O S
NH
O
O
(15)
U. Gerlach et al.52 have synthesized various methanesulfonamide derivative (16)
containing chroman moiety for development as an antiarrhythmic drug.
O
Cl
N S O
O
OH
(16)
N. T. Hatzenbuhler et al.53 have worked on combining 3-aminochroman scaffold
(having affinity for 5-HT1A receptor ) and 5-fluoroindole analogues(having affinity for
5-HT reputake site ) linked through a common basic nitrogen via an alkyl chain attached
at the 1- or 3-position of the indole  evaluated for dual affinity at both the 5-HT reuptake
site and the 5-HT1A receptor.
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O
NH2O
F
N
N
H
F
(17)
P. Holmberg et al.54 have synthesized novel 2-aminotetralin and 3-aminochroman
derivatives (18) as selective serotonin 5-HT7 receptor agonists and antagonists.
O
N
OMeMeO
(18)
Thus the important role displayed by chromene and its derivatives for various
therapeutic and biological activities prompted us to synthesize some Schiff base,
Oxadiazole and Aryl amide derivatives bearing chromene moiety in order to achive
compounds having better biological activities.
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SECTION-I
SYNTHESIS AND CHARACTERIZATION OF 6-FLUORO-3,4-DIHYDRO-2H-
CHROMENE-2-CARBOHYDRAZIDE
REACTION SCHEME
Methanolic
Ethanol, Reflux
5 hrs
O
F
COOH
O
F
COOMe
O
F
CONHNH2
3 hrsHCl
NH2NH2H2O
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IR SPECTRUM OF 6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZID
E
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2943
2847
1437
1384
2975-2920
2880-2860
1470-1435
1395-1370
55
”
”
”
Aromatic,
Hetocycle
C-H str.
C=C str
C-H i.p. def.
3049
1498
1074
3100-3000
1585-1480
1125-1090
”
”
”
Ether C-O-C 1219 1275-1200 ”
Amide
Amine
C=O
-NH str.(secondry)
-NH str.(primary)
1651
3217
3294, 3323
1700-1650
3320-3140
3400-3200
”
”
”
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1H-NMR SPECTRUM OF 6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-
CARBOHYDRAZIDE
Internal Standard: TMS; Solvent: CDCl3 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
4
5
6
7
2.00-2.10
2.36-2.43
2.70-2.92
3.91
4.57-4.67
6.76-6.86
7.77
1H
1H
2H
2H
1H
3H
1H
multiplet
multiplet
multiplet
broad singlet
double doublet
multiplet
broad singlet
-CH (a)
-CH (a)
-CH (b)
-NH2 (e)
-CH (c)
Ar-H (f,g,h)
-CO-NH (d)
-
-
-
-
3.0 & 9.3
-
-
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EXPANDED 1H-NMR SPECTRUM
MASS SPECTRUM OF 6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-
CARBOHYDRAZIDE
O
F
CON
Mol. Wt.= 210
m/z = 211.0 (M
HNH2
.2
+1)
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EXPERIMENTAL
SYNTHESIS AND CHARACTERIZATION OF 6-FLUORO-3,4-DIHYDRO-2H-
CHROMENE-2-CARBOHYDRAZIDE
[A] PREPARATION OF METHYL 6-FLUORO-3,4-DIHYDRO-2H-
CHROMENE-2-CARBOXYLATE
A mixture of 6-fluoro-3,4-dihydro-2H-chromene-2-carboxylic acid (0.1 mole,
19.6 gm) and solution of 10 % HCl (59.1 ml, 3 V/W) in methanol was stirred at 30 oC for
3 hr. The progress of the reaction was monitored by TLC using mobile phase
Methanol/chloroform (9.5/0.5), after completion of the reaction solvent was removed
under reduced pressure to give an oily product (21 gm) which was directly used in the
next step.
[B] PREPARATION OF 6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-
CARBOHYDRAZIDE
A mixture of methyl 6-fluoro-3,4-dihydro-2H-chromene-2-carboxylate (21.0 gm,
0.1 mole) and hydrazine hydrate 99 % (10 gm, 0.2 mole) in 63 ml ethanol was stirred and
refluxed for 5 hr. The progress of reaction was monitored by TLC using mobile phase
Methanol/chloroform (9.5/0.5), after completion the reaction mixture was then kept in
deep-freezer for overnight. The precipitated product was filtered off, washed with hexane
(100 ml) and crystallized from isopropyl alcohol (IPA) to give 14.91 gm off white solid.
Yield: 71 %.
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INTRODUCTION
The condensation of primary amines with carbonyl compounds was first reported
by Schiff 1, and the condensation products are often referred to as Schiff bases. The
general structure of these bases is
R'
R''
N R
(1)
Where R, R’ and R” are H or alkyl or cycloalkyl or aryl or heterocycle, which
may be in derived form. This condensation reaction, along with the chemical and physical
properties of Schiff bases have been reviewed.2-4 Schiff bases are also known as Schiff”s
bases or azo methines or imines, they are well known intermediate for the preparation of
azetidinone, thiazolidinone and many other pharmaceutically important entities. These are
the compounds containing characteristic >C=N– group. Various studies have been shown
that the >C=N- group has considerable biological importance.
In recent years, there has been an increasing interest in the design and
development of Schiff base derivatives because they are associated with antibacterial,
antifungal and antitubercular activities and have diverse biological activities 5. Schiff
bases are known to be useful in perfumery6,7, as corrosion inhibitor8,9, as complexing
agents10,11 and as intermediate in many reactions12-16. They are used in optical and
electrochemical sensors, as well as in various chromatographic methods, to enable
detection of enhance selectivity and sensitivity17-19. In literature, some other applications
of schiff bases have also been reported in various fields 20-24. Some of these compounds
and their metal complexes have also been used in the preparation of various medicines25-
29. Further, many workers30-37 reported a wide range of biological activities of various
schiff bases. Besides, several schiff bases have been reported to possess remarkable
antibacterial38-42, antifungal43-48, anticancer49-53, anti HIV54-56, anti-inflammatory57-60,
antiparasitic61,62 and diuretic63 activities.
Schiff’s bases are obtained mainly by warming the aldehyde & aromatic amine
together. However, it is more convenient to work in a solvent such as alcohol, dilute
acetic acid or glacial acetic acid. Some time the reaction is aided by trace of acid in
other cases the hydrochloride of the amines can be used in the synthesis. In general
Schiff’s bases do not react further with either of the reagents used in their preparation as
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do most of the other types of simple intermediates. Synthetic Schiff’s base derivatives
contribute in huge libraries owing to their wide applicability in different fields.
SYNTHETIC ASPECT
Different methods for the preparation of azomethine derivatives documented in
literature are described as under.
1. A.  J.  Gallant et. al.64 have  prepared  schiff’s  bases  by  condensation  of
equimolar quantity of 3,6-diformyl catechol and substituted o-phenylene
diamine.
O OH
OH
N
NH2
OR
OR
O OH
OH
O
NH2
NH2
OR
OR
+
2. General account of the summary of reaction of aldehydes with amine (aromatic
or aliphatic) has been reviewed by M. S. Murray.65
R-CHO R'-NH2 R-CH=N-R'+
3. A new one pot procedure for the generation of azomethine has been
investigated by R. J. Anderson and co-workers.66
N
O R2
O
O
R1 N+
O R2
O
Cl
R1
COCl2
4. Strache67 and Van Alphen68 have prepared imine involves in two steps.
(a) Add. of the amine to the aldehyde gives aldol, which are rarely capable of
isolation.
R-CHO R'-NH2+ R-CHOHNHR'
(b) The loss of water to give an imine (azomethine), this corresponds to the
“crotonaldehyde stage” of the aldol condensation.
R-CH=N-R' H2OR-CHO  R'-NH 2+ +
5. Oddo and Tognacchini69 have introduced the comparative rates of formation of
Schiff‘s base from aromatic amines and aldehydes using a cryscopic method
follow the course of reaction.
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6. P. L. Beaulieu and co-workers70 have synthesized (E)-N-phenyl methylene
glycine ethyl ester by the cyclocondensation of glycine ethyl ester
hydrochloride with benzaldehyde in methyl t-butyl ether (MTBE) in presence of
anhydrous Na2SO4 and triethylamine
NH2
COOEt
PhCHO Et3N
Na2SO4 TBME
HCl.
N COOEt48 hrs
THERAPEUTIC IMPORTANCE
Literature survey reveals that various schiff’s bases reported as potential drugs
and are known to possess broad spectrum of biological activites.
1. Antiviral71
2. Antifungal72
3. Antiparasitic73
4. Antibacterial74
5. Antipyretic75
6. Antiinflammatory76
7. Antitubercular77
Pandey Taruna et al.78 prepared azomethines and their boron complexes and
screened for their antifungal and antibacterial properties. It is evident that azomethines
alone were quite toxic but their activity increased after complexation. Omar et al.79 have
determined cyclocondensation of azomethines having good antischistosomal activity.
Praveen M. and co-workers80 have synthesized a novel class of acetyl ferrocene derived
from Schiff bases having antimicrobial activity. Ram Tilak et al.81 have synthesized some
Schiff’s bases, thiazolidinones 4-triazolines, and formazones of 2-chloro phenothiazines
and screened as anti-inflamatory agent. The thiazolidinones showed promising anti-
inflammatory activity.
Ravindra V. Chambhare et al.82 have prepared some azomethines and tested for
their antimicrobial activity. B. Shivarama Holla et. al.83 have synthesized azomethines (2)
having antibacterial and anti-inflammatory activity.
R = 2-NO2, 4-NO2,4-Br etc.Cl
Cl
Cl
S
N NHN O R
(2)
Studies on Biologically Active... 100
Chapter-3 Studies on Schiff Base...
R. H. Mehta et al.84 have synthesized schiff’s base derivatives (3) containing
coumarin moiety and examined for their antibacterial activity. A. K. Khalafallah and M.
E. Hassan85 have prepared some styryl schiff base derivatives as potential antibacterial
and antifungal agent. P. Perumal86 have synthesized some azomethine derivatives (4)
having good antibacterial activity.
O ONR NO N
R
( 3 ) ( 4 )
M. D. Deshmukh and A. G. Doshi87 have prepared some schiff’s bases having
good antimicrobial activity against test organism S. aureus, E. coli, S. dysenteridse and S.
typhi. Wang et al.88 have synthesized diazomethines having good plant hormone activity.
S. Castellano et. al.89 have prepared azomethine derivatives and evaluated in vitro against
several pathogenic fungi responsible for human disease. Ali yusuf et al.90 have
synthesized some schiff’s base derivatives of glucose containing acetylenic bond. The
prepared schiff bases were tested for their bactericidal activity against E. coli and S.
aureus.
Smalders et. al.91 reported Schiff’s base as potential antitumor agents. Sharaf El-
Din and Nabaweyal92 have synthesized some Schiff’s base derivatives (5) having good
antibacterial activity. Chohan et. al.93 have synthesized Schiff’s bases, which have been
screened and compared for their antibacterial action against bacterial  species E. coli, P.
aeruginose and K. pneumoniase.
N
OH
OH
OH
O
R=3,4-OH, 3,4-NO2
(5)
Joydip Das et. al.94 reported trans-N-refinylidene-n-butylamine (6) which found
stabillized in liposomes of phophatidylcholine. The rate of formation of the Schiff’s base
is found to decrease with increasing cholesteral concentration in the membrane. V. M.
Patel et.al.95 synthesized some new Schiff’s bases having good antibacterial activity.
N But
Me Me MeMe
(6)
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A. Cascaval et al.96 have synthesized azomethines, which have good analgesic and
antipyretic properties. S. N. Pandeya et al.97 have synthesized schiff bases showed good
activity against Vibrio cholerae non-o., Shigella boydii, Salmonella typhi, Enterococcus
faecalis and Edwaredsiella torla with MIC in the rang of 10-25 μg/ml. Some compounds
were found to be active against Vibro cholerae non-o. and Salmonella typhi. K. N.
Venugopal et al.98 have synthesized schiff base of 4-hydroxy-6-carboxyhaydrazino
benzothiophene analog with different substituted aldehydes and determined
pharmacological study. Ergenc and coworkers99 have synthesized azomethine derivatives
having antifungal activity. B. Yadav and S. S. Sangapure100 have synthesized some
azomethines and tested for their biological activity.
Perumal Panneerselvam et al.101 have been synthesized some novel Schiff’s bases
by condensation of 3-amino-6,8-dibromo-2-phenylquinazolin-4(3H)-ones with different
aromatic aldehydes via cyclized intermediate 6,8-dibromo-2-phenyl benzoxazin-4-one.
The synthesized compounds 3-(benzylideneamino)-6,8-dibromo-2-phenylquinazolin-
4(3H)-one (7) were screened for anti-bacterial and anti-fungal activity by paper disc
diffusion technique.
N
N
Br
Br
O
C6H5
N=CH-R
R=Aryl
(7)
S. J. Wadher et. al.102 have been synthesized schiff base derivatives (8) having
antibacterial and anti-fungal activity.
R=Aryl
CHR
N SO2 N
CHR
(8)
J. R. Dimmock et. Al.103 have reported Schiff’s bases as Cytotoxic agents. A.
Adnan et. al.104 have synthesized Schiff’s bases possessing significant antibacterial and
antifungal activity. Iana Vazzana et. al105 described sets of Schiff bases (9) and (10)
(diaryl- and arylheteroaryl azomethines) endowed with strong and long lasting
antiinflammatory activity against the rat hind paw edema induced by carrageenan.
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N
CH N
CF3
CH NS
O
O
NH2 F
(9)                                          (10)
Vijay Kumar. M. M. J. et. al.106 have synthesized some Schiff bases (11)
containing different functional groups and check antimicrobial activity against gram-
positive and gram-negative bacteria.
N
N
HCl
F
N
OCH3
OH
O
NH
(11)
Gundibasappa K. Nagaraja et. al.107 have been  synthesized some Schiff bases (12)
and screened for their antibacterial and antifungal activities.
O
NH
O
N N
Cl
R
(12)
Work done from our laboratory
K. M. Thaker et al.108 have prepared some schiff bases bearing benzo[b]thiophene
nucleus and tested for their antitubercular and antimicrobial activity. S. L. Vasoya109
reported facile synthesis of some new azomethines bearing benzo[b]thiophene nucleus as
a potent biological active agent.
T. K. Dave have been reported synthesis and pharmacological study of Mannich
bases of 4-amino-3-mercapto-5-pyridin-3'-yl-[1,2,4]-triazole110 and schiff base111 bearing
nicotinic acid nucleus with antitubercular and antimicrobial evaluation.
Looking to the interesting properties of Schiff’s bases, we have synthesized some
new Schiff’s bases, which have been described as under.
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SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF N'-ARYL
METHYLIDENE-2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-
YL)ACETOHYDRAZIDE
SECTION-II: SYNTHESIS AND BIOLOGICAL SCREENING OF N'-(1-ARYL
ETHYLIDENE)-2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-
YL)ACETOHYDRAZIDE
SECTION-III:SYNTHESIS AND BIOLOGICAL SCREENING OF N'-ARYL
METHYLIDENE-6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-
CARBOHYDRAZIDE
SECTION-IV:SYNTHESIS AND BIOLOGICAL SCREENING OF N'-(1-ARYL
ETHYLIDENE)-6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-
CARBOHYDRZIDE
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF N'-ARYLMETHYLIDENE-2-
(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRAZIDE
Looking to the interesting properties of azomethines, with an intension to
synthesizing better therapeutic agents, azomethine derivatives of Type-(III) have been
synthesized by the condensation of 2-(4-(2,3-dichlorophenyl)piperazin-1-
yl)acetohydrazide with different aromatic aldehydes in order to study their biodynamic
behavior.
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
REACTION SCHEME
+
(Type-III)
R = 4-OH, 3-Cl, 2,4-di Cl, 4-OCH3, 4-F etc.
N
N
O
HN N
Cl
Cl
Cl Cl
N N
NH
O
NH2
R
CHO
R
4 to 6 Hrs
refluxEthanol
CH3COOH
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IR SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N'-((4-
METHOXYPHENYL)METHYLIDENE)ACETOHYDRAZIDE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2939
2823
1450
1305
2975-2920
2880-2860
1470-1435
1395-1370
112
”
”
”
Aromatic
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
3110
1512
1132
840
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Azomethine N=C str.C-N str.
1554
1249
1650-1580
1350-1200
”
”
Carbonyl
Ether (-OMe)
Halide
C=O
C-O-C
C-Cl
1670
1230
771
1700-1650
1275-1200
850-650
”
”
”
500750100012501500175020002500300035004000
1/cm
30
40
50
60
70
80
90
100
%T
29
39
.61
28
23
.8
8
16
70
.4
1
15
54
.6
8
15
12
.24
14
50
.5
2
13
05
.85
12
49
.91
11
32
.25
10
26
.1
6
95
2.8
7
77
1.
55
66
1.6
1
55
7.
45
49
1.8
6
45
5.2
2
43
0.1
4
41
4.7
1
SB OMe4
N
N
O
HN N
Cl
Cl
OMe
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1H-NMR SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N'-((4-
METHOXYPHENYL)METHYLIDENE)ACETOHYDRAZIDE
Internal Standard: TMS; Solvent: CDCl3 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
4
5
6
7
8
9
2.79-2.82
3.12-3.14
3.28
3.84
6.91-6.99
7.14-7.21
7.70-7.73
8.16
10.00
4H
4H
2H
3H
3H
2H
2H
1H
1H
triplet
triplet
singlet
singlet
multiplet
multiplet
doublet
singlet
singlet
-CH2 (g,g’)
-CH2 (h,h’)
-CH2 (f)
-OCH3 (a)
Ar-H (b,b’,i)
Ar-H (j,k)
Ar-H(c,c’)
-N=CH (d)
-CO-NH (e)
-
-
-
-
-
-
8.7
-
-
N
N
O
HN N
Cl
Cl
b'
c
c'
de
f
gg'
hh'
i
j k
OMea
b
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EXPANDED 1H-NMR SPECTRUM
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MASS SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N'-((4-
METHOXYPHENYL)METHYLIDENE)ACETOHYDRAZIDE
MASS SPECTRUM OF N'-((2,4-DICHLOROPHENYL)METHYLIDENE)-2-(4-(2,3-
DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRAZIDE
N
N
O
Exa
m/z
N
N
O
HN
Cl
Cl
Exact
m/z =
HN N
Cl
Cl
OMe
ct Mass = 420.1
= 421.2 (M+1)
N
Mass = 458
459.2 (M+1)
Cl
Cl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF N'-ARYLMETHYLIDENE-2-
(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRAZIDE
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. 60 % Ethyl acetate in
hexane was used as a mobile phase.
[A] SYNTHESIS OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-
YL)ACETOHYDRAZIDE
See, Chapter-2, Part-I, Section-I, Experimental [B], page no. 72.
[B] SYNTHESIS OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N'-((4-
METHOXYPHENYL)METHYLIDENE)ACETOHYDRAZIDE
A mixture of 2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetohydrazide (3.02 gm,
0.01 mol) and 4-methoxybenzaldehyde (1.36 gm, 0.01 mol) in ethanol (20 ml) in
presence of catalytic amount of glacial acetic acid (2-3 drops) was refluxed for 4 hrs. The
contents were cooled and poured in crused ice so solid precipitation was obtained, The
product was filtered and dried. Isolated product was crystallized from ethanol. Yield: 85
%, M. P. 133-136 °C (C20H22Cl2N4O2; Required: C, 57.01; H, 5.26; N, 13.30; Found: C,
56.84; H, 5.14; N, 13.18 %).
Similarly other N'-arylmethylidene-2-(4-(2,3-dichlorophenyl)piperazin-1-
yl)acetohydrazide (3a-j) were prepared. The physical constants are recorded in Table-3a,
Page no. 110.
[C] BIOLOGICAL SCREENING OF N'-ARYLMETHYLIDENE-2-(4-(2,3-
DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRAZIDE
Antimicrobial testing was carried out as described in Chapter-1, Section-I,
Experimental [C], Page no. 37. The results obtained from antimicrobial testing are
recorded in Table-3b, Page no. 111.
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TABLE-3a: PHYSICAL CONSTANTS OF N'-ARYLMETHYLIDENE-2-(4-(2,3-
DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRAZIDE
Sr.
No.
Substitution
R
Molecular
Formula/
Molecular Weight
M.P.
°C
Yield
%
% Composition
Calcd./Found
C H N
3a H C19H20Cl2N4O391.29 176-178 88
58.32
58.04
5.15
5.09
14.32
14.16
3b 4-OMe C20H22Cl2N4O2421.32 133-136 83
57.01
56.84
5.26
5.14
13.30
13.18
3c 4-F C19H19Cl2FN4O409.28 191-194 94
55.76
55.49
4.68
4.56
13.69
13.54
3d 3-Cl C19H19Cl3N4O425.74 171-173 81
53.60
53.41
4.50
4.38
13.16
13.11
3e 2,4-di Cl C19H18Cl4N4O460.18 188-191 76
49.54
49.46
3.94
3.88
12.17
12.04
3f 4-N(Me)2 C21H25Cl2N5O434.36 154-156 84
58.07
57.89
5.80
5.72
16.12
16.07
3g 2,5-di OMe C21H24Cl2N4O3451.35 178-181 79
55.88
55.79
5.36
5.32
12.41
12.36
3h 4-NO2 C19H19Cl2N5O3436.29
230
decompose 89
52.31
52.20
4.39
4.33
16.05
15.91
3i 4-OH C19H20Cl2N4O2407.29 170-171 86
56.03
55.84
4.95
4.82
13.76
13.64
3j 2-OH C19H20Cl2N4O2407.29 183-186 82
56.03
55.87
4.95
4.87
13.76
13.69
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TABLE-3b: BIOLOGICAL SCREENING OF N'-ARYLMETHYLIDENE-2-(4-(2,3-
DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRAZIDE
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 3a 500 500 100 200 1000 500 500
2 3b 250 250 62.5 100 1000 1000 >1000
3 3c 250 500 250 50 500 500 500
4 3d 500 500 200 200 250 500 500
5 3e 250 500 200 200 1000 1000 1000
6 3f 200 200 500 250 200 1000 >1000
7 3g 500 500 200 100 250 1000 >1000
8 3h 500 100 250 250 1000 500 500
9 3i 100 100 200 250 500 250 250
10 3j 250 250 200 200 1000 200 200
MINIMAL INHIBITION CONCENTRATION
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
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ANTIBACTERIAL ACTIVITY:
From screening results, substituted Schiff bases 3f (R= 4-N(Me)2) & 3i (R= 4-
OH) against S.aureus, 3b (R= 4-OMe) against E-coli and 3c (R= 4-F) against
P.aeruginosa possesses excellent activity compare to ampicillin. While 3c (R= 4-F) & 3e
(R= 2,4-di Cl) against S.aureus, 3h (R= 4-NO2) & 3i (R= 4-OH) against S.pyogenus, 3a
(R= -H) against E-coli and 3b (R= 4-OMe) & 3g (R= 2,5-di OMe) against P.aeruginosa,
possess moderate activity as compare to ampicillin. The remaining schiff bases display
moderate to poor activity against all four bacterial species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data shows that substituted schiff bases 3d (R= 3-Cl), 3f (R=
4-N(Me)2) & 3g (R= 2,5-di OMe) show highly promising activity against C.albicans
compare to greseofulvin. While 3i (R = 4-OH) & 3j (R = 2-OH) possess good activity
against A.niger and A.clavatus compare to standard drug. The remaining compounds
exhibit moderate to poor activity.
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SECTION-II
SYNTHESIS AND BIOLOGICAL SCREENING OF N'-(1-ARYLETHYLIDENE)-
2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRAZIDE
Schiff base play a vital role owing of their wide range of biological activity and
with an aim to synthesised better molecule, it was considered worthwhile to synthesize
some azomethine derivatives of Type-(IV) by the condensation of 2-(4-(2,3-
dichlorophenyl)piperazin-1-yl)acetohydrazide with different aromatic acetophenones in
order to study their biodynamic behavior.
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
REACTION SCHEME
+
(Type-IV)
R = 4-OH, 4-Cl, 4-F, 3-Br etc.
N
N
O
HN N
Cl
Cl
Cl Cl
N N
NH
O
NH2
R
R
O
9 to 12 Hrs
refluxEthanol
CH3COOH
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IR SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N'-(1-
PHENYLETHYLIDENE)ACETOHYDRAZIDE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2951
2868
1444
1377
2975-2920
2880-2860
1470-1435
1395-1370
112
”
”
”
Aromatic
C-H str.
C=C str.
C-H i.p. def.
C-H o.o.p. def.
3034
1494
1111
877
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Azomethine N=C str.C-N str.
1600
1246
1650-1580
1350-1200
”
”
Carbonyl
Halide
C=O
C-Cl
1658
763
1700-1650
850-650
”
”
500750100012501500175020002500300035004000
1/cm
-30
-15
0
15
30
45
60
75
90
%T 34
43
.0
5
31
82
.65 30
34
.13
29
51
.1
9
29
28
.04
28
68
.2
4
27
27
.4
4
16
78
.13
16
58
.84
16
00
.97
15
46
.96
14
94
.88
14
44
.73 1
37
7.2
2
13
03
.92 12
46
.06
11
93
.98
11
55
.40
11
11
.03
10
57
.03
10
24
.24 8
77
.6
4
76
3.8
4
69
4.4
0
64
8.1
0
SPA-01
N
N
O
HN N
Cl
Cl
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1H-NMR SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N'-(1-
PHENYLETHYLIDENE)ACETOHYDRAZIDE
Internal Standard: TMS; Solvent: CDCl3 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
4
5
6
7
8
9
2.30
2.83-2.86
3.13-3.17
3.34
6.96-7.00
7.14-7.21
7.38-7.43
7.83-7.86
10.25
3H
4H
4H
2H
1H
2H
3H
2H
1H
singlet
triplet
triplet
singlet
multiplet
multiplet
multiplet
multiplet
singlet
-CH3(a)
-CH2 (b,b’)
-CH2 (c,c’)
-CH2 (d)
Ar-H (e)
Ar-H (f,g)
Ar-H(h,i,i’)
Ar-H(j,j’)
-CO-NH (k)
-
-
-
-
-
-
-
-
-
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EXPANDED 1H-NMR SPECTRUM
Studies on Biologically Active... 117
Chapter-3 Studies on Schiff Base...
MASS SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N'-(1-
PHENYLETHYLIDENE)ACETOHYDRAZIDE
MASS SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N'-(1-(4-
HYDROXYPHENYL)ETHYLIDENE)ACETOHYDRAZIDE
N
N
O
HN N
Cl
Cl
Exact Mass = 404.1
m/z = 405.2 (M+1)
N
N
O
HN N
Cl
Cl
Exact Mass = 420.1
m/z = 421.2 (M+1)
OH
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF N'-(1-ARYLETHYLIDENE)-
2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRAZIDE
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. 50 % Ethyl acetate in
hexane was used as a mobile phase.
[A] SYNTHESIS OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-
YL)ACETOHYDRAZIDE
See, Chapter-2, Part-I, Section-I, Experimental [B], page no. 72.
[B] SYNTHESIS OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N'-(1-
PHENYLETHYLIDENE)ACETOHYDRAZIDE
A mixture of 2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetohydrazide (3.02 gm,
0.01 mol) and acetophenone (1.20 gm, 0.01 mol) in ethanol (20 ml) in presence of
catalytic amount of glacial acetic acid was refluxed for 10 hrs. The contents were cooled
and poured in crused ice so solid precipitation was obtained, The product was filtered and
dried. Isolated product was crystallized from ethanol. Yield: 85 %, M. P. 175-178 °C,
(C20H22Cl2N4O; Required: C, 59.27; H, 5.47; N, 13.82; Found: C, 59.09; H, 5.41; N,
13.73 %).
Similarly, other N'-(1-arylethylidene)-2-(4-(2,3-dichlorophenyl)piperazin-1-
yl)acetohydrazide (4a-j) were prepared. The physical constants are recorded in Table-4a,
Page no. 119.
[C] BIOLOGICAL SCREENING OF N'-(1-ARYLETHYLIDENE)-2-(4-(2,3-
DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRAZIDE
Antimicrobial testing was carried out as described in Chapter-1, Section-I,
Experimental [C], Page no. 37. The results obtained from antimicrobial testing are
recorded in Table-4b, Page no. 120.
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TABLE-4a: PHYSICAL CONSTANTS OF N'-(1-ARYLETHYLIDENE)-2-(4-(2,3-
DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRAZIDE
N
N
O
HN N
Cl
Cl
R
Sr.
No.
Substitution
R
Molecular
Formula/
Molecular Weight
M.P.
°C
Yield
%
% Composition
Calcd./Found
C H N
4a H C20H22Cl2N4O405.32 175-178 85
59.27
59.09
5.47
5.41
13.82
13.73
4b 4-Me C21H24Cl2N4O419.35 151-153 81
60.15
60.01
5.77
5.71
13.36
13.28
4c 4-F C20H21Cl2FN4O423.31 185-188 91
56.75
56.54
5.00
4.94
13.24
13.18
4d 4-Cl C20H21Cl3N4O439.77 176-178 83
54.62
54.48
4.81
4.77
12.74
12.59
4e 2,4-di Cl C20H20Cl4N4O474.21 163-165 73
50.66
50.49
4.25
4.19
11.81
11.73
4f 4-Br C20H21BrCl2N4O484.22 181-182 88
49.61
49.53
4.37
4.33
11.57
11.45
4g 3-Br C20H21BrCl2N4O484.22 198-201 83
49.61
49.43
4.37
4.29
11.57
11.46
4h 4-OH C20H22Cl2N4O2421.32 188-191 79
57.01
56.84
5.26
5.14
13.30
13.21
4i 4-NH2 C20H23Cl2N5O420.34 176-179 75
57.15
56.91
5.52
5.43
16.66
16.52
4j 2-NO2 C20H21Cl2N5O3450.32 211-213 80
53.34
53.11
4.70
4.66
15.55
15.44
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TABLE-4b: BIOLOGICAL SCREENING OF N'-(1-ARYLETHYLIDENE)-2-(4-(2,3-
DICHLOROPHENYL)PIPERAZIN-1-YL)ACETOHYDRAZIDE
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 4a 250 200 500 500 500 500 500
2 4b 200 200 100 250 250 500 500
3 4c 500 100 250 250 500 1000 1000
4 4d 500 500 200 250 500 1000 1000
5 4e 250 500 250 500 250 500 500
6 4f 500 500 200 250 1000 500 500
7 4g 500 500 100 500 1000 500 500
8 4h 250 250 500 250 1000 200 200
9 4i 250 250 62.5 100 >1000 >1000 >1000
10 4j 500 250 500 500 200 >1000 >1000
MINIMAL INHIBITION CONCENTRATION
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
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ANTIBACTERIAL ACTIVITY:
From screening results, substituted Schiff base 4b (R= 4-Me) against S.aureus and
4i (R= 4-NH2) against E-coli exhibit outstanding activity compare to ampicillin. While 4e
(R= 2,4-di Cl) & 4i (R= 4-NH2) against S.aureus, 4c (R= 4-F) against S.pyogenus, 4b (R=
4-Me) & 4g (R= 3-Br) against E-coli and 4i (R= 4-NH2) against P.aeruginosa, possess
moderate activity as compare to ampicillin. The remaining schiff bases show moderate to
poor activity against all four bacterial species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data showed that substituted schiff bases 4b (R= 4-Me), 4e
(R= 2,4-di Cl) & 4j (R= 2-NO2) display highly promising activity against C.albicans as
compare to greseofulvin. While 4h (R = 4-OH) possess good activity against A.niger and
A.clavatus compare to standard drug. The remaining compounds exhibit moderate to poor
activity.
Studies on Biologically Active... 122
Chapter-3 Studies on Schiff Base...
SECTION-III
SYNTHESIS AND BIOLOGICAL SCREENING OF N'-ARYLMETHYLIDENE-6-
FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Schiff’s base derivatives represent one of the modest classes of biological active
agent which have been deeply studies during search on new potential drugs, these have
been reported to be active as antimicrobial, antitubercular, anthelmintics etc. In view of
these findings, it appeared of interest to synthesize Schiff’s base derivatives of Type-(V)
by the condensation of 6-fluoro-3,4-dihydro-2H-chromene-2-carbohydrazide with
different aromatic aldehydes.
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
REACTION SCHEME
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IR SPECTRUM OF 6-FLUORO-N'-((4-METHOXYPHENYL)METHYLIDENE)-3,4-
DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2964
2841
1431
1357
2975-2920
2880-2860
1470-1435
1395-1370
112
”
”
”
Aromatic
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
3070
1510
1089
833
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Azomethine N=C str.C-N str.
1606
1311
1650-1580
1350-1200
”
”
Carbonyl
Ether
Amide
C=O
C-O-C
-NH str.
1678
1261
3213
1700-1650
1275-1200
3200-3400
”
”
”
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1H-NMR SPECTRUM OF 6-FLUORO-N'-((4-METHOXYPHENYL)METHYLIDENE)-
3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Internal Standard: TMS; Solvent: CDCl3 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
4
5
6
7
8
9
2.05-2.16
2.47-2.56
2.76-2.94
3.84
4.64-4.68
6.79-6.93
7.70-7.72
8.14
9.40
1H
1H
2H
3H
1H
5H
2H
1H
1H
multiplet
multiplet
multiplet
singlet
double doublet
multiplet
doublet
singlet
singlet
-CH2 (a)
-CH2 (a)
-CH2 (b)
-OCH3 (c)
-CH (d)
Ar-H (e to i)
Ar-H(j,k)
-N=CH (l)
-CO-NH (m)
-
-
-
-
3.0 & 9.9
-
8.7
-
-
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EXPANDED 1H-NMR SPECTRUM
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MASS SPECTRUM OF 6-FLUORO-N'-((4-METHOXYPHENYL)METHYLIDENE)-3,4-
DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
MASS SPECTRUM OF N'-((4-(DIMETHYLAMINO)PHENYL)METHYLIDENE)-
6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF N'-ARYLMETHYLIDENE-6-
FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. 60 % Ethyl acetate in
hexane  was used as a mobile phase.
[A] SYNTHESIS OF 6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-
CARBOHYDRAZIDE
See, Chapter-2, Part-II, Section-I, Experimental [B], page no. 93.
[B] SYNTHESIS OF 6-FLUORO-N'-((4-METHOXYPHENYL)METHYLID-
ENE)-3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
A mixture of 6-fluoro-3,4-dihydro-2H-chromene-2-carbohydrazide (2.10 gm, 0.01
mol) and 4-methoxybenzaldehyde (1.36 gm, 0.01 mol) dissolved in ethanol (20 ml) in
presence of catalytic amount of glacial acetic acid was refluxed for 6 hrs. The contents
were cooled and poured in crused ice so solid precipitation was obtained, The product
was filtered and dried. Isolated product was crystallized from ethanol. Yield: 85 %, M. P.
164-167 °C, (C18H17FN2O3; Required: C, 65.84; H, 5.22; N, 8.53; Found: C, 65.56; H,
5.10; N, 8.41 %).
Similarly, other N'-arylmethylidene-6-fluoro-3,4-dihydro-2H-chromene-2-
carbohydrazide were (5a-j) prepared. The physical constants are recorded in Table-5b,
Page no. 128.
[C] BIOLOGICAL SCREENING OF N'-ARYLMETHYLIDENE-6-FLUORO-
3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Antimicrobial testing was carried out as described in Chapter-1, Section-I,
Experimental Section-[C], Page no. 37. The results obtained from antimicrobial testing
are recorded in Table-5b, Page no. 129.
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TABLE 5a: PHYSICAL CONSTANTS OF N'-ARYLMETHYLIDENE-6-FLUORO-
-3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Sr.
No.
Substitution
R
Molecular
Formula/
Molecular Weight
M.P.
°C
Yield
%
% Composition
Calcd./Found
C H N
5a H C17H15FN2O2298.31 158-160 79
68.45
68.29
5.07
5.01
9.39
9.23
5b 4-OMe C18H17FN2O3328.34 164-167 85
65.84
65.56
5.22
5.10
8.53
8.41
5c 4-F C17H14F2N2O2316.30 173-176 81
64.55
64.22
4.46
4.39
8.86
8.72
5d 3-Cl C17H14ClFN2O2332.76 151-153 86
61.36
61.08
4.24
4.19
8.42
8.27
5e 2,4-di Cl C17H13Cl2FN2O2367.20 182-183 77
55.60
55.43
3.57
3.51
7.63
7.51
5f 4-N(Me)2 C19H20FN3O2341.38 166-169 80
66.85
66.62
5.91
5.85
12.31
12.24
5g 4-OH,3-OMe C18H17FN2O4344.34 171-173 79
62.79
62.55
4.98
4.90
8.14
8.03
5h 4-NO2 C17H14FN3O4343.31 182-185 75
59.47
59.29
4.11
4.03
12.24
12.07
5i 4-OH C17H15FN2O3314.31 165-167 87
64.96
64.80
4.81
4.73
8.91
8.82
5j 2-OH C17H15FN2O3314.31 177-180 82
64.96
64.73
4.81
4.68
8.91
8.78
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TABLE 5b: BIOLOGICAL SCREENING OF N'-ARYLMETHYLIDENE-6-FLUORO-
3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 5a 200 100 62.5 100 500 200 200
2 5b 200 200 200 50 1000 1000 1000
3 5c 100 500 100 250 500 >1000 >1000
4 5d 250 500 200 500 250 >1000 >1000
5 5e 500 250 200 250 1000 200 200
6 5f 500 500 100 100 200 >1000 >1000
7 5g 500 500 200 250 1000 >1000 >1000
8 5h 500 250 500 500 500 1000 1000
9 5i 100 100 500 500 500 1000 1000
10 5j 250 200 500 500 250 >1000 >1000
MINIMAL INHIBITION CONCENTRATION
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
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ANTIBACTERIAL ACTIVITY:
From screening results, substituted Schiff bases 5c (R= 4-F) & 5i (R = 4-OH)
against S.aureus, 5a (R= -H) against E-coli and 5b (R= 4-OMe) against P.aeruginosa
possess excellent activity compared to ampicillin. While 5a (R= -H) & 5b (R= 4-OMe)
against S.aureus, 5a (R= -H) & 5i (R= 4-OH) against S.pyogenus, 5c (R= 4-F) & 5f (R=
4-N(Me)2) against E-coli and 5a (R= -H) & 5f (R= 4-N(Me)2) against P.aeruginosa,
display moderate activity as compared to ampicillin. The remaining schiff bases
demonstrate poor activity against all four bacterial species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data showed that substituted schiff bases 5d (R= 3-Cl), 5f
(R= 4-N(Me)2) & 5j (R= 2-OH) show very good activity against C.albicans as compared
to greseofulvin. While 5a (R= -H) & 5e (R= 2,4-di Cl) exhibit good activity against
A.niger and A.clavatus compare to standard drug. The remaining compounds display poor
activity against all three bacterial species.
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SECTION-IV
SYNTHESIS AND BIOLOGICAL SCREENING OF N'-(1-ARYLETHYLIDENE)-
6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRZIDE
Synthesis of schiff base derivatives has attracted considerable attention in
view of therapeutic applications. Looking to this, schiff base derivative of Type-(VI)
have been synthesised by the condensation of 6-fluoro-3,4-dihydro-2H-chromene-2-
carbohydrazide with different substituted aromatic acetophenones.
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
REACTION SCHEME
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IR SPECTRUM OF 6-FLUORO-N'-(1-(4-METHYLPHENYL)ETHYLIDENE)-3,4-
DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2935
2850
1444
1373
2975-2920
2880-2860
1470-1435
1395-1370
112
”
”
”
Aromatic
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
3030
1554
1101
868
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Azomethine N=C str.C-N str.
1654
1265
1650-1580
1350-1200
”
”
Carbonyl
Amide
C=O
-NH str.
1683
3178
1700-1650
3200-3400
”
”
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1H-NMR SPECTRUM OF 6-FLUORO-N'-(1-(4-METHYLPHENYL)ETHYLIDENE)-3,4-
DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Internal Standard: TMS; Solvent: CDCl3 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value
in HZ
1
2
3
4
5
6
7
8
9
10
2.12-2.21
2.23
2.37
2.44-2.55
2.77-2.96
4.72-4.76
6.74-6.94
7.17-7.20
7.72-7.75
9.40
1H
3H
3H
1H
2H
1H
3H
2H
2H
1H
multiplet
singlet
singlet
multiplet
multiplet
double doublet
multiplet
doublet
doublet
singlet
-CH2 (a)
-N=C-CH3 (b)
Ar-CH3 (c)
-CH2 (a)
-CH2 (d)
-CH (e)
Ar-H (f,g,h)
Ar-H (i)
Ar-H (j)
-CO-NH (k)
-
-
-
-
-
3.0 & 9.0
-
8.1
8.4
-
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EXPANDED 1H-NMR SPECTRUM
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MASS SPECTRUM OF 6-FLUORO-N'-(1-(4-METHYLPHENYL)ETHYLIDENE)-3,4-
DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
MASS SPECTRUM OF 6-FLUORO-N'-(1-PHENYLETHYLIDENE)-3,4-DIHYDRO-2H-
CHROMENE-2-CARBOHYDRAZIDE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF N'-(1-ARYLETHYLIDENE)-
6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRZIDE
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. 60 % Ethyl acetate in
hexane was used as a mobile phase.
[A] SYNTHESIS OF 6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-
CARBOHYDRAZIDE
See, Chapter-2, Part-I, Section-I, Experimental [B], Page no. 93.
[B] 6-FLUORO-N'-(1-(4-METHYLPHENYL)ETHYLIDENE)-3,4-DIHYDRO-
2H-CHROMENE-2-CARBOHYDRAZIDE
A mixture of 6-fluoro-3,4-dihydro-2H-chromene-2-carbohydrazide (2.10 gm, 0.01
mol) and 4’-methyl acetophenone (1.34 gm, 0.01 mol) dissolved in ethanol (20 ml) in
presence of catalytic amount of glacial acetic acid was refluxed for 9 hrs. The contents
were cooled and poured in crused ice so solid precipitation was obtained, The product
was filtered and dried. Isolated product was crystallized from ethanol. Yield: 81 %, M. P.
196-199 °C, (C19H19FN2O2; Required: C, 69.92; H, 5.87; N, 8.58; Found: C, 69.73; H,
5.69; N, 8.44 %).
Similarly, other N’-(1-arylethylidene)-6-fluoro-3,4-dihydro-2H-chromene-2-
carbohydrzide were (6a-j) prepared. The physical constants are recorded in Table-6a,
Page no. 137.
[C] BIOLOGICAL SCREENING OF N'-(1-ARYLETHYLIDENE)-6-FLUORO-
3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRZIDE
Antimicrobial testing was carried out as described in Chapter-1, Section-I,
Experimental Section-[C], Page no. 37. The results obtained from antimicrobial testing
are recorded in Table-6b, Page no. 138.
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TABLE6a:PHYSICAL CONSTANTS OF N'-ARYLMETHYLIDENE-6-FLUORO-
3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
O
HN NO
F
R
Sr.
No.
Substitution
R
Molecular
Formula/
Molecular Weight
M.P.
°C
Yield
%
% Composition
Calcd./Found
C H N
6a H C18H17FN2O2312.34 181-182 85
69.22
69.03
5.49
5.36
8.97
8.81
6b 4-Me C19H19FN2O2326.36 196-199 81
69.92
69.73
5.87
5.69
8.58
8.44
6c 4-F C18H16F2N2O2330.33 175-178 89
65.45
65.28
4.88
4.77
8.48
8.30
6d 4-Cl C18H16ClFN2O2346.78 153-156 76
62.34
62.26
4.65
4.52
8.08
7.92
6e 3-Cl C18H16ClFN2O2346.78 169-170 72
62.34
62.06
4.65
4.56
8.08
7.96
6f 2,4-(Cl)2 C18H15Cl2FN2O2381.23 188-191 66
56.71
56.43
3.97
3.84
7.35
7.22
6g 3-Br C18H16BrFN2O2391.23 171-174 75
55.26
55.03
4.12
4.01
7.16
7.09
6h 4-OH C18H17FN2O3328.34 192-195 83
65.84
65.51
5.22
5.13
8.53
8.39
6i 4-NH2 C18H18FN3O2327.35 182-184 61
66.04
65.87
5.54
5.41
12.84
12.68
6j 2-NO2 C18H16FN3O4357.34 204-206 88
60.50
60.36
4.51
4.43
11.76
11.69
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TABLE 6b: BIOLOGICAL SCREENING OF N'-ARYLMETHYLIDENE-6-FLUORO-
3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 6a 250 500 250 500 250 500 500
2 6b 500 500 62.5 200 100 500 500
3 6c 250 50 250 250 100 250 250
4 6d 500 500 250 200 200 500 500
5 6e 100 500 500 500 500 >1000 >1000
6 6f 250 500 100 100 250 >1000 >1000
7 6g 250 250 250 200 200 1000 1000
8 6h 100 100 250 500 500 >1000 >1000
9 6i 200 500 250 250 500 1000 1000
10 6j 250 250 500 500 200 >1000 >1000
MINIMAL INHIBITION CONCENTRATION
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
Studies on Biologically Active... 139
Chapter-3 Studies on Schiff Base...
ANTIBACTERIAL ACTIVITY:
From screening results, substituted Schiff bases 6e (R= 3-Cl) & 6h (R= 4-OH)
against S.aureus, 6c (R= 4-F) against S.pyogenus and 6b (R= 4-Me) against E-coli
possess very good activity compared to ampicillin. While 6i (R= 4-NH2) against S.aureus,
6h (R= 4-OH) against S.pyogenus and 6f (R= 2,4-di Cl) against E-coli & P.aeruginosa,
demonstrate moderate activity as compared to ampicillin. The remaining schiff bases
exhibit moderate to poor activity against all four bacterial species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data shows that substituted schiff bases 6b (R= 4-Me) & 6c
(R= 4-F) display highly promissing activity against C.albicans as compared to
greseofulvin. While 6d (R= 4-Cl) & 6j (R= 2-NO2) against C.albicans and 6c (R= 4-F)
against A.niger & A.clavatus, possess moderate activity compare to standard drug. The
remaining compounds show moderate to poor activity against all three bacterial species.
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STUDIES ON THIAZOLIDINONE
DERIVATIVES
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INTRODUCTION
Thiazolidinones, which belong to an important group of heterocyclic compounds,
have been widely explored for their applications in the field of medicine. Thiazolidinones
play a vital role due to their wide range of biological activities and industrial importance.
Thiazolidinones, with a carbonyl group at position 2 in structure (1), position 4 in
structure (2) and position 5 in structure (3) have been subjected to widespread study in the
recent past.
4-Thiazolidinones are always being an attraction point for researchers because of
its efficiency towards various pharmacological usages. Numerous gossips have appeared
in the literatures which underscore their chemistry and use. The derivatives of 4-
thiazolidinone nucleus have occupied a unique place in the field of medicinal chemistry
due to wide range of biological activities like antibacterial, antitubercular, anticancer,
anticonvulsant and antifungal.1 They have interesting activity profiles mainly cox-1
inhibitors, inhibitors of bacterial enzyme, non nucleoside inhibitors of HIVRT and
antihistaminic agents.2 4-thiazolidinones are derivatives of thiazolidinone with carbonyl
group at the 4th position and formed by the attack of sulphur nucleophile on imine carbon
followed by intramolecular cyclisation with elimination of water. Substituent in the 2, 3
and 5 positions may be varied, but the greatest different in structure and properties is
exerted by the groups attached to carbon atom at the 2-position and to nitrogen atom at
the 3-position. The cyclic structure was assigned after recognition of mercaptoacetic acid
as a primary product of hydrolysis of 3-phenyl-2-phenylimino-4-thiazolidinones.3
A well known antibiotic, actithiazic acid (4), isolated from a species of
streptomyces shows specific in vitro activity against M. tuberculosis, but it is inactive in
vivo probably due to antagonisation by biotin, bears the 4-thiazolidinone skeleton. A
recent literature search revealed that 4–thiazolidinone derivatives may exhibit
antibacterial4,5, antituberculosis6-8, antiviral9-14 and anticancer15-18 activities. According to
Andres et al.4, 4-thiazolidinones may be considered as phosphate bioisosteres and
therefore inhibit the bacterial enzyme Murb which is involved in the biosynthesis of
peptidoglycan layer of the cell wall4. In addition, some thiazolidinones were recently
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reported as novel inhibitors of mycobacterial rhamnose synthetic enzymes19. This new
approach is believed to be selective as rhamnose which is not found in humans, has been
shown to be essential for mycobacterial cell wall synthesis19.
SYNTHETIC ASPECT
Synthesis of 4-thiazolidinones has been reported either by cyclisation of acyclic
compounds or by interconversion among appropriately substituted thiazolidinone
derivatives. Several methods for the preparation of 4-thiazolidinones are narrated in
literature.20-29
1. Hongyu Zhou et al.30 have reported Microwave-Assisted Fluorous Synthesis of
4-thiazolidinone and generte 4-thiazolidinone libraries.
2. Ravindra K. Rawal et al.31 designed and synthesized a series of 2-aryl-3-
heteroaryl-1,3-thiazolidin-4-ones and evaluated for anti-HIV-1 RT activity.
3. Tumul Srivastava et al.32 have synthesized some new 4-thiazolidinones by DCC
mediated three-component reaction of amine, aldehyde and mercaptoacetic acid.
DCC /THFR-NH2
HSCH2COOH
N SR R1
O
+
R1
HO
4. Zhong-Zheng Zhou et al.33 have reported one-pot liquid-phase combinatorial
synthesis of 2-(4-oxo-4H-1-benzopyran-3-yl)-4-thiazolidinones bearing diverse
substituents at the 3-position under microwave irradiation.
Microwave
Irradiation
O
O O
H
NH2
R
O
O S
N O
R
+
Na2SO4, PTSA
Benzene
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5. Christopher J. Hobbs et al.34 have synthesized some new calcium channel
blockers from the ‘hit’ structures 2-(3-bromo-4-fluorophenyl)-3-(2-pyridin-2-
ylethyl)thiazolidin-4-one and its 2-[4-(4-bromophenyl)pyridin-3-yl]-3-isobutyl
analogues.
N
OH Br
N
N BrS
O
HSCH2CO2H
Benzene, 70 oC,18 hr
+
NH2
6. Adele Bolognese et al.35 have been describe the thiazolidin-4-one formation.
Mechanistic and synthetic aspects of the reaction between imines and
mercaptoacetic acid under microwave and conventional heating.
dry benzene
N HSCH2COOH
N
S O
7. Joan Fraga-Dubreuil et al36 have been explained efficient combination of task-
specific ionic liquid and microwave dielectric heating applied to one-pot three
component synthesis of a small library of 4-thiazolidinones.
O
O
NO N
S
OHSCH2COOH
O
O
OIonic liquidMW irradation
8. Bioactive venlafaxine analogs such as 2,3-disubstituted-1,3-thiazolidinones  have
been synthesized and reported as antimicrobial agent by C. V. Kavitha and
coworkers.37
DCC, THF
H3CO
NH2OH R-CHO
HSCH2COOH H3CO NOH S
O
R
+
9. Denis R. St. Laurent et al.38 have synthesized 4-thiazolidinone derivatives by the
cyclization of unsymmetrical thiourea. H. S. Joshi and co-workers39 have
synthesized thiazolidinones bearing benzo[b]thiophenenucleus from N-
rylaminothioxomethyl derivatives with chloroacetic acid in ethanol.
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NaoAc
R= Aryl
S
Cl
O
N
S
O
N
R
Cl-CH2COOHS
Cl
O
NH
N
S
H
R
10. M. Shrinivas et al.40 have reported some new thiazolidinones from isoxazolyl
thiourea on treatment with chloroacetic acid and fused anhydrous sodium acetate
in ethanol.
R = Aryl
O N
NH S
NH
R
ClCH2COOH
CH3COONa
O N
N
S
N
O
R
THERAPEUTIC IMPORTANCE
The thiazolidinone derivatives substituted at 2- and 3-position are associated with
diverse biological activities which have been reported as under.
1. Analgesic41
2. Antibacterial42 ,43
3. Antidiabetic44
4. Ant i funga l 4 5 - 4 7
5. Anti HIV and anti cancer48
6. Ant-microbial49 ,50
7. Ant iulcer 5 1 , 5 2
8. Anti-tumor53
9. Anti-tubuercular54,55
10. Anti-viral56
11. Anthelmintics57,58
12. Cardiovascular59
13. Herbicidal60
14. Hypnotic61-63
15. Insectidal64
17. Local anaesthetic65
K. Mogliaiah and Co-workers66,67 isolated some 4-thiazolidinones
derivativies and tested their antibacterial activity. H. Y. Hassan et. al.68 has prepared
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2-amino-4-thiazolidinones which have been found to possess antimicrobial activity.
G. S. Gadaginamath et.al.69 also prepared thiazolidinones derivatives, as antimicrobial
agent.
R. S.  Lodhi and co-workers70 have been synthesized and studied
antimicrobial, anti-inflammatory and analgesic activity of 4-thiazolidinone and arylidene
derivatives (5).
N
N
O
NH N S
O
Z
R1
R = (Un) Substituted aryl
Z = H2
Z = CH2R2
R1 = Substituted aryl
(5)
G. Bhawana et. al.71 have been synthesized thiazolidinone
derivatives and compared their anti-inflammatory potency, ulcerogenic liability,
cardiovascular and CNS effect. R. P. Pawar and co-workers72 reported synthesis and in
vitro antibacterial activity of some 4-thiazolidinone derivatives. In other
study, some thiazolidinone derivatives have been found to be promising
antibacterial agent.73
Morever, Albuquerque and co-workers74 have prepared 4-thiazolidinones
which show antidiabetic and antiinflammatory activity. Tagami and co-worker75 have
synthesized 4-thiazolidinone derivatives as allergy inhibitor. M. Siddique et. al.76
have prepared substituted thiazolidinones (6) and reported their antibacterial,
antifungal, antithyroid and amoebicidal properties.
S N
R1
R2
O
S
R5 R4
R3
R1 = OH
R2,R4,R5 = H
R3 = Me(6)
H. H. Parekh and et. al.77 have been synthesized some new thiazolidinones (7) as
antimicrobial agent.
N Cl
N
S
OR
(7) R=Aryl
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K. R. Desai et.al.78 have been synthesized some new 4-thiazolidinones (8) as
antimicrobial agent.
N
S
N S
O
CN
N
R
(8) R= Aryl
S. V. Bhandari  et .al . 79 have been synthesized thiazolidinone
derivatives (9) and tested for electrocardiographic,  antiarrhythmic,
vasorelaxing and antihypertensive activity as well as for in -vitro nitric
oxide (NO) releasing ability.
N
S
N
O
R
OH
NH
CONHNHCOCH2ONO2
(9) R= Substituted phenyl
In view of getting better therapeutic activities showed by 4-thiazolidinones,
prompted us to synthesize 4-thiazolidinone derivatives, which have been described as
under.
SECTION-I:SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2-ARYL-4-
OXOTHIAZOLIDIN-3-YL)-2-(4-(2,3-DICHLOROPHENYL)PIPERA-
ZIN-1-YL)ACETAMIDE
SECTION-II:SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2-ARYL-5-
METHYL-4-OXOTHIAZOLIDIN-3-YL)-2-(4-(2,3-DICHLOROPHE-
NYL)PIPERAZIN-1-YL)ACETAMIDE
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2-ARYL-4-
OXOTHIAZOLIDIN-3-YL)-2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)
ACETAMIDE
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
REACTION SCHEME
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IR SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N-(4-OXO-2-
PHENYLTHIAZOLIDIN-3-YL)ACETAMIDE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc).
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2968
2874
1452
1381
2975-2920
2880-2860
1470-1435
1395-1370
80
”
”
”
Aromatic
C-H str.
C=C str.
C-H i.p. def.
C-H o.o.p. def.
3061
1512
1153
835
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Thiazolidinone
C=O str.
C-N str.
C-S str.
1730
1205
709
1760-1655
1220-1020
750-600
81
”
”
Carbonyl
Halide
C=O str.
C-Cl str.
1697
792
1700-1650
850-650
”
”
500750100012501500175020002500300035004000
1/cm
15
30
45
60
75
90
105
%T
30
61
.1
3
29
68
.5
5
28
74
.03
28
20
.0
2
23
57
.0
9
17
30
.21 16
97
.41
15
77
.8
2
15
12
.2
4
14
79
.45
14
52
.45
14
25
.44
13
81
.08
13
30
.9
3
12
44
.1
3
12
22
.91 1
20
5.5
5
11
53
.47
95
4.
80 86
2.2
1
83
5.
21 81
3.
99
79
2.7
7
70
9.
83
57
4.
81
50
9.
22
47
8.3
6
46
1.
00
43
9.
78
Thsb-simple
N
N
O
HN N
Cl
Cl
S
O
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1H-NMR SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N-(4-OXO-
2-PHENYLTHIAZOLIDIN-3-YL)ACETAMIDE
Internal Standard: TMS; Solvent: DMSO-d6 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
4
5
6
7
8
9
10
2.41-2.2
2.86
3.72-3.88
2.99-3.00
5.83
7.06-7.09
7.26-7.30
7.34-7.39
7.43-7.46
9.98
4H
4H
2H
2H
1H
1H
2H
3H
2H
1H
broad doublet
broad singlet
multiplet
multiplet
singlet
double doublet
multiplet
multiplet
multiplet
singlet
-CH2 (a,a’)
-CH2 (b,b’)
-CH2 (c)
-CH2 (d)
-CH (e)
Ar-H (f)
Ar-H (g,h)
Ar-H (i,j,j’)
Ar-H (k,k’)
-CO-NH (l)
4.2
-
-
-
-
3.2 & 6.3
-
-
-
-
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EXPANDED 1H-NMR SPECTRUM
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MASS SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N-(4-OXO-2-
PHENYLTHIAZOLIDIN-3-YL)ACETAMIDE
MASS SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N-(2-(4-
FLUOROPHENYL)-4-OXOTHIAZOLIDIN-3-YL)ACETAMIDE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2-ARYL-4-
OXOTHIAZOLIDIN-3-YL)-2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)
ACETAMIDE
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. 5 % Methanol in chloroform
was used as a mobile phase.
[A] SYNTHESIS OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N'-
(PHENYLMETHYLIDENE)ACETOHYDRAZIDE
See, Chapter-3, Section-I, Experimental [B], Page no. 109.
[B] SYNTHESIS OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N-(4-
OXO-2-PHENYLTHIAZOLIDIN-3-YL)ACETAMIDE
A mixture of 2-(4-(2,3-dichlorophenyl)piperazin-1-yl)-N'-(phenylmethylidene)
acetohydrazide (3.91 gm, 0.01 mol) and thioglycolic acid (1.84 gm, 0.02 mol) in toluene
(20 ml) was refluxed for 8 hrs. Seperated water from the reaction was continuesly
removed by azeotropic distillation using a Dean-Stark separator. Progress of rhe reaction
was monitered by TLC, after completion of reaction excess of toluene was distilled off
and the resulting residue was partioned between ethyl acetate and saturated NaHCO3
solution to remove unreacted thioglycolic acid, organic layer was washed with brine,
dried over sodium sulphate, evaporated to give crude product. The crude product was
recrystallized from mixture of isopropyl alcohol:hexane. Yield 65%, M. P. 135-138 0C.
(C21H22Cl2N4O2S; Required: C, 54.20; H, 4.76; N, 12.04 %; Found: C, 53.94; H, 4.73; N,
11.98 %).
Similarly, other N-(2-aryl-4-oxothiazolidin-3-yl)-2-(4-(2,3-dichlorophenyl)
piperazin-1-yl)acetamide (7a-j) were prepared. The physical constants are recorded in
Table-7a, Page no. 159.
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[C] BIOLOGICAL SCREENING OF N-(2-ARYL-4-OXOTHIAZOLIDIN-3-
YL)-2-(4-(2,3-DICHLOROPHENYL)PIPERA- ZIN-1-YL)ACETAMIDE
Antimicrobial testing was carried out as described in Chapter-1, Section-I,
Experimental [C], Page no. 37. The results obtained from antimicrobial testing are
recorded in Table-7b, Page no. 160
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TABLE-7a: PHYSICAL CONSTANTS OF N-(2-ARYL-4-OXOTHIAZOLIDIN-3-
YL)-2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)ACETAMIDE
N
N
O
HN N
Cl
Cl
S
O
R
Sr.
No.
Substitution
R
Molecular
Formula/
Molecular Weight
M.P.
°C
Yield
%
% Composition
Calcd./Found
C H N
7a H C21H22Cl2N4O2S465.40 135-138 65
54.20
53.94
4.76
4.73
12.04
11.98
7b 4-OMe C22H24Cl2N4O3S495.42 169-171 76
53.34
54.08
4.88
4081
11.31
11.22
7c 4-F C21H21Cl2FN4O2S483.39 144-146 71
52.18
51.96
4.38
4.29
11.59
11.45
7d 3-Cl C21H21Cl3N4O2S499.84 211-214 64
50.46
50.31
4.23
4.19
11.21
11.14
7e 2,4-(Cl)2 C21H20Cl4N4O2S534.29 188-190 54
47.21
47.03
3.77
3.71
10.49
10.36
7f 4-N(Me)2 C23H27Cl2N5O2S508.36 111-112 63
54.33
54.11
5.35
5.29
13.95
13.80
7g 2,5-(OMe)2 C23H26Cl2N4O4S525.45 158-161 58
52.57
52.41
4.99
4.92
10.66
10.57
7h 4-NO2 C21H21Cl2N5O4S510.39 148-151 73
49.42
49.24
4.15
4.11
13.72
13.64
7i 4-OH C21H22Cl2N4O3S481.40 170-171 62
52.39
52.21
4.61
4.56
11.64
11.61
7j 2-OH C21H22Cl2N4O3S481.40 182-185 55
52.39
52.24
4.61
4.51
11.64
11.55
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TABLE-7b: BIOLOGICAL SCREENING OF N-(2-ARYL-4-OXOTHIAZOLIDIN-3-
YL)-2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)ACETAMIDE
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 7a 250 500 200 250 250 500 500
2 7b 500 500 250 100 500 250 250
3 7c 250 500 62.5 100 200 500 500
4 7d 200 250 250 200 500 1000 1000
5 7e 500 250 200 250 500 >1000 >1000
6 7f 500 250 500 250 250 1000 >1000
7 7g 500 500 250 200 500 500 500
8 7h 500 500 250 500 500 1000 1000
9 7i 250 100 100 250 500 500 1000
10 7j 500 250 250 200 500 1000 >1000
MINIMAL INHIBITION CONCENTRATION
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
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ANTIBACTERIAL ACTIVITY:
From screening results, substituted thiazolidinone 7d (R= 3-Cl) against S.aureus
and 7c (R= 4-F) against E-coli possess excellent activity compared to ampicillin. While
7c (R= 4-F) & 7i (R= 4-OH) against S.aureus, 7i (R= 4-OH) against S.pyogenus & E-coli
and 7b (R= 4-OMe) & 7c (R= 4-F) against P.aeruginos, exhibit moderate activity as
compared to ampicillin. The remaining compounds demonstrate moderate to poor activity
against all four bacterial species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data shows that substituted thiazolidinones 7a (R= -H), 7c
(R= 4-F) & 7f (R= 4-N(Me)2) show highly promissing activity against C.albicans while
7b (R= 4-OMe) display moderate activity against A.niger & A.clavatus as compare to
greseofulvin. The remaining compounds show moderate to poor activity against all three
bacterial species.
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SECTION-II
SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2-ARYL-5-METHYL-4-
OXOTHIAZOLIDIN-3-YL)-2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)
ACETAMIDE
4-Thiazolidinone derivatives represent one of the most active classes of
compounds possessing a wide spectrum of biological activities, such as significant in
vitro activity against DNA and RNA viruses including polio viruses, hypnotic, sedative,
analgesic, diuretic, antitubercular, anticonvulsant, antifungal, antibacterial activity etc.
These valid observations led us to synthesize some new 4-thiazolidinone derivatives. 2-
(4-(2,3-dichlorophenyl)piperazin-1-yl)-N-(5-methyl-4-oxo-2-arylthiazolidin-3-yl)acetam-
ide of type (VIII) have been synthesized by the cyclization of N'-phenylmethylidene-2-(4-
(2,3-dichlorophenyl)piperazin-1-yl)acetohydrazide of Type (III) with thiolactic acid.
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
REACTION SCHEME
Studies on Biologically Active... 163
Chapter-4 Studies on Thiazolidinone...
IR SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N-(2-(4-
FLUOROPHENYL)-5-METHYL-4-OXOTHIAZOLIDIN-3-YL)ACETAMIDE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2945
2823
1448
1377
2975-2920
2880-2860
1470-1435
1395-1370
80
”
”
”
Aromatic
C-H str.
C=C str.
C-H i.p. def.
C-H o.o.p. def.
3070
1508
1132
856
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Thiazolidinone
C=O str.
C-N str.
C-S str.
1728
1155
713
1760-1655
1220-1020
750-600
81
”
”
Carbonyl
Halide
C=O str.
C-Cl str.
1697
781
1700-1650
850-650
”
”
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1H-NMR SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N-(2-(4-
FLUOROPHENYL)-5-METHYL-4-OXOTHIAZOLIDIN-3-YL)ACETAMIDE
Internal Standard: TMS; Solvent: DMSO-d6 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value
in HZ
1
2
3
4
5
6
7
8
9
10
1.64-1.66
2.36-2.69
2.82-2.89
3.01-3.22
4.03-4.08
5.92
6.83-6.87
7.07-7.19
7.39-7.43
8.53
3H
4H
4H
2H
1H
1H
1H
4H
2H
2H
doublet
multiplet
multiplet
multiplet
quartet
doublet
multiplet
multiplet
multiplet
singlet
-CH3 (a)
-CH2 (b,b’)
-CH2 (c,c’)
-CH2 (d)
-CH (e)
-CH (f)
Ar-H (g)
Ar-H (h,i,j,j’)
Ar-H (k,k’)
-CO-NH (l)
7.2
-
-
-
-
0.9
-
-
-
-
N
N
O
HN N
Cl
Cl
S
O
F
a
b b'
c c'
d
e
f
g
h i
j
j'k k'l
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EXPANDED 1H-NMR SPECTRUM
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MASS SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N-(2-(4-
FLUOROPHENYL)-5-METHYL-4-OXOTHIAZOLIDIN-3-YL)ACETAMIDE
MASS SPECTRUM OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N-(2-(4-
METHOXYPHENYL)-4-OXOTHIAZOLIDIN-3-YL)ACETAMIDE
Exact Mass = 508.1
m/z = 509.2 (M+1)
N
N
O
HN N
Cl
Cl
S
O
OMe
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF N-(2-ARYL-5-METHYL-4-
OXOTHIAZOLIDIN-3-YL)-2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)
ACETAMIDE
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. 5 % Methanol in chloroform
was used as a mobile phase.
[A] SYNTHESIS OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N'-((4-
FLUOROPHENYL)METHYLIDENE)ACETOHYDRAZIDE
See, Chapter-3, Section-I, Experimental [B], Page no. 109.
[B] SYNTHESIS OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)-N-(2-
(4-FLUOROPHENYL)-5-METHYL-4-OXOTHIAZOLIDIN-3-YL)ACETA-
MIDE
A mixture of 2-(4-(2,3-dichlorophenyl)piperazin-1-yl)-N'-((4-fluorophenyl)
methylidene)acetohydrazide (4.09 gm, 0.01 mol) and thiolactic acid (2.12 gm, 0.02 mol)
in toluene (20 ml) was refluxed for 12 hrs. Seperated water from the reaction was
continuesly removed by azeotropic distillation using a Dean-Stark separator. Progress of
rhe reaction was monitered by TLC, after completion of reaction excess of toluene was
distilled off and the resulting residue was partioned between ethyl acetate and saturated
NaHCO3 solution to remove unreacted thioglycolic acid, organic layer was washed with
brine, dried over sodium sulphate, evaporated to give crude product. The crude product
was recrystallized from mixture of isopropyl alcohol and hexane. Yield 68%, M. P.
1320C. (C22H23Cl2FN4O2S; Required: C, 53.12; H, 4.66; N, 11.26; Found: C, 52.89; H,
4.52; N, 11.20 %).
Similarly, other 2-(4-(2,3-dichlorophenyl)piperazin-1-yl)-N-(2-aryl-5-methyl-4-
oxothiazolidin-3-yl)acetamide (8a-j) were prepared. The physical constants are recorded
in Table-8a, Page no. 169
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[C] BIOLOGICAL SCREENING OF 2-(4-(2,3-DICHLOROPHENYL)PIPERA-
ZIN-1-YL)-N-(2-ARYL-5-METHYL-4-OXOTHIAZOLIDIN-3-YL)
ACETAMIDE
Antimicrobial testing was carried out as described in Chapter-1, Section-I,
Experimental Section-[C], Page no. 37. The results obtained from antimicrobial testinng
are recorded in Table-8b, Page no. 170.
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TABLE-8a: PHYSICAL CONSTANTS OF N-(2-ARYL-5-METHYL-4-OXOTHI-
AZOLIDIN-3-YL)-2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-
YL)ACETAMIDE
Sr.
No.
Substitution
R
Molecular
Formula/
Molecular Weight
M.P.
°C
Yield
%
% Composition
Calcd./Found
C H N
8a H C22H24Cl2N4O2S479.42 143-145 68
55.12
51.91
5.05
5.00
11.69
11.61
8b 4-OMe C23H26Cl2N4O3S509.45 152-155 62
54.22
54.03
5.14
5.07
11.00
10.92
8c 4-F C22H23Cl2FN4O2S497.41 129-131 58
53.12
52.89
4.66
4.52
11.26
11.20
8d 3-Cl C22H23Cl3N4O2S513.87 180-182 66
51.42
51.24
4.51
4.42
10.90
10.82
8e 2,4-(Cl)2 C22H22Cl4N4O2S548.31 164-167 51
48.49
48.32
4.04
3.99
10.22
10.13
8f 4-N(Me)2 C24H29Cl2N5O2S522.49 78-81 57
55.17
51.91
5.59
5.52
13.40
13.31
8g 2,5-(OMe)2 C24H28Cl2N4O4S539.47 171-173 49
53.43
53.27
5.23
5.14
10.39
10.25
8h 4-NO2 C22H23Cl2N5O4S524.42 135-137 63
50.39
50.16
4.42
4.33
13.35
13.23
8i 4-OH C22H24Cl2N4O3S495.42 154-156 52
53.34
53.15
4.88
4.85
11.31
11.24
8j 2-OH C22H24Cl2N4O3S495.42 166-168 45
53.34
53.21
4.88
4.79
11.31
11.21
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TABLE-8b: BIOLOGICAL SCREENING OF N-(2-ARYL-5-METHYL-4-OXOTHI-
AZOLIDIN-3-YL)-2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)
ACETAMIDE
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 8a 500 500 250 250 250 500 1000
2 8b 500 500 250 500 500 1000 1000
3 8c 100 500 62.5 100 250 500 >1000
4 8d 250 100 200 250 500 250 200
5 8e 500 250 500 500 500 500 >1000
6 8f 500 250 500 250 500 >1000 1000
7 8g 250 500 200 500 500 1000 500
8 8h 500 250 500 250 500 1000 500
9 8i 500 50 200 100 500 250 200
10 8j 500 200 100 200 1000 500 500
MINIMAL INHIBITION CONCENTRATION
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
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ANTIBACTERIAL ACTIVITY:
From screening results, substituted thiazolidinone 8c (R= 4-F) against S.aureus, 8i
(R= 4-OH) against S.pyogenus and 8c (R= 4-F) against E-coli possess very good activity
compared to ampicillin. While 8d (R= 3-Cl) against S.pyogenus, 8j (R= 2-OH) against E-
coli and 8c (R= 4-F) & 8i (R= 4-OH) against P.aeruginos, exhibit moderate activity as
compared to ampicillin. The remaining compounds show moderate to poor activity
against all four bacterial species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data shows that substituted thiazolidinones 8a (R= -H) & 7c
(R= 4-F) display excellent activity against C.albicans while 8d (R= 3-Cl) & 8i (R= 4-OH)
possess moderate activity against A.niger & A.clavatus as compare to greseofulvin. The
remaining compounds demonstrate moderate to poor activity against all three bacterial
species.
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INTRODUCTION
Oxadiazoles are five-membered aromatic heterocycles (having one oxygen and
two nitrogen atom in five member ring system) with great utility in synthetic chemistry,
medicinal chemistry and materials science. In the field of medicinal chemistry,
oxadiazole derivatives are utilized as ester or amide surrogates (bioisosteres) 1 and they
also having good fluorescence properties.2 It is well documented that oxadiazoles are
of four types which are numbered by designating the hetero atoms at particular
position.
N
N
O NO
N
NON
N
O
N
(1) (2) (3) (4)
1,3,4-Oxadiazole is a heterocyclic molecule with oxygen atom at 1 and two
nitrogen atoms at 3 and 4 position. 1,3,4-Oxadiazoles belong to an important group of
heterocyclic compounds having –N=C-O- linkage. 1,3,4-oxadiazole (4) is a thermally
stable aromatic heterocycle and exist in partially reduced forms; 2,3-dihydro-1,3,4-
oxadiazole(1,3,4-oxadiazoline) (5) and 2,5-dihydro-1,3,4-oxadiazole (1,3,4-oxadiazoline)
(6) depending on the position of the double bond. The completely reduced form of the
1,3,4-oxadiazole is known as 2,3,4,5-tetrahydro-1,3,4-oxadiazole (1,3,4-oxadiazolidine)
(7).
N
H
O
N N
O
N N
H
O
N
H
(5) (6) (7)
They have been known for about 80 years, it is only in the last decade
that investigations in this field have been intensified. This is because of large number
of applications of 1,3,4-oxadiazoles in the most diverse areas viz. drug
synthesis, dye stuff industry, heat resistant materials, heat resistant polymers and
scintillators. Reviews of the relevant literature prior to 1965 are available.3
SYNTHETIC ASPECT
To the best of our knowledge, limited methodology exists for the synthesis of
1,3,4-oxadiazoles. Typically, a two step protocol is utilized where acylhydrazide and
carboxylic acid derivatives are coupled under amide bond forming conditions and the
resulting diacylhydrazide intermediate isolated and cycliszed using standard reagents
such as Ph3P/CCl4/Et3N,4 Burgess reagent,5 H2SO4,6 SOCl2,7 P2O5,8 POCl39 and triflic
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anhydride.10 A few one pot methods have been reported in the literature. Different
methods for the synthesis have been cited in literature.11-16
1. S. Wagle et al.17 have synthesized oxadiazoles by the reaction of hydrazide with
aromatic acid in presence of POCl3.
POCl3 + R-COOH
110 oC
N
N
O
O
NHNH2
N
N
O
N
O
N
R
2. D. Ramesh and B. Sreenivasan18 have synthesized 1,3,4-oxadiazoles from
semicarbazide derivative in presense of POCl3.
N N
NH O
NH NH
OR
POCl3
Ref. 4 h. N N
NH N
O N
R
3. V. K. Tandon and R. B. Choor19 described a simple, efficient and convenient
synthesis of 1,3,4-oxadiazoles using BF3.Et2O as a cyclodehydrating agent.
R
Cl
O
1) NH2-NH2.H2O
2) BF3.Et2O
Dioxane
O
NN
R R
4. K. Mogilaiah & B. Sakram20 have prepared 1,3,4-oxadiazole from
Acetophenone-2-trifluoromethyl-1,8-naphthyridine-3-carbonyl hydrazone in
presence of acetic anhydride.
N N
NH
O
CF3
N
Ar
AC2O
N N CF3
N
O
N
O
Ar
5. Yu Yuve21 have reported microwave-assisted synthesis protocol with 91 % yield.
R NH
O
NH2 R1
O
OH O
N N
R R1
POCl3
MW, 12 min
+
6. M. Chande et al.22 reported the reaction of thiosemicarbazide (RNHCSNHNH2)
with carbon oxysulfide and benzyl chloride, which yields amino-oxadiazolyl
thioethers.
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RNH
S
NH
NH2
N
O
N
NHR
S
O=C=S
Cl
7. Silica sulfuric acid catalyst used for the rapid and ecofriendly synthesis of 1,3,4-
oxadiazoles at ambient temperature by M. Dabiri et al.23
R C(OEt)3 R1 NH
O
NH2 O
N N
R R1
Silica, H2SO4
MW,10min+
8. A. L. Polozov et al.24 prepared 2-amino-1,3,4-oxadiazoles by reacting hydrazide
derivative with cyanogen bromide in aqueous p-dioxane in the presence of sodium
carbonate.
N
F
RO NH
NH2
BrCN/NaHCO3
p-dioxane/Water
rt, 2 h
N
F
RON
N
NH2
9. Solvent free microwave mediated one pot synthesis of 1,3,4-oxadiazoles were
reported by V. Polshettiwar.25
R C(OEt)3 R
1
NH
O
NH2 O
N N
R R1
MW
80 oC, 10 min+
10. H. A. Rajakapse et al.26 reported a mild and efficient one pot synthesis of 1,3,4-
oxadiazoles from acyl hydrazides and carboxylic acids by using CDI/Ph3P/CBr4.
Ph NH
O
NH2 + OH
O
NHPG
Ph
CDI, Ph3P, CBr4
CH2Cl2, 0 oC to rt
O
NN
Ph
NHPG
Ph
THERAPEUTIC IMPORTANCE
1,3,4-Oxadiazoles constitute one of the most active class of compounds
possessing diverse pharmacological and microbiological activity. 1,3,4-Oxadiazole
derivatives have been examined for various pharmacological activities, which have
been summarized as under.
1. Antibacterial27
2. Antifungal28
3. Antiinflammatory29
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4. Analgesic30
5. Antiviral and anticancer31
6. Antihypertensive32
7. Anticonvulsant33
8. Antiproliferative34
9. Cardiovascular35
10. Hypoglycemic36
11. Hypnotic and Sedative37
12. MAO inhibitor38
13. Insecticidal39
K. Mogilaiah and K. Vidya synthesized some 1,3,4-oxadiazole derivatives and
screened for antibacterial activity.40 S. R. Bishnoi et al.41 have screened oxadiazoles for
their antimicrobial activity. A. El-Azzouny et al.42 have synthesized 1,3,4-oxadiazole
derivatives and evaluated for their analgesic, anti-inflammatory, ulcerogenic effects
and inhibitory activity on plasma prostaglandin E2 (PGE2) Level. S. V. Bhandari et
al.43 have reported 1,3,4-oxadiazoles for their anti-inflammatory activity.
Song Cao et al.44 have investigated some oxadiazoles possessing insecticidal
activity. G. V. Suresh Kumar et al.45 have discovered oxadiazole derivatives and
reported their antimycobacterial activity. Ali Almasired et al.46 have prepared 1,3,4-
oxadiazoles of type (8) as anticonvulsant agent. Meria Grazia Mamolo et al.47 have
synthesized 3-substituted-5-(pyridine-4-yl)-3H-1,3,4-oxadiazole-2-one of type (9) and
studied their antimycobacterial activity. Krishna Kant Jha et al.48 have reported
antimicrobial activity of oxadiazole derivatives.
O
N N
O NH2
F
(8)
N
O
N N
X
O
(9)
Hagen-Heinrich Hennies and coresearchers49 have patented some novel 2-
pyrrolidin-2-yl-(1,3,4)-oxadiazole derivatives which have a pronounced anti-depressive
and analgesic effect. J. A. Christopher et al.50 have documented effect of 1,3,4-
oxadiazoles on human immunodeficiency virus. S. J. Gilani et al.51 have synthesized
some oxadiazoles as anti-inflammatory and analgesic agents. K. Subrahmanya Bhat et
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al.52 have prepared new fluorine containing 1,3,4-oxadiazoles (10) and reported them as
potential antibacterial and anticancer agents. T. P. Mohan et al.53 have synthesized
2,5-disubstituted-1,3,4-oxadiazole derivatives (11) and screened for their insecticidal
activity. Ronald Kim et al.54 have discovered oxadiazole derivatives useful as
protease inhibitors.
(10)
O O
N N
R
F
(11)
N
O
N
ClCl
F R
Mohd Amir and Kumar Shikha55 have documented anti-inflammatory,
analgesic and ulcerogenic activity of some newly synthesized oxadiazoles. A. Ali et
al.56 have investigated some oxadiazole derivatives possessing antimicrobial and
anti-HIV-1 activity. A. Sherif et al.57 have reported oxadiazoles as potential
antitumor and anti-HIV agents. A. Zarghi et al.58 have synthesized 2-amino-5-(2-
benzyloxyphenyl)-1,3,4-oxadiazoles (12) possessing anticonvulsant activity. M. Tareq
et al.59 have synthesized 2,5-disubstituted-1,3,4-oxadiazoles (13) useful as tyrosinase
inhibitors.
N
O
N
NH2
O
F(22)
N
O
N
Br
N
(23)
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Example of some drugs & derivatives (containing oxadiazole scaffold) under
Preclinical / clinical trials.
Sr.
No Chemical structure Activity Phase Originator
1 N
N N
N N
ON
H3C
CH3
O
O CH3 Antitussive,
Bronchodilator Phase-I
Sanofi-
Synthlabo
2 O N
N
CH3
O
NO
CH3
F3C
CH3
Antirhinoviral,
Antiviral Phase-III Viro pharma
3
Antihypertensive,
Antianginal,
Antiglaucoma
agent,
Beta-
adrenoceptor
antagonist
Phase-II
Center for
Chemistry
of Drugs
4
Antidepressants,
Anxiolytic, 5-
HT1D Antagonist
Biological
testing
Smithkline
Beecham
5
Antidepressants,
Anxiolytic,
5-HT1D Inverse
agonist
Preclinical SmithklineBeecham
6
Cognition
enhancing drug,
GABA(A)
receptor
modulator,
GABA(A) B2 site
inverse
agonist
Preclinical Dainopponpharma
7 Analgesic Preclinical
Universidade
federal
pernambuco
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Sr. No Chemical structure Activity Phase Originator
8
OH
NO2SHN
N O
N
FF
Antiobesity drug,
Antidiabetic drug,
Beta3 adrenoce tor
agonist
Preclinical Merck
9
OH
NO2SHN
N O
N
OCF3
Antiobesity drug,
Antidiabetic drug,
Beta3 adrenoceptor
agonist
Preclinical Merck
10
Bronchodilator,
Phosphodiesterase
Inhibitor
Preclinical
Smithkline
Beecham
11 Antitrypanosomal Preclinical Universidaddelarepublica
12
Antiepileptic
drug,Neuronal
Injury Inhibitor,
Sodium channel
blocker
Preclinical BoehringerIngelaeim
In view of getting enhanced biological activities showed by 1,3,4-oxadiazoles, to
prompted us to synthesize 1,3,4-oxadiazole derivatives, which have been described as
under.
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF 5-ARYL-2-((4-
(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-1,3,4-
OXADIAZOLE
SECTION-II:SYNTHESIS AND BIOLOGICAL SCREENING OF 5-ARYL-2-(6-
FLUORO-3,4-DIHYDRO-2H-CHROMEN-2-YL)-1,3,4-
OXADIAZOLE
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF 5-ARYL-2-((4-(2,3-
DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-1,3,4-OXADIAZOLE
A large number of heterocycles bearing oxadiazole moiety have been reported for
various biological activities. Oxadiazole derivatives have been drawn the attention of
chemist due to their diversified biological activities. In view of these facts, the
synthesis of some novel 2,5-disubstituted-1,3,4-oxadiazole derivative was undertaken.
Oxadiazoles of type (IX) have been prepared by condensation of 2-(4-(2,3-
dichlorophenyl)piperazin-1-yl)acetohydrazide with different aromatic acid in
phosphorous oxychloride.
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
REACTION SCHEME
N
N
N
O
N
Cl
Cl
N
N
Cl
Cl
NHNH2
O
COOH
R+
8 to 10 Hrs
reflux
R
(Type-IX)
R = 4-OCH3, 4-CH3, 4-Cl, 4-OH etc.
POCl3
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IR SPECTRUM OF 2-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-5-
PHENYL-1,3,4-OXADIAZOLE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2960
2870
1454
1346
2975-2920
2880-2860
1470-1435
1395-1370
60
”
”
”
Aromatic
C-H str.
C=C str.
C-H i.p. def.
C-H o.o.p. def.
3049
1523
1116
850
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Oxadiazole
C=N str.
N-N str.
-C-O-C- str.
1606
1224
1062
1650-1580
1220-1020
1075-1020
61
”
”
Halide C-Cl str. 850 850-650 62
500750100012501500175020002500300035004000
1/cm
15
30
45
60
75
90
105
%T
30
49
.5
6
29
60
.83
29
18
.40
28
70
.17
16
27
.97
16
06
.7
6
15
41
.1
8
15
23
.82 1
48
9.
10
14
54
.3
8
13
46
.3
6
12
86
.56
12
24
.84
11
16
.8
2
10
62
.81
97
4.0
8
85
0.6
4 74
6.4
8
70
9.
83 6
75
.1
1
N
N
Cl
Cl
N N
O
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1H-NMR SPECTRUM OF 2-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-
5-PHENYL-1,3,4-OXADIAZOLE
Internal Standard: TMS; Solvent: CDCl3 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
4
5
6
7
2.83-2.86
3.10-3.13
3.98
6.94-6.97
7.11-7.18
7.49-7.58
8.07-8.11
4H
4H
2H
1H
2H
3H
2H
triplet
triplet
singlet
double doublet
multiplet
multiplet
double doublet
-CH2 (a,a’)
-CH2 (b,b’)
-CH2 (c)
Ar-H (d)
Ar-H (e,f)
Ar-H (g,h,h’)
Ar-H (i,i’)
-
-
-
2.7 & 6.6
-
-
2.4 & 8.1
N
N
Cl
Cl
N N
O
a a'
b b'
c
d
e f
i
i'
g
h
h'
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EXPANDED 1H-NMR SPECTRUM
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MASS SPECTRUM OF 2-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-5-
PHENYL-1,3,4-OXADIAZOLE
MASS SPECTRUM OF 2-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-5-
(4-METHOXYPHENYL)-1,3,4-OXADIAZOLE
Exact Mass = 388.
m/z = 389.2 (M+1
N
N
Cl
Cl
N N
O
1
)
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17
EXPERIMENTAL
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. 40 % Ethyl acetate in
hexane was used as a mobile phase.
[A] SYNTHESIS OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)
ACETOHYDRAZIDE
See, Chapter-2, Part-I, Section-I, Experimental [B], Page no. 72.
[B] SYNTHESIS OF 2-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)
METHYL)-5-PHENYL-1,3,4-OXADIAZOLE
A mixture of 2-(4-(2,3-dichlorophenyl)piperazin-1-yl)acetohydrazide (1.51g,
0.005 mol) and benzoic acid (0.61g, 0.005 mol) in phosphorous oxychloride (5 ml)
was refluxed for 8 hrs. The content was cooled, poured into crushed ice and
neutralized with sodium bicarbonate solution. Obtained solid was filtered out, washed
with water and dried. The crude product was purified by column chromatography on
silica gel (60-120 mesh size) (Eluent = Ethyl acetate:hexane (3:7)) to obtain pure product.
Yield 69 %, M. P. 192-194 °C (C19H18Cl2N4O; Required: C, 58.62; H, 4.66; N, 14.39
%; Found: C, 58.36; H, 4.58; N, 14.30 %).
Similarly other 1-(2,3-dichlorophenyl)-4-((5-aryl-1,3,4-oxadiazol-2-yl)methyl)
piperazine (9a-j) were prepared. The physical constants are recorded in Table-9a, Page
no. 190.
[C] BIOLOGICAL EVALUATION OF 5-ARYL-2-((4-(2,3- DICHLOROPHEN-
YL)PIPERAZIN-1-YL)METHYL)-1,3,4-OXADIAZOLE
Antimicrobial testing was carried out as described in Chapter-1, Section-I,
Experimental Section [C], Page no. 37. The results obtained from antimicrobial testing
are recorded in Table-9b, Page no. 191
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TABLE-9a: PHYSICAL CONSTANTS OF 5-ARYL-2-((4-(2,3-DICHLOROPHEN-
YL)PIPERAZIN-1-YL)METHYL)-1,3,4-OXADIAZOLE
N
N
N
O
N
Cl
Cl
R
Sr.
No.
Substitution
R
Molecular
Formula/
Molecular Weight
M.P.
°C
Yield
%
% Composition
Calcd./Found
C H N
9a H C19H18Cl2N4O389.28 192-194 69
58.62
58.36
4.66
4.58
14.39
14.30
9b 4-OCH3 C20H20Cl2N4O2419.30 205-208 76
57.29
57.18
4.81
4.77
13.36
13.22
9c 4-CH3 C20H20Cl2N4O403.30 168-171 70
59.56
59.41
5.00
4.86
13.89
13.72
9d 4-NO2 C19H17Cl2N5O3434.28 256-257 62
52.55
52.36
3.95
3.91
16.13
15.96
9e 4-F C19H17Cl3N4O407.27 230-233 68
53.06
52.78
4.21
4.06
13.76
13.51
9f 4-Cl C19H17Cl3N4O423.72 221-222 75
53.86
53.58
4.04
3.89
13.22
13.04
9g 4-Br C19H17BrCl2N4O468.17 233-236 71
48.74
48.52
3.66
3.78
11.97
11.84
9h 4-OH C19H18Cl2N4O2405.28 231-233 54
56.31
56.09
4.48
4.33
13.82
13.71
9i 3- CH3 C20H20Cl2N4O403.30 185-188 68
59.56
59.39
5.00
4.88
13.89
13.80
9j 2-NO2-5-Cl C19H16Cl3N5O3468.72 244-247 62
48.69
48.57
3.44
3.38
14.94
14.83
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TABLE-9b: BIOLOGICAL SCREENING OF 5-ARYL-2-((4-(2,3-DICHLOROPHEN-
YL)PIPERAZIN-1-YL)METHYL)-1,3,4-OXADIAZOLE
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 9a 500 500 200 200 1000 250 500
2 9b 250 100 500 100 250 500 500
3 9c 250 500 100 250 500 500 500
4 9d 500 250 200 200 1000 1000 >1000
5 9e 100 500 200 250 500 200 250
6 9f 500 250 62.5 100 200 1000 >1000
7 9g 250 500 200 100 500 1000 >1000
8 9h 200 250 500 250 500 >1000 >1000
9 9i 500 250 250 500 500 500 1000
10 9j 250 100 250 250 1000 250 500
MINIMAL INHIBITION CONCENTRATION
Standard Drugs /S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
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ANTIBACTERIAL ACTIVITY:
From screening results, substituted oxadiazole 9e (R= 4-F) against S.aureus and 9f
(R= 4-Cl) against E-coli possess excellent activity compared to ampicillin. While 9h (R=
4-OH) against S.aureus, 9b (R= 4-OMe) & 9j (R= 2-NO2-5-Cl) against S.pyogenus, 9c
(R= 4-Me) against E-coli and 9b (R= 4-OMe) & 9f (R= 4-Cl) against P.aeruginos,
exhibit moderate activity as compared to ampicillin. The remaining compounds display
moderate to poor activity against all four bacterial species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data shows that substituted oxadiazoles 9b (R= 4-OMe) & 9f
(R= 4-Cl) demonstrate highly promissing activity against C.albicans as compared to
greseofulvin. While 9a (R= -H), 9e (R= 4-F) & 9j (R= 2-NO2-5-Cl) against A.niger and
9e (R= 4-F) against A.clavatus, possess moderate activity as compare to greseofulvin. The
remaining compounds show moderate to poor activity against all three bacterial species.
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SECTION-II
SYNTHESIS AND BIOLOGICAL SCREENING OF 5-ARYL-2-(6-FLUORO-3,4-
DIHYDRO-2H-CHROMEN-2-YL)- 1,3,4-OXADIAZOLE
Synthesis of 1,3,4-oxadiazole derivatives has attracted considerable attention in
view of therapeutic applications. A large number of heterocycles bearing oxadiazole
moiety have been reported for various biological activities. Looking to this, the synthesis
of 1,3,4-oxadiazoles was undertaken. Oxadiazoles of type (X) have been prepared by
condensation of 6-fluoro-3,4-dihydro-2H-chromene-2-carbohydrazide with different
aromatic acids in phosphorous oxychloride.
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay
like antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
REACTION SCHEME
N
O
N
COOH
R+
10 to 11 Hrs
reflux
R
(Type-X)
R = 4-CH3, 4-OCH3, 4-Cl, 4-OH etc.
POCl3
O
F
NHNH2
O
O
F
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IR SPECTRUM OF 2-(6-FLUORO-3,4-DIHYDRO-2H-CHROMEN-2-YL)-5-PHENYL-
1,3,4-OXADIAZOLE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2972
2843
1429
1369
2975-2920
2880-2860
1470-1435
1395-1370
60
”
”
”
Aromatic
C-H str.
C=C str.
C-H i.p. def.
C-H o.o.p. def.
3072
1492
1087
819
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Oxadiazole
C=N str.
N-N str.
-C-O-C- str.
1581
1172
1057
1650-1580
1220-1020
1075-1020
61
”
”
Halide C-F str. 819 850-650 62
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1H-NMR SPECTRUM OF 2-(6-FLUORO-3,4-DIHYDRO-2H-CHROMEN-2-YL)-5-
PHENYL-1,3,4-OXADIAZOLE
Internal Standard: TMS; Solvent: CDCl3 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
4
5
6
2.43-2.52
2.96-3.01
5.41-5.45
6.79-6.88
7.49-7.56
8.06-8.09
2H
2H
1H
3H
3H
2H
multiplet
triplet
double doublet
multiplet
multiplet
multiplet
-CH2 (a)
-CH2 (b)
-CH (c)
Ar-H (d,e,f)
Ar-H (g,h,h’)
Ar-H (i,i’)
-
-
4.2 & 7.8
-
-
-
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EXPANDED 1H-NMR SPECTRUM
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MASS SPECTRUM OF 2-(6-FLUORO-3,4-DIHYDRO-2H-CHROMEN-2-YL)-5-PHENYL-
1,3,4-OXADIAZOLE
MASS SPECTRUM OF 2-(6-FLUORO-3,4-DIHYDRO-2H-CHROMEN-2-YL)-5-(4-
METHOXYPHENYL)-1,3,4-OXADIAZOLE
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17
EXPERIMENTAL
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. 30 % Ethyl acetate in
hexane was used as a mobile phase.
[A] SYNTHESIS OF OF 6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-
CARBOHYDRAZIDE
See, Chapter-2, Part-II, Section-I, Experimental [B], Page no. 93.
[B] SYNTHESIS OF 2-(6-FLUORO-3,4-DIHYDRO-2H-CHROMEN-2-YL)-5-
PHENYL-1,3,4-OXADIAZOLE
A mixture of 6-fluoro-3,4-dihydro-2H-chromene-2-carbohydrazide (1.05g, 0.005
mol) and benzoic acid (0.61g, 0.005 mol) in phosphorous oxychloride (5 ml) was
refluxed for 10 hrs. The content was cooled, poured into crushed ice and
neutralized with sodium bicarbonate solution. Obtained solid was filtered out, washed
with water and dried. The crude product was purified by column chromatography on
silica gel (60-120 mesh size) (Eluent = Ethyl acetate:hexane (2:8)) to obtain pure product.
Yield: 74 %, M. P . 153-156 °C (C17H13FN2O2 ; C, 68.91; H, 4.42; N, 9 .45 %;
Found:  C, 68.70; H,  4.33; N,  9.39 %).
Similarly other 1-(2,3-dichlorophenyl)-4-((5-aryl-1,3,4-oxadiazol-2-yl)methyl)
piperazine (10a-j) were prepared. The physical constants are recorded in Table-10a,
Page no. 199.
[C] BIOLOGICAL EVALUATION OF 5-ARYL-2-(6-FLUORO-3,4-DIHYDRO-
2H-CHROMEN-2-YL)- 1,3,4-OXADIAZOLE
Antimicrobial testing was carried out as described in Chapter-1, Section-I,
Experimental Section-[C], Page no. 37. The results obtained from antimicrobial testing
are recorded in Table-10b, Page no. 200.
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TABLE-10a: PHYSICAL CONSTANTS OF 5-ARYL-2-(6-FLUORO-3,4-
DIHYDRO-2H-CHROMEN-2-YL)- 1,3,4-OXADIAZOLE
Sr.
No.
Substitution
R
Molecular
Formula/
Molecular Weight
M.P.
°C
Yield
%
% Composition
Calcd./Found
C H N
10a H C17H13FN2O2296.30 153-156 74
68.91
68.70
4.42
4.33
9.45
9.39
10b 4-OCH3 C18H15FN2O3326.32 129-131 67
66.25
66.09
4.63
4.51
8.58
8.51
10c 4-CH3 C18H15FN2O2310.32 118-120 70
69.67
69.52
4.87
4.81
9.03
8.92
10d 4-NO2 C17H12FN3O4341.29 171-172 59
59.83
59.69
3.54
3.48
12.31
12.24
10e 4-F C17H12F2N2O2314.29 146-149 65
64.97
64.68
3.85
3.74
8.91
8.80
10f 4-Cl C17H12ClFN2O2330.74 104-105 73
61.73
61.51
3.66
3.58
8.47
8.41
10g 4-Br C17H12BrFN2O2375.19 118-121 68
54.42
54.32
3.22
3.18
7.47
7.41
10h 4-OH C17H13FN2O3312.30 169-172 52
65.38
65.24
4.20
4.14
8.97
8.89
10i 3- CH3 C18H15FN2O2310.32 136-138 66
69.67
69.56
4.87
4.85
9.03
9.00
10j 2-NO2-5-Cl C17H11ClFN3O4375.74 166-168 56
54.34
54.25
2.95
2.91
11.18
11.11
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TABLE-10b: BIOLOGICAL SCREENING OF 5-ARYL-2-(6-FLUORO-3,4-DIHYDRO-
2H-CHROMEN-2-YL)- 1,3,4-OXADIAZOLE
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 10a 100 200 500 250 1000 250 500
2 10b 250 250 50 250 1000 >1000 >1000
3 10c 250 500 200 200 500 500 500
4 10d 500 250 250 200 500 1000 >1000
5 10e 200 100 250 100 250 500 500
6 10f 500 200 100 200 500 1000 1000
7 10g 500 500 250 500 500 >1000 >1000
8 10h 500 500 500 250 1000 200 200
9 10i 500 500 250 500 500 1000 1000
10 10j 100 200 200 200 500 >1000 >1000
MINIMAL INHIBITION CONCENTRATION
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
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ANTIBACTERIAL ACTIVITY:
From screening results, substituted oxadiazole 10e (R= 4-F) against S.aureus and
10b (R= 4-OMe) against E-coli display very good activity compared to ampicillin. While
10b (R= 4-OMe) & 10c (R= 4-Me) against S.aureus, 10e (R= 4-F) against S.pyogenus,
10f (R= 4-Cl) against E-coli and 10e (R= 4-F) against P.aeruginos, possess moderate
activity as compared to ampicillin. The remaining compounds exhibite moderate to poor
activity against all four bacterial species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data shows that substituted oxadiazoles 10e (R= 4-F) exhibit
excellent activity against C.albicans as compared to greseofulvin. While 10a (R= -H) &
10h (R= 4-OH) against A.niger and 10h (R= 4-OH) against A.clavatus, show moderate
activity as compare to greseofulvin. The remaining compounds display moderate to poor
activity against all three bacterial species.
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INTRODUCTION
Triazoles are important class of heterocyclic compounds, found in many potent
biologically active molecules.Triazole derivatives have occupied an important place in
novel drug discovery process. Triazoles are well known five membered heterocyclic
compounds and several procedures for their synthesis have been extensively studied.
Such studies have been stimulated by various promising applications, especially in the
case of nitrogen containing heterocyclic entities.
The knowledge of such applications has pointed out that nitrogen containing
heterocycles are important target to be prepared for our research on biologically active
heterocyclic analogous. Triazoles are of two types 1,2,3-triazole and 1,2,4-triazole .
NN
H
N
NHN
N
NN
H
N
NN
N
H
1,2,3-Triazoles
1,2,4-Triazoles
Isomeric forms of triazole
1,2,4-Triazoles represents a rapid developing field in morden heterocyclic
chemistry. From literature it is predictable that, 1,2,4-triazoles represents important
pharmacophores, and play a vital role as medicinal agents. A degree of respectability has
been bestowed for 1,2,4-triazole derivatives due to their wide range of biological
activities such as antifungal,1 antitubercular2 and anticancer.3 Certain 1,2,4-triazoles also
find applications in the preparation of photographic plates, polymers, and as analytical
agents.4
Z. M. Hao5 and S. T. Steven6 have been studied briefly with the chemistry of
1,2,4-triazoles. Bladin7,8 is a pioneer scientist in the field of triazole, who had
synthesized the first derivative of 1,2,4-triazole in 1885. 1,2,4-Triazole derivatives not
only known for their medicinal applications, but they are also used as analytical
reagents9, dyes and photographic chemicals10 corrosion inhibitors11,12 and in the
preparation of polymers13.
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SYNTHETIC ASPECT
Several methods have been reported in the literature for the synthesis of 1,2,4-
triazoles.
1. Ahmet Demirbas et al14. have synthesized 1,2,4-triazole derivative from the
reaction of acetohydrazide dreivative with CS2/KOH followed by hydrazine
hydrate and aromatic aldehydes.
1) CS2/KOH
2) NH2NH2.H2O
N N
N
O
NHNH2
O
Ar-
NH2
N N
N
O
Ar- NH2
N
N
N
NH2
SH Ar'-CHO N N
N OAr-
N
N
N
N
N
SH
Ar'
Ar'
Reflux
2. Mashooq A. Bhat et al15. Synthesized 3-(4-(((aryl)methylene)imino)-5-thioxo-4,5-
dihydro-1H-1,2,4-triazol-3-yl)-2H-chromen-2-ones from 2-oxo-2H-cromene-3-
carbohydrazide in 3 step.
O O
O
NHNH2
1) CS2, KOH
2) NH2NH2.H2O
O O
N
N NHNH2 S
CHO
R
O O
N
N NHN SR
3. Reid and Heindel16 reported that the reaction of aryl acid hydrazide with
CS2/KOH and hydrazine hydrate yields triazoles.
R
O
NHNH2 CS2
KOH
R
O
NHNH S-K+
S NH2NH2.H2O N N
NR
NH2
SH
4. A .K. Mishra et al17 have reported synthesis and antimicrobial activity of some
triazole derivatives starting from 2-substituted-1H-benzimidazole.
CS2 / KOHN
N
O NH
NH2
N
N
N
N
O
SH
N
N
N
N
N
SH
NH2
NH2 NH2.H2O
5. K. S. Bhat et al.18 have synthesized 4-amino-3-(2,4-dichloro-5-fluorophenyl)-
1,2,4-triazol-5-thiol with the help of thiocarbohydrazide and 2,4-dichloro-5-fluoro
benzoic acid.
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F
Cl
Cl
COOH + NH2 NHS NHNH2
N N
N
Cl
Cl
F
NH2
SHH2SO4
Heat
6. N. U. Guzeldemirci et al.19 have prepared 1,2,4-triazoles in the presence of NaOH
from Aryl acid hydrazide.
R NH
O
NH2 RNCS NHNH NH
S
RR
O
NaOH
N
N N
H
S
R
R
7. S. F. Barbuceanu et al.20 have reported 5-[4-(4-X-phenylsulfonyl)phenyl]-4H-
1,2,4-triazole-3-thioles and It is prepared from 4-(4-X-phenylsulfonyl)-benzoicacid
hydrazide.
SO2
NH
O
NH2X KSCN
H+ SO2
NH
O
NHX NH2
S
SO2
X
N
N
H
N
SHHO- Where R = -Cl, -F
8. Sumesh eswaran et al.21 also synthesized triazole derivative by the reaction of 4-
hydroxy-8-(trifluoromethyl)quinoline-3-carbohydrazide.
N
OH
NH
O
NH2
CF3
N
OH
NH
O
CF3
NH NH
S
R1
N
OH
CF3
N
N
N
SH
R1
9. L. Labanauskas et al.22 have prepared triazoles by the addition reaction of
thiosemicarbazide with substituted benzoyl chloride in the presence of pyridine.
Then the substituted thiosemicarbazide cyclised in water in the presence of alkaline
catalyst.
NHNH
O
S
NHR1
N
N NH
SR1
Alkaline catalyst
RR
10. K. Paulvannam et al23 have developed an improved synthesis of 1,3,5-
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trisubstituted 1,2,4-triazoles via Ag2CO3 mediated cyclization of triazenes. The
reaction was complete within 3h and the products were isolated in moderate to
high yields.
R'-CN/ AlCl3
120oCPh
N
Cl
N
H NN
N
Ph
R'
THERAPEUTIC IMPORTANCE
Triazoles are potential bioactive agents due to their wide spectrum of therapeutic
importance. Literature survey reveals that various 1,2,4-triazole derivatives display
significant biological activities. 3-Amino-1,2,4-triazole was the first 1,2,4-
triazole to be manufactured on large scale from amino guanidine format, useful
as herbicides24, therapeutic activity of 1,2,4-triazoles are as under.
Bactericidal25, Diuretic26, Fungicidal27, Herbicidal28, Insecticidal and
acaricidal29, Plant growth regulator30, Anticancer and Anti-HIV31, Antileshmanial32,
Antitumor33,34, Anti-depressant and anxiolytic35, Antimicrobial36, Antiviral37,
Antiinflammatory38, Antihypertensive39 and Anticonvulsant40.
Hoong-Kun Fun et al.41 have investigated 4-Amino-3-(1-naphthyloxymethyl)-
1H-1,2,4-triazole-5(4H)-thione. B. Kahveci et a l . 4 2 h a v e prepared 4-Arylmethyl-
idene-amino-3-(R-benzyl)-4,5-dihydro-1H-1,2,4-triazol-5-ones via microwave
assisted synthesis which exhibited remarkable antifungal activity. Ram Janam Singh
et al.43 have synthesized 4-Aryl-5-(isomeric pyridoyl)-3H-1,2,4-triazoles as potent
bacteriocidal agents which active against S. aureus, E. coli, B. subtilis and P.
aeruginosa. Najim A. Al-Masoudi et al.44 have suggested 5-Amino-4-phenyl-4H-1,2,4-
triazole-3-thiol and their metal complexes which posses vitro anti-HIV activity. E. De
Clercq et al.45 screened ribavarin (11) for their antiviral and antimetabolic activities.
Mckendry and co-workers46 have synthesized triazole derivatives (12) and reported
them as broad spectrum broadleaf herbicides.
O N
NH N
OH
OH OH
CONH2
NHNN
H
N
H
OEt
F
SO2
NH
Cl
Cl
(11) (12)
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Sherin M. El-Feky et al47 have synthesized a new series of 3,5-disubstituted
triazoles (13) and evaluated for invitro antifungal and antibacterial activity. All the tested
compounds showed significant antifungal activity against micromycetes compared to the
commercial fungicide clotrimazole.
N
N N
SR S N
NN
H
N
F
F
(13)
H. A. Abdel-Aziz et al.48 have synthesized some piperidine based 1,3-thiazole,
1,3,4-thiadiazole, and 1,3-thiazolo[2,3-c]-1,2,4-triazole derivatives which posses anti-
arrhythmic activity. B. F. Abdel-Wahab et al.49 have reported 1,2,4-triazoles useful for
antimicrobial agent.
Hakan Bekats et al50 have synthesized some novel 2,4,5-trisubstituted-2,4-
dihydro-3H-1,2,4-triazole-3-one (14) and all these compounds were screened for their
antimicrobial activities and some of which were found to possess good or moderate
activities against the test microorganisms.
NN
NCl N
O
O
O
NN
S
R
(14)
Daniele Binchi et al.51 have screened pure stereoisomer of two triazole
derivatives (15,16) for their antifungal activity against variety of fungi.
Cl
Cl OH
N
N N
(15)
N
N N
OCF2CHF2
Cl
Cl
(16)
M. A. Kaldrikyan et al.52 have discovered some benzofuryl-substituted-1,2,4-
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triazoles and reported their antitumor activity. Dae-Kee Kim et al.53 have been
synthesized 1,2,4-triazole derivatives (17) and screened for their significant ALKS
inhibitory activity. K. J. Fisher et al.54 have synthesized 1,2,4-triazole derivatives
(18) to study their pesticidal and herbicidal activity. Xiang-Shu Cui et al.55 have
formulated 3-substituted-4-(4-hexyloxyphenyl)-4H-1,2,4-triazoles as
anticonvulsant agent. Maarouf et al.56 have documented analgesic and anti-
inflammatory activity of 1,2,4-triazole derivatives.
N
NN
N
R3R2
R1
(17)
NHSNH
NN
H
Cl
ClO
F3C
Et
(18)
Drug molecules having 1,2,4-triazole nucleus with their activity are listed as
under.
N
N
NN
Cl
1. Estazoalm
Receptor Agonist
NN
N
NC CN
2. Letrozole
Antineoplastic
3. Fluotrimazole
NN
N
CF3
Fungicide
4. Ribavarin
Antiviral, Antiinfection
O
N
N
NH
H2NOC
OH OH
OH
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O O Cl
Cl
NN
N
N
N N
N O
O
Cl
Cl
7. Azaconazole
Antifungal
8. Rilmazafone
Sedative,hypnotic
Sn
NN
N
NN
N
H
NH2
9. Azocyclotin
Pesticide
10. Amitrole
Antithyroid activity
5. Triazolam
N
N
N
N
Cl
Plant growth regulator
6. Triadimenol
N
NN O
O Cl
Fungicide
Thus the important role displayed by triazole moiety for various
therapeutic and medicinal activities prompted us to synthesize some Schiff base
derivative bearing triazole moiety, which have been described as under.
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF 4-((ARYLME-
THYLIDINE)AMINO)-5-((4-(2,3-DICHLOROPHENYL)PIPERAZIN
-1-YL)METHYL)-4H-1,2,4-TRIAZOLE-3-THIOL
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF 4-((ARYLMETHYLIDINE)
AMINO)-5-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-4H-1,2,4-
TRIAZOLE-3-THIOL
1,2,4-Triazoles nucleus and their derivatives emerge rapidly with the advance of
modern heterocyclic chemistry, promising a variety of medical applications such as
antibacterial, antifungal, anticancer, antitumor, anticonvulsant, anti-inﬂammatory and
analgesic properties. Schiff bases of 1,2,4-triazoles ﬁnd diverse applications and
extensive biological activity. Looking to this, schiff base derivative of type-XI have
been synthesised by the condensation of 4-amino-5-((4-(2,3-
dichlorophenyl)piperazin-1-yl)methyl)-4H-1,2,4-triazole-3-thiol with different
substituted aromatic aldehyde.
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
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REACTION SCHEME
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IR SPECTRUM OF 5-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-4-(((4-
METHOXYPHENYL)METHYLIDENE)AMINO)-4H-1,2,4-TRIAZOLE-3-THIOL
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2951
2875
1465
1392
2975-2920
2880-2860
1470-1435
1395-1370
57
”
”
”
Aromatic
C-H str.
C=C
C-H i.p. def.
C-H o.o.p. def.
3059
1512
1130
839
3100-3000
1585-1480
1125-1090
860-810
”
”
”
”
Triazole ring
& Azomethine
N=C str.
C-N str.
N-N str.
-S-H str.
1593
1307
1157
2538
1650-1580
1350-1200
1220-1020
2600-2550
58
”
”
Ether (-OMe)
Halide
C-O-C
C-Cl
1224
813
1275-1200
850-650
57
”
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1H-NMR SPECTRUM OF 5-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-
4-(((4-METHOXYPHENYL)METHYLIDENE)AMINO)-4H-1,2,4-TRIAZOLE-3-THIOL
Internal Standard: TMS; Solvent: MeOD Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
4
5
6
7
8
9
3.37
3.12-3.14
3.88
4.74
7.06-7.09
7.15-7.17
7.28-7.31
7.89-7.92
10.26
4H
4H
3H
2H
2H
1H
2H
2H
1H
broad singlet
broad singlet
singlet
singlet
doublet
double doublet
multiplet
doublet
singlet
-CH2 (a,a’)
-CH2 (b,b’)
-OCH3 (c)
-N-CH2 (d)
Ar-H (e,e’)
Ar-H (f)
Ar-H(g,h)
Ar-H (i,i’)
-N=CH (j)
-
-
-
-
9.0
3.0 & 6.6
-
8.7
-
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EXPANDED 1H-NMR SPECTRUM
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MASS SPECTRUM OF 5-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-4-
(((4-METHOXYPHENYL)METHYLIDENE)AMINO)-4H-1,2,4-TRIAZOLE-3-THIOL
MASS SPECTRUM OF 5-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-4-
(((4-FLUOROPHENYL)METHYLIDENE)AMINO)-4H-1,2,4-TRIAZOLE-3-THIOL
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF 4-((ARYLMETHYLIDINE)
AMINO)-5-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-4H-1,2,4-
TRIAZOLE-3-THIOL
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. 70 % Ethyl acetate in
hexane was used as a mobile phase.
[A] SYNTHESIS OF 2-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-
YL)ACETOHYDRAZIDE
See, Chapter-2, Part-A, Section-I, Experimental [B], page no. 72.
[B] SYNTHESIS OF POTASSIUM 2-(2-(4-(2,3-DICHLOROPHENYL)
PIPERAZIN-1-YL)ACETYL)HYDRAZINECARBODITHIOATE
To the mixture of potassium hydroxide (8.40g, 0.15mol) and 2-
(4-(2,3-dichlorophenyl)piperazin-1-yl)acetohydrazide (30.2g, 0.1mol) in ethanol (100
ml), carbon disulphide (11.4g, 0.15mol) was added. This mixture was stirred for
24 hrs at room temperature. It was then diluted with dry ether (400 ml) and thus the
solid obtained was filtered and washed with ether and dried. There is no need to purify
the salt for further reaction.
[C] SYNTHESIS OF 4-AMINO-5-((4-(2,3-DICHLOROPHENYL)
PIPERAZIN-1-YL)METHYL)-4H-1,2,4-TRIAZOLE-3-THIOL
A suspension of the potassium salt (41.74g, 0.1mol), hydrazine hydrate (25 ml,
0.5mol), water (10 ml) and ethanol (50 ml) was refluxed with stirring for 8 hrs. The color
of the reaction mixture changed to green, hydrogen sulfide was evolved and a
homogeneous solution resulted. Dilute the solution with cold water (300 ml) and
neutralized with glacial acetic acid, precipitated a white solid. The product was
filtered, washed with cold water and crystallized from dioxane yield 60 %.
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[D] SYNTHESIS OF 5-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)
METHYL)-4-(((4-METHOXYPHENYL)METHYLIDENE)AMINO)-4H-
1,2,4-TRIAZOLE-3-THIOL
A mixture of 4-amino-5-((4-(2,3-dichlorophenyl)piperazin-1-yl)methyl)-4H-
1,2,4-triazole-3-thiol (3.58 gm, 0.01 mol), 4-methoxybenzaldehyde (1.36 gm, 0.01 mol)
and ethanol (20 ml) in presence of con. HCl (2 drops) was refluxed for 8 hrs. The
contents were cooled and solid was filtered, dried and isolated product was recrystallized
from ethanol. Yield: 81 %, M. P. 208-210 °C, (C21H22Cl2N6OS; Required: C, 52.83; H,
4.64; N, 17.60 %; Found: C, 52.75; H, 4.56; N, 17.55 %).
Similarly, other 4-((arylmethylidine)amino)-5-((4-(2,3-dichlorophenyl)piperazin-
1-yl)methyl)-4H-1,2,4-triazole-3-thiol (11a-j) were prepared. The physical constants are
recorded in Table-11a, Page no. 221.
[E] BIOLOGICAL SCREENING OF 4-((ARYLMETHYLIDINE)AMINO)-5-
((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-4H-1,2,4-
TRIAZOLE-3-THIOL
Antimicrobial testing was carried out as described in Chapter-1, Section-I,
Experimental [C], Page no. 37. The results obtained from antimicrobial testing are
recorded in Table-11b, Page no. 222.
Studies on Biologically Active... 221
Chapter-6 Studies on Triazole...
TABLE-11a: PHYSICAL CONSTANTS OF 4-((ARYLMETHYLIDINE)AMINO)-
5-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)METHYL)-4H-
1,2,4-TRIAZOLE-3-THIOL
N N
Cl Cl
N N
N
SH
N R
Sr.
No.
Substitution
R
Molecular
Formula/
Molecular Weight
M.P.
°C
Yield
%
% Composition
Calcd./Found
C H N
11a H C20H20Cl2N6S447.38 193-196 86
53.59
53.41
4.51
4.46
18.78
18.69
11b 4-OMe C21H22Cl2N6OS477.41 208-210 81
52.83
52.75
4.64
4.56
17.60
17.55
11c 4-F C20H19Cl2FN6S465.37 218-220 89
51.62
51.38
4.12
4.04
18.06
17.97
11d 3-Cl C20H19Cl3N6S481.83 184-186 82
49.85
49.70
3.97
3.89
17.44
17.35
11e 2,3-di Cl C20H18Cl4N6S516.27 211-212 76
46.53
46.38
3.51
3.46
16.28
16.21
11f 4-N(Me)2 C22H25Cl2N7S490.45 176-179 84
53.88
53.71
5.14
5.07
19.99
19.86
11g 3-OMe-4-OH C21H22Cl2N6O2S493.41 229-231 74
51.12
50.94
4.49
4.37
17.03
16.92
11h 4-NO2 C20H19Cl2N7O2S492.38 222-225 87
48.79
48.66
3.89
3.84
19.91
19.82
11i 3-NO2 C20H19Cl2N7O2S492.38 198-200 79
48.79
48.58
3.89
3.84
19.91
19.83
11j 4-OH C20H20Cl2N6OS463.38 208-210 83
51.84
51.56
4.35
4.23
18.14
18.02
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TABLE-11b: BIOLOGICAL SCREENING OF 4-((ARYLMETHYLIDINE)
AMINO)-5-((4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-
YL)METHYL)-4H-1,2,4-TRIAZOLE-3-THIOL
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 11a 250 200 100 200 250 1000 1000
2 11b 250 250 200 62.5 250 1000 >1000
3 11c 100 200 100 200 500 250 250
4 11d 200 100 250 250 1000 >1000 >1000
5 11e 100 200 50 100 500 500 500
6 11f 500 500 500 250 >1000 >1000 >1000
7 11g 200 500 250 500 1000 500 500
8 11h 250 250 500 500 1000 1000 1000
9 11i 500 250 500 250 500 1000 >1000
10 11j 500 500 250 250 500 500 1000
MINIMAL INHIBITION CONCENTRATION
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
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ANTIBACTERIAL ACTIVITY:
From screening results, substituted triazole 11c (R= 4-F) against S.aureus, 11e
(R= 2,3-di Cl) against E-coli and 11b (R= 4-OMe) against P.aeruginos show excellent
activity compared to ampicillin. While 11d (R= 3-Cl) & 11g (R= 3-OMe-4OH) against
S.aureus, 11d (R= 3-Cl) against S.pyogenus, 11a (R= -H) & 11c (R= 4-F) against E-coli
and 11e (R= 2,3-di Cl) against P.aeruginos, display moderate activity as compared to
ampicillin. The remaining compounds demonstrate moderate to poor activity against all
four bacterial species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data shows that substituted triazoles 11a (R= -H) & 11b (R=
4-OMe) possess highly promisssing activity against C.albicans as compared to
greseofulvin while 11c (R= 4-F) display moderate activity against A.niger and A.clavatus.
The remaining compounds show moderate to poor activity against all three bacterial
species.
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Chapter-7
STUDIES ON ARYL AMIDE
DERIVATIVES
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INTRODUCTION
The characteristic group present in the simple carboxylic amide is CONH2. They are the
acyl substitution products of ammonia. Many natural products are amides (-CO-NH-),
urea (-NH-CO-NH-) and diamides (-CO-NH-CO-NH) derivatives of carbonic acid. The
peptides and proteins are linear structure of cyclic polyamides. The alkaloids of pepper,
piperidine and chavicine are N-substituted amides of unsaturated acid. N-isobutyl amides
of certain highly unsaturated aliphatic acids occur in plants, shows insecticidal activity.1
Amides derived from polyacetylenic acid have been isolated from certain fungi.2
SYNTHETIC ASPECT
Various methods for the synthesis of aryl amides are described in literature.3-9
1. Marayama, Tatsuya, Suzuki Onda10 have synthesized arylamide as under.
NH2
NH
OHPh
Cl
N N
Cl
O
N N
NH
Cl
O
NH
OH
Ph
+
Pyridine
2. An effective protocol by thermal condensation of carboxylic acids with amines
has been reported by L. J. Gooben et al.11
R1
O
OH
+ NH
R2
R3 neat, 160OC
2-24 hr.
R1
N
O
R2
R3
3. Z. Huang et al.12 have prepared borane-tetrahydrofuran complex used to generate
triacyloxyboranes, which can be effectively reacted with various nucleophiles
(alkylamines, arylamines, hydrazides, alcohols, phenols) at reflux temperature in
toluene to provide the corresponding amides.
R1
O
OH
i) 0.35eq.BH3-THF, Toluene
ii) 1.2 eq. R2R3NH, reflux, 12 hr.
R1
O
N R3
R2
4. D. J. Hardee and coworkers13 suggested that the conversion of carboxylic acids to
their corresponding acid chlorides occurs rapidly in the presence a tertiary amine
base and 3,3-dichlorocyclopropenes via aromatic cation-activated nucleophilic
acyl substitution to give the corresponding amides.
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R1
O
OH
DIPEA, CH2Cl2 R1
O
Cl
BnNH2
15 min. R
1 O
NHBnClCl
5. G. E. Veitch et al.14 have used magnesium nitride as a convenient source of
ammonia allows a direct transformation of esters to primary amides. Methyl,
ethyl, isopropyl, and tert-butyl esters are converted to the corresponding
carboxamides in good yields.
R1
O
O R2
R1
O
NH2
5 eq. Mg3N2
MeOH, 80OC
6. C. Larrive-Aboussafy et al.15 have synthesized DBU catalyzed corresponding
amides derivatives.
Ph OH
O
DBU, 2-Me THF
Ph NH
O ArCDI, Ar-NH2
7. Multivalent metal salts, such as ferric chloride and sulfate, are active and versatile
catalysts for the amidation of aliphatic fatty acids with long-chain aliphatic amines
was reported by Y. Terada et al.16
O
OH
CH3
+ NH2
2 mol-% FeCl3.6H2O
mesitylene, reflux NHO( )n
( )n
8. J. Bures et al.17 have reported 2,2′-dipyridyl diselenide catalyzed direct reaction of
carboxylic acids with azides and trimethylphosphine at room temperature.
R1
O
OH
+ N3 R2
Me3P,  2,2'-PySeSePy
toluene, rt.
R1
O
NH R2
9. I. Azumaya et al.18 have prepared various tertiary benzanilide derivatives in high
yields from a broad range substituted benzoic acid and N-monoalkylated anilines
using dichlorotriphenylphosphorane in chloroform.
Ar N
H
R1
+
Ar'
O
OH Ph3PCl2CHCl3, reflux
Ar N
R1
O
Ar'
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10. Deoxo-Fluor is a versatile and mild reagent for acyl fluoride generation and
subsequent one-pot amide coupling. J. M. White et al.19 have reported the
conversion of acids to amides and the use of deoxo-fluor as peptide-coupling
reagent. Products were isolated after facile purification in good yields.
R1
R2
O
OH
+ F3S
OCH3
OCH3
DIPEA
CH2Cl2
R1
R2
O
F
NHR3R4 R
1
R2
O
N
R3
R4
11. D. M. Shendage et al.20 have prepared stereoconservative protection and
deprotection method of amino and carboxyl groups includes the generation of N-
phthaloyl N'-alkyl secondary amides from N-phthaloyl amino acids by using a
mixedanhydridemethod.
PGN
R1
O
OH (1) isobutyl chloroformate, Et3N
(2) R2NH2, NaHCO3 PGN R1
O
NHR2
THERAPEUTIC IMPORTANCE
Amides, aryl amides and heterocyclic aryl amides showed various
pharmacological activities. The biological activities of aryl amide derivatives have been
reported as under.
1. Anticonvulsant21
2. Herbicidal22
3. Cardiotonic23
4. Antimicrobial24,25
5. Analgesic26
6. Antiulcer27
7. MAO inhibitor28
8. Anticancer29,30
9. Antiinflammatory31
10. Anti-HIV32
11. Sodium channel blockers33,34
G. Shattat et al.35 have synthesized and evaluated anti-hyperlipidemic activity of
N-(benzoylphenyl)-5-fluoro-1H-indole-2-carboxamide (1) derivatives. H. B. Rubins and
coworkers36 have studied carboxamide derivatives as pharmacological mechanism of
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fibrates, including bezafibrate, by the induction of lipoprotein lipase and reduction of
apolipoprotein C-III synthesis leading to increased hydrolysis of triglycerides (TG). S.
Olgen et al.37 and G. Liu et al.38 have studies the potential role for carboxamide
derivatives as anti-allergics and antioxidants.
N
H
F NH
O
O
(1)
A. K. Mallams39 has reported arylamide derivatives as antitumor agent. More over
S. J. Laulloo et al40 and J. Hazarika41 have prepared some new biologically active
arylamide derivatives and reported them as antimicrobial agents. Dhanak Dushyant et
al.42 have synthesized arylamide (2) useful as urotensin-II antagonist. E. J. Sanderson
Philip et al.43 (3) have synthesized aryl amides and studied their biological activity.
Cl
Cl
O NH N
S
O
O
O
N
H
Cl
Cl
NH O
NH NH
(2)                                                             (3)
C. Kishor Kumar et al.44 have synthesized some 3-oxoisoindoline-5-carboxamides
and studied their antioxidant activity.
M. B. Anthony et al.45 have reported aryl amide derivatives as antiulcer agents. J.
E. Foster et al.46 have synthesized some new amide derivatives as potent anticonvulsant.
A. R. Mulik et al.47 have studied some aryl amides shows antibiotic activity. G. Bridge et
al.48 have screened arylamides as anti-HIV agent. L. Bettineti and co-workers49 have
prepared arylamides as antibacterial agents. D. W. Hobbs et al.50 have designed some
amides and reported them as MCH-receptor antagonist.
S. Henning et al.51 have reported carboxamide derivatives (4), as renin inhibitors
and renin-angiotensin modulators useful in the treatment of hypertension. C. Zhong et
al.52 have synthesized and reported antitumor activities of some carboxamide derivatives.
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R. Aleksandra et al.53 have documented rational design, synthesis, and potency of 1H-
indole-5-carboxamide as potential fructose 1,6-bisphosphatase inhibitors.
N
OH
CH3
CH3
F
O N NH
(4)
S. Tabuchi et al.54 have screened arylamide derivatives as novel potent antagonist
of human neuropeptide YY5 receptor. J. H. Chan55 has reported substituted
benzophenone-arylamide derivatives as inhibitor reverse transcriptase. L. Pieters et al.56
have synthesized new diazene carboxamides (5) as anticancer agent. N. J. Anthony and
co-workers57 have investigated amides for anti-HIV activity. G. Chen et al.58 have
reported aryl amides (6) as antitumor agents.
NH
N
O
N
F F
F
FF
N
NH
O
CF3
N
NH
F(5)                                                                 (6)
G.  A. Doherty et al.59 have synthesized indole-5-carboxamide derivatives (7) as
DP2 receptor modulators for treating immunological diseases. Indole carboxamide
derivatives applied as p38α-selective MAP kinase inhibitor which reduces tumor growth
in mouse xenograft models of multiple myeloma and SD-282 reduces inflammation in a
subchronic model by S. Medicherla et al.60
N CNO
NH
Cl COOH
(7)
CONTRIBUTION FROM OUR LABORATORY
Some new arylamide derivatives bearing benzimidazol moiety (8) were assessed
by H. H. Parekh et al.61 and evaluated its antimicrobial activity. A. R. Parikh et al.62-65
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have synthesized new arylamide derivatives (9), (10) and reported them as antimicrobial
agents.
N
N
HO
NHNH
R
O
N
N
S
N
NH R
NH2O
N
N
R
O
NH2
OH
(8) (9) (10)
V. H. Shah et al.66 have synthesized some new aryl amides (11) and evaluated
their antimicrobial activity.
N
N
OH
O
R
O
N
N
Cl
O
R
O
N
N
NH
O
R
O
NH2
N
N
O
O
R
O
OH
O
(11)
V. N. Patoliya et al.67-70 have synthesized and evaluated antimicrobial activity of
some aryl amide derivative (12). D. M. Purohit et al.159 have reported new aryl amides
derivatives having piperazine moiety as a antimicrobial agent.
N
S
COR COOH
N
N NH R
OO
OH
R
N
N
O
O NH
O N
N
O
NH R
O
Cl
(12)
Looking to the interesting properties of aryl amide derivatives, we have
synthesized some aryl amides bearing a chromene moiety, which have been described as
under.
SECTION-I: SYNTHESIS AND BIOLOGICAL SCREENING OF N'-
(ARYLCARBONYL)-6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-
2-CARBOHYDRAZIDE
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SECTION-I
SYNTHESIS AND BIOLOGICAL SCREENING OF N'-(ARYLCARBONYL)-6-
FLUORO- 3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Arylamide derivatives showed different biological activity such as antihista
manic, anti-inflammatory, anticonvulsant, antitubercular, antipyretic, analgesic, antiseptic
etc. To getting better therapeutic agent and to evaluate its pharmacological profile, we
have synthesize aryl amides of type-(XII) by the condensation of 6-fluoro-3,4-dihydro-
2H-chromene-2-carbohydrazide with different aromatic acid in the presence of N-[3-(
dimethylamino)propyl]-N'-ethylcarbodiimide hydrochloride (EDCI), 1-hydroxybenzotri-
azole (HOBt) and triethylamine (TEA).
The constitution of the synthesized products have been characterized by using
elemental analysis, IR & 1H-NMR spectroscopy and further supported by mass
spectroscopy.
All the compounds have been evaluated for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards A. niger, C. Albicans and A. Clavatus at a different
concentration. The biological activities of synthesized compounds were compared with
standard drugs.
REACTION SCHEME
(Type-XII)
R = 4-OCH3, 4-CH3, 4-Cl, 3-Br etc.
O
HN NH R
O
HN
O
NH2
F
O
F
HOBt
EDCI.HCl
TEA
DCM
10 hrs
O
COOH
R
+
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IR SPECTRUM OF 6-FLUORO-N'-(PHENYLCARBONYL)-3,4-DIHYDRO-2H-
CHROMENE-2-CARBOHYDRAZIDE
Instrument: SHIMADZU FTIR 8400 Spectrophotometer; Frequency range:
4000-400 cm-1 (KBr disc.)
Type VibrationMode
Frequency cm-1 Ref.Observed Reported
Alkane
C-H str. (asym.)
C-H str. (sym.)
C-H def. (asym.)
C-H def. (sym.)
2941
2866
1435
1338
2975-2920
2880-2860
1470-1435
1395-1370
72
”
”
”
Aromatic
C-H str.
C=Cstr.
C-H i.p. def.
3009
1535 & 1492
1089
3100-3000
1585-1480
1125-1090
”
”
”
Amide
C=O str.
-NH str.
C-N str.
1697 & 1649
3211
1101
1700-1650
3320-3140
1250-1020
”
”
Ether C-O-C 1261 1275-1200 ”
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1H-NMR SPECTRUM OF 6-FLUORO-N'-(PHENYLCARBONYL)-3,4-DIHYDRO-2H-
CHROMENE-2-CARBOHYDRAZIDE
Internal Standard: TMS; Solvent: CDCl3 Instrument: BRUKER Spectrometer
(300MHz)
Sr.
No.
Chemical
Shift
In δppm
Relative No.
of Protons Multiplicity Inference
J Value in
HZ
1
2
3
4
5
6
7
8
9
10
2.04-2.17
2.42-2.46
2.82-2.90
4.66-4.70
6.77-6.92
7.44-7.49
7.54-7.59
7.82-7.84
8.82
9.26
1H
1H
2H
1H
3H
2H
1H
2H
1H
1H
multiplet
multiplet
multiplet
double doublet
multiplet
triplet
triplet
doublet
singlet
singlet
-CH2 (a)
-CH2 (a)
-CH2 (b)
-CH (c)
Ar-H (d,e,f)
Ar-H(g,g’)
Ar-H(h)
Ar-H(i,i’)
-CO-NH
-CO-NH
-
-
-
3.0 & 9.6
-
-
-
7.2
-
-
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EXPANDED 1H-NMR SPECTRUM
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MASS SPECTRUM OF 6-FLUORO-N'-(PHENYLCARBONYL)-3,4-DIHYDRO-2H-
CHROMENE-2-CARBOHYDRAZIDE
MASS SPECTRUM OF 6-FLUORO-N'-((4-METHYLPHENYL)CARBONYL)-3,4-
DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL SCREENING OF N'-(ARYLCARBONYL)-6-
FLUORO- 3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Melting points of all the synthesized compounds were taken in open capillary bath
on controlled temperature heating mental. The crystallization of all the compounds was
carried out in appropriate solvents. TLC was carried out on silica gel-G F254 coated
aluminum sheet (Merck prepared plates) as stationary phase. 10 % Methanol in
chloroforrm was used as a mobile phase.
[A] SYNTHESIS OF 6-FLUORO-3,4-DIHYDRO-2H-CHROMENE-2-
CARBOHYDRAZIDE
See, Chapter-2, Part-B, Section-I, Experimental [B], Page no. 93.
[B] SYNTHESIS OF 6-FLUORO-N'-(PHENYLCARBONYL)-3,4-DIHYDRO-
2H-CHROMENE-2-CARBOHYDRAZIDE
To the stirred solution of benzoic acid (1.22 g, 0.01 mol) in dry DCM (20 ml),
HOBt (N-hydroxybenzotrizole) (1.53 g, 0.01 mol) and EDCI (N,N'-dicyclohexylcarbodi-
imide) (2.87 g, 0.015) was added at 0 oC. The obtained solution was stirred for 15 minute
at 0 oC. To this solution 6-fluoro-3,4-dihydro-2H-chromene-2-carbohydrazide (2.10 g,
0.01 mol) was added portionwise, then after 2 minute TEA (2.08 ml 0.015 mol) was
added. The reaction mixture was stirred for 10 hour at room temperature (monitored by
TLC). The solvent was distillled out, residue was poured into water. The product was
extracted with ethylacetate (20 ml × 3), and the combined organic layers were washed
with water followed by brine and dried over anhydrous Na2SO4. The solvent was
evaporated under vacuum and the residue was purified by column chromatography on
silica gel (mesh size: 60-120 (eluent: 2 % methanol in DCM) to obtain pure product.
Yield: 79 %, M. P. 203-204 °C, (C17H15FN2O3; Required: C, 64.96; H, 4.81; N, 8.91 %;
Found: C, 64.61; H, 4.72; N, 8.85 %).
Similarly, other N'-(arylcarbonyl)-6-fluoro-3,4-dihydro-2H-chromene-2-
carbohydrazide were (12a-j) prepared. The physical constants are recorded in Table-12a,
Page no. 241.
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[C] BIOLOGICAL SCREENING OF N'-(ARYLCARBONYL)-6-FLUORO-3,4-
DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Antimicrobial testing was carried out as described in Chapter-1, Section-I,
Experimental [C], Page no. 37. The results obtained from antimicrobial testing are
recorded in Table-12b, Page no. 242.
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TABLE-12a: PHYSICAL CONSTANTS OF N’-(ARYLCARBONYL)-6-FLUORO-
3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Sr.
No.
Substitution
R
Molecular
Formula/
Molecular Weight
M.P.
°C
Yield
%
% Composition
Calcd./Found
C H N
12a H C17H15FN2O3314.31 203-204 79
64.96
64.61
4.84
4.72
8.91
8.85
12b 4-OMe C18H17FN2O4344.34 185-187 73
62.79
62.48
4.98
4.91
8.14
8.01
12c 4-CH3 C18H17FN2O3328.34 197-198 76
65.84
65.68
5.22
5.17
8.53
8.39
12d 4-NO2 C17H14FN3O5359.31 226-228 69
56.83
56.66
3.93
3.88
11.69
11.57
12e 4-F C17H14F2N2O3332.30 177-179 65
61.44
61.32
4.25
4.16
8.43
8.38
12f 4-Cl C17H14ClFN2O3348.76 192-194 72
58.55
58.31
4.05
3.98
8.03
7.94
12g 3-Br C17H14BrFN2O3393.21 183-185 67
51.93
51.78
3.59
3.48
7.12
7.02
12h 3-OMe C18H17FN2O4344.34 205-208 64
62.79
62.57
4.98
4.93
8.14
8.05
12i 3- CH3 C18H17FN2O3328.34 217-219 68
65.84
65.68
5.22
5.14
8.53
8.47
12j 2-NO2-5-Cl C17H13ClFN3O5393.75 199-201 59
51.86
51.72
3.33
3.29
10.67
10.53
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TABLE 12b: BIOLOGICAL SCREENING OF N'-(ARYLCARBONYL)-6-FLUORO-
3,4-DIHYDRO-2H-CHROMENE-2-CARBOHYDRAZIDE
Sr.
No. Code
Antibacterial Activity Antifungal activity
Minimal bactericidal concentration μg/ml Minimal fungicidal concentration
μg/mlGram +ve Bacteria Gram –ve Bacteria
S.aureus S.pyogenus E.coli P.aeruginosa C.albicans A.niger A.clavatus
1 12a 500 250 250 250 250 1000 500
2 12b 200 500 500 500 1000 >1000 500
3 12c 250 50 200 250 1000 >1000 >1000
4 12d 500 250 500 500 500 1000 >1000
5 12e 250 100 200 250 1000 >1000 1000
6 12f 200 200 62.5 100 500 200 250
7 12g 500 500 250 250 500 1000 >1000
8 12h 250 250 250 500 1000 500 500
9 12i 500 250 500 250 500 1000 1000
10 12j 500 250 100 250 250 500 1000
MINIMAL INHIBITION CONCENTRATION
Standard Drugs S.aureus S.pyogenus E.coli P.aeruginosa(microgramme/ml)
Gentamycin 0.25 0.5 0.05 1
Ampicillin 250 100 100 100
Chloramphenicol 50 50 50 50
Ciprofloxacin 50 50 25 25
Norfloxacin 10 10 10 10
MINIMAL FUNGICIDAL CONCENTRATION
Standard Drugs C.Albicans A.Niger A.Clavatus(microgramme/ml)
Nystatin 100 100 100
Greseofulvin 500 100 100
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ANTIBACTERIAL ACTIVITY:
From screening results, substituted aryl amide 12b (R= 4-OMe) & 12f (R= 4-Cl)
against S.aureus, 12c (R= 4-Me) against S.pyogenus and 12f (R= 4-Cl) against E-coli
exhibit very good activity compared to ampicillin. While 12c (R= 4-Me) & 12e (R= 4-F)
against S.aureus, 12e (R= 4-F) against S.pyogenus, 12j (R= 2-NO2-5-Cl) against E-coli
and 12f (R= 4-Cl) against P.aeruginos, show moderate activity as compared to ampicillin.
The remaining compounds demonstrate moderate to poor activity against all four
bacterial species.
ANTIFUNGAL ACTIVITY:
Antifungal screening data shows that substituted aryl amide 12a (R= -H) & 12j
(R= 2-NO2-5-Cl) display excellent activity against C.albicans as compared to
greseofulvin while 12f (R= 4-Cl) exhibit moderate activity against A.niger and
A.clavatus. The remaining compounds show moderate to poor activity against all three
bacterial species.
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